WorldWideScience

Sample records for cancer institute nih

  1. Selected National Cancer Institute Breast Cancer Research Topics | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... For Breast Cancer Selected National Cancer Institute Breast Cancer Research Topics Past Issues / Summer 2014 Table of Contents ... Trials www.cancer.gov/clinicaltrials/Taking-Part-in-Cancer-Treatment-Research-Studies MedlinePlus tutorial www.nlm.nih.gov/medlineplus/ ...

  2. NIH Research Leads to Cervical Cancer Vaccine

    Science.gov (United States)

    ... Transmitted Diseases NIH Research Leads to Cervical Cancer Vaccine Past Issues / Fall 2008 Table of Contents For ... Douglas Lowy (left) and John Schiller developed the vaccine to prevent HPV infection in women, the cause ...

  3. NIH Roadmap & the Common Fund - Cancer Imaging Program

    Science.gov (United States)

    The NIH Roadmap for Medical Research is a series of high impact, trans-NIH programs supported by the NIH Common Fund. These programs address challenges that are priorities for the NIH and medical research but are issues that require the cooperation of more than one NIH institute to address.

  4. 75 FR 20370 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-04-19

    ....395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93...@mail.nih.gov . Name of Committee: National Cancer Institute Special Emphasis Panel, Breast Cancer... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  5. 78 FR 50065 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-08-16

    ...@mail.nih.gov . Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Therapy... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  6. Support for National Institutes of Health (NIH) Implementation of the Revised Public Access Policy

    OpenAIRE

    Richard K Johnson

    2008-01-01

    Comments submitted by SPARC (Scholarly Publishing and Academic Resources Coalition) in response to the U.S. National Institutes of Health (NIH) “Request for Information: NIH Public Access Policy” issued on March 31, 2008 (73 Federal Register 16881).

  7. NIH scientists provide new insight into rare kidney cancer

    Science.gov (United States)

    NIH scientists have discovered a unique feature of a rare, hereditary form of kidney cancer that may provide a better understanding of its progression and metastasis, possibly laying the foundation for the development of new targeted therapies.

  8. DCP Leading NIH Glycoscience Common Fund Program; Funding Opportunities Open | Division of Cancer Prevention

    Science.gov (United States)

    NCI's Division of Cancer Prevention is a leading participant for a key initiative in the National Institutes of Health (NIH) Glycoscience Common Fund program. This program supports development of accessible and affordable new tools and technologies for studying the role complex carbohydrates in health and disease. |

  9. Prostate Cancer Research Trial Helps John Spencer Treat His Cancer | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn Javascript on. Feature: Prostate Cancer Prostate Cancer Research Trial Helps John Spencer Treat His Cancer ... because of timely detection and treatment of his prostate cancer. He participated in an NIH-sponsored clinical trial. ...

  10. NIH Research: Cancers: A "Constellation" of Diseases | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... understanding affect how we think about cancer and cancer research? What we've learned can be grouped into ... some of the opportunities that you see in cancer research? The National Cancer Institute is ready to take ...

  11. Five Decades of Discovery: National Institute of General Medical Sciences | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Five Decades of Discovery: National Institute of General Medical Sciences Past Issues / Summer 2012 Table of Contents It ... 50th anniversary of the National Institute of General Medical Sciences (NIGMS), known to many as NIH's "basic research ...

  12. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory

    OpenAIRE

    Johnson, Karin E.; Neta, Gila; Dember, Laura M.; Coronado, Gloria D.; Suls, Jerry; Chambers, David A; Rundell, Sean; Smith, David H.; Liu, Benmei; Taplin, Stephen; Stoney, Catherine M.; Farrell, Margaret M; Glasgow, Russell E.

    2016-01-01

    Background The National Institutes of Health (NIH) Health Care Systems Research Collaboratory (NIH Collaboratory) seeks to produce generalizable knowledge about the conduct of pragmatic research in health systems. This analysis applied the PRECIS-2 pragmatic trial criteria to five NIH Collaboratory pragmatic trials to better understand 1) the pragmatic aspects of the design and implementation of treatments delivered in real world settings and 2) the usability of the PRECIS-2 criteria for asse...

  13. NIH researchers complete whole-exome sequencing of skin cancer

    Science.gov (United States)

    A team led by researchers at NIH is the first to systematically survey the landscape of the melanoma genome, the DNA code of the deadliest form of skin cancer. The researchers have made surprising new discoveries using whole-exome sequencing, an approach that decodes the 1-2 percent of the genome that contains protein-coding genes.

  14. National Institutes of Health (NIH) Chronic GVHD Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis

    OpenAIRE

    Baird, K.; Steinberg, S. M.; Grkovic, L; Pulanic, D.; Cowen, E.W.; Mitchell, S A; Williams, K. M.; Datiles, M B; Bishop, R.; Bassim, C.W.; Mays, J.W.; Edwards, D; Cole, K.; Avila, D.N.; Taylor, T.

    2013-01-01

    Between 2004 and 2010, 189 adult patients were enrolled on the National Cancer Institute (NCI) cross-sectional chronic Graft-versus-Host disease (cGVHD) natural history study. Patients were evaluated by multiple disease scales and outcome measures including the 2005 NIH Consensus Project cGVHD severity score. The purpose of this study is to assess the validity of the NIH scoring variables as determinants of disease severity in severely affected patients in order to standardize clinician evalu...

  15. Braving Breast Cancer: Just Do It! | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Braving Breast Cancer: Just Do It! Past Issues / Spring - Summer 2010 Table of Contents Breast cancer survivor Jana Brightwell, pictured here on the NIH ...

  16. NIH Study Offers Insight into Why Cancer Incidence Increases with Age

    Science.gov (United States)

    ... NIH study offers insight into why cancer incidence increases with age The accumulation of age-associated changes ... of many types of cancer, but why aging increases cancer risk remains unclear. Researchers suspect that DNA ...

  17. Intakes of Fruit, Vegetables, and Specific Botanical Groups in Relation to Lung Cancer Risk in the NIH-AARP Diet and Health Study

    OpenAIRE

    Wright, Margaret E.; Park, Yikyung; Subar, Amy F; Neal D Freedman; Albanes, Demetrius; Hollenbeck, Albert; Leitzmann, Michael F.; Schatzkin, Arthur

    2008-01-01

    Increased fruit and vegetable consumption may protect against lung cancer, although epidemiologic findings are inconclusive. The authors prospectively examined associations between lung cancer risk and intakes of fruit, vegetables, and botanical subgroups in 472,081 participants aged 50–71 years in the National Institutes of Health (NIH)-AARP Diet and Health Study. Diet was assessed at baseline (1995–1996) with a 124-item dietary questionnaire. A total of 6,035 incident lung cancer cases were...

  18. Peralta Cancer Research Institute

    International Nuclear Information System (INIS)

    The investigators in the cell biology program at PCRI have pioneered in the development of techniques for culturing human epithelial cells. The cancer diagnosis program has been concerned with researching new techniques for early diagnosis of breast cancer in women. The cancer treatment program has been concerned with applying cell biology and biochemistry advances to improve cancer management

  19. National Cancer Institute

    Science.gov (United States)

    ... Español 1-800-4-CANCER Live Chat Publications Dictionary Menu Contact Dictionary Search About Cancer Causes and Prevention Risk Factors ... Contacts Other Funding Find NCI funding for small business innovation, technology transfer, and contracts Training Cancer Training ...

  20. 78 FR 18613 - Notice of the Implementation of the National Institutes of Health (NIH) Electronic Vendor Invoice...

    Science.gov (United States)

    2013-03-27

    ... Health (NIH) Electronic Vendor Invoice Program (eVIP) SUMMARY: The purpose of this notice is to announce the future implementation of the Electronic Vendor Invoice Program (eVIP) at the National Institutes... policies, procedures, and clauses for implementing prompt payment regulations. Electronic...

  1. NIH study confirms risk factors for male breast cancer

    Science.gov (United States)

    Pooled data from studies of about 2,400 men with breast cancer and 52,000 men without breast cancer confirmed that risk factors for male breast cancer include obesity, a rare genetic condition called Klinefelter syndrome, and gynecomastia.

  2. Dietary flavonoid intake and thyroid cancer risk in the NIH-AARP Diet and Health Study

    OpenAIRE

    Xiao, Qian; Park, Yikyung; Hollenbeck, Albert R.; Kitahara, Cari M.

    2014-01-01

    Experimental studies suggested that flavonoids may influence thyroid carcinogenesis, but epidemiological evidence is sparse. No study has examined different classes of flavonoids in relation to thyroid cancer risk. Using data from the NIH-AARP Diet and Health Study, which enrolled 491,840 U.S. men and women, ages 50 to 71 at baseline, we prospectively examined the risk of thyroid cancer in relation to dietary intakes of catechins, flavanones, flavonols, anthocyanidins, flavones, isoflavones, ...

  3. Trends in Research on Energy Balance Supported by the National Cancer Institute

    OpenAIRE

    Ballard-Barbash, Rachel; Siddiqi, Sameer M.; Berrigan, David A.; Ross, Sharon A.; Nebeling, Linda C.; Dowling, Emily C.

    2013-01-01

    Over the past decade, the body of research linking energy balance to the incidence, development, progression and treatment of cancer has grown substantially. No prior NIH portfolio analyses have focused on energy balance within one institute. This portfolio analysis describes the growth of National Cancer Institute (NCI) grant research on energy balance–related conditions and behaviors from 2004 to 2010 following the release of an NCI research priority statement in 2003 on energy balance and ...

  4. 75 FR 61763 - Submission of OMB Review; Comment Request; Drug Accountability Record (Form NIH 2564) (NCI)

    Science.gov (United States)

    2010-10-06

    ... instruments, contact Charles L. Hall, Jr., Chief, Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, Division of the Cancer Treatment and Diagnosis, and Centers, National Cancer Institute, Executive... collection projects, the National Cancer Institute, the National Cancer Institute (NIH) has submitted to...

  5. ICMIC Institutions - Cancer Imaging Program

    Science.gov (United States)

    ICMIC grants facilitate interaction among scientists from a variety of fields to conduct multidisciplinary research on cellular and molecular imaging related to cancer. Pre-ICMIC planning grants have provided time and funds for investigators and institutions to prepare themselves, organizationally and scientifically, to establish ICMICs.

  6. NIH mouse study finds gut microorganisms may determine cancer treatment outcome

    Science.gov (United States)

    An intact gut commensal microbiota, which is a population of microorganisms living in the intestine, is required for optimal response to cancer therapy, according to a mouse study by scientists at the National Cancer Institute (NCI)

  7. 78 FR 25281 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-04-30

    ... patentable material, and personal information concerning individuals associated with the grant applications... grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road...@mail.nih.gov . (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction;...

  8. 78 FR 69426 - Submission for OMB Review; 30-Day Comment Request: NIH NCI Central Institutional Review Board...

    Science.gov (United States)

    2013-11-19

    ... review. The benefits to the National Clinical Trials Network and Experimental Therapy-Clinical Trials... for Participants 25 1 2 50 Treatment Studies. NCI Adult/Pediatric CIRB Application for Participants 10... National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and...

  9. American Institute for Cancer Research

    Science.gov (United States)

    ... Order Publications Shop AICR Health @ Work Healthy Recipes Cancer Research Update AICR eNews AICR Newsletter ScienceNow CancerResource Where ... Patients and Survivors Materials for Health Professionals Our Cancer Research Research Grants Conference Continuous Update Project Research Progress ...

  10. Mitochondrial DNA from colorectal cancer cells induces the mutation of NIH3T3 cells%大肠癌线粒体DNA诱导NIH3T3细胞D-环突变

    Institute of Scientific and Technical Information of China (English)

    姬宏莉; 姬宏娟; 宋卫兵; 马永全; 杜芳; 王辉; 肖冰

    2011-01-01

    Objective To investigate the mtDNA mutation in NIH3T3 cell, which was transfected with mutated mtDNA from colorectal cancer cell line. Methods Recombinant eukaryotic vector, expressing plasmid of the mutated mtDNA, was transfected into NIH3T3 cell using Lipofection 2000 TM and screened by G418. The mutated mtDNA of transfected NIH3T3 cell was detected by PCR. Results Mutation and polymorphism was observed in NIH3T3 cell transfected with mutated mtDNA. Conclusion MtDNA mutations in colorectal cancer cell affects NIH3T3 cell mtDNA loci, though further study is required.%目的 观察突变的大肠癌细胞线粒体DNA(mtDNA)转染 NIH3T3 细胞后转染细胞mtDNA D-环突变特性.方法 通过脂质体法(Lipofection 2000TM) 将大肠癌细胞突变的 mtDNA 真核表达载体转染 NIH3T3细胞,利用 G418 抗性筛选克隆细胞;用PCR法检测转染细胞线粒体突变情况.结果 突变mtDNA 导致转染细胞 mtDNA 的突变和多态性变化.结论 突变的大肠癌 mtDNA可致NIH3T3细胞mtDNA位点变化,但具体的机制和过程有待于进一步研究.

  11. Videos from the National Eye Institute: Eye Diseases | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Feature: Vision Videos from the National Eye Institute: Eye Diseases Past Issues / Winter 2012 Table of Contents Watch ... comprehensive dilated exams in the early detection of eye disease. Share these videos with friends, family and colleagues. ...

  12. Single Institution Feasibility Trials - Cancer Imaging Program

    Science.gov (United States)

    Within the CIP program, the current R21 mechanism provides potential funding for small, single institution feasibility trials. The current announcement is titled In Vivo Cancer Imaging Exploratory/Developmental Grants.

  13. 78 FR 27977 - Office of Biotechnology Activities; Recombinant DNA Research: Proposed Actions Under the NIH...

    Science.gov (United States)

    2013-05-13

    ... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... Acid Molecules (NIH Guidelines) SUMMARY: The NIH Office of Biotechnology Activities (NIH OBA) proposes... by mail to the NIH Office of Biotechnology Activities, National Institutes of Health, 6705...

  14. 78 FR 20118 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-04-03

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Biology and Therapy. Date: April 17... Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  15. 78 FR 25459 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-05-01

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Therapy (Omnibus). Date: June 27-28....395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  16. 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research | Division of Cancer Prevention

    Science.gov (United States)

    The NIH Pain Consortium will convene the 11th Annual NIH Pain Consortium Symposium on Advances in Pain Research, featuring keynote speakers and expert panel sessions on Innovative Models and Methods. The first keynote address will be delivered by David J. Clark, MD, PhD, Stanford University entitled “Challenges of Translational Pain Research: What Makes a Good Model?” |

  17. Reducing cancer health disparities: Perspective of the National Cancer Institute

    OpenAIRE

    Chu, Kenneth C.; Hubbell, F. Allan

    2008-01-01

    The National Cancer Institute created the Special Population Network (SPN) to develop cancer awareness, research and training with partnerships from community and research organizations. This paper provides background information about the Pacific Islander Cancer Control Network, one of the SPNs, and about the seven research projects that are described in this Supplement.

  18. Breast Cancer: Surgery at the South Egypt Cancer Institute

    OpenAIRE

    Salem, Ahmed A.S.; Mohamed Abou Elmagd Salem; Hamza Abbass

    2010-01-01

    Breast cancer is the most frequent malignant tumor in women worldwide. In Egypt, it is the most common cancer among women, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men) among the Egypt National Cancer Institute’s (NCI) series of 10,556 patients during the year 2001, with an age-adjusted rate of 49.6 per 100,000 people. In this study, the data of all breast cancer patients presented to the surgical department of the South Egypt cancer Institute (SECI) hospital durin...

  19. 77 FR 67015 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-11-08

    ... Committee: National Cancer Institute Special Emphasis Panel NCI Omnibus and Cancer Therapy. Date: November... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  20. 78 FR 8157 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-05

    ... Committee: National Cancer Institute Special Emphasis Panel; Provocative Questions: Cancer Therapy and... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  1. 78 FR 36200 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-17

    ... Committee: National Cancer Institute Special Emphasis Panel; Cancer Biology and Therapy. Date: June 24, 2013... Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  2. 78 FR 59362 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-26

    ... Committee: National Cancer Institute Special Emphasis Panel Provocative Questions--Group D: Cancer Therapy... Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  3. 76 FR 50487 - National Cancer Institute Notice of Closed Meetings

    Science.gov (United States)

    2011-08-15

    ... Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE in Childhood ALL, Skin, Brain, Lung....395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute Notice of Closed...

  4. NIH Study Finds Regular Aspirin Use May Reduce Ovarian Cancer Risk

    Science.gov (United States)

    ... NIGMS NIMH NIMHD NINDS NINR NLM CC CIT CSR FIC NCATS NCCIH OD About NIH Who We ... limited treatment options and poor prognoses, making preventive strategies potentially important for controlling this disease. Chronic or ...

  5. 76 FR 576 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-01-05

    ...-Therapy Breast Cancer Patients. Date: March 3, 2011. Time: 12 p.m. to 5 p.m. Agenda: To review and....395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  6. 78 FR 27408 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-10

    ... Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients. Date: June 4, 2013... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  7. 78 FR 58321 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-23

    ... Emphasis Panel, Provocative Questions: Cancer Therapy & Outcomes. Date: November 7-8, 2013. Time: 8:00 a.m..., Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  8. 75 FR 21002 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-04-22

    ...; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer... Panel, SPORE in Lymphoma and Breast Cancer. Date: June 15-16, 2010. Time: 5 p.m. to 5 p.m. Agenda: To... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  9. 75 FR 3239 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-01-20

    ... Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research... Special Emphasis Panel, Basal-like Breast Cancer Assay. Date: March 10, 2010. Time: 8 a.m. to 7 p.m... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  10. Institutional shared resources and translational cancer research.

    Science.gov (United States)

    De Paoli, Paolo

    2009-01-01

    The development and maintenance of adequate shared infrastructures is considered a major goal for academic centers promoting translational research programs. Among infrastructures favoring translational research, centralized facilities characterized by shared, multidisciplinary use of expensive laboratory instrumentation, or by complex computer hardware and software and/or by high professional skills are necessary to maintain or improve institutional scientific competitiveness. The success or failure of a shared resource program also depends on the choice of appropriate institutional policies and requires an effective institutional governance regarding decisions on staffing, existence and composition of advisory committees, policies and of defined mechanisms of reporting, budgeting and financial support of each resource. Shared Resources represent a widely diffused model to sustain cancer research; in fact, web sites from an impressive number of research Institutes and Universities in the U.S. contain pages dedicated to the SR that have been established in each Center, making a complete view of the situation impossible. However, a nation-wide overview of how Cancer Centers develop SR programs is available on the web site for NCI-designated Cancer Centers in the U.S., while in Europe, information is available for individual Cancer centers. This article will briefly summarize the institutional policies, the organizational needs, the characteristics, scientific aims, and future developments of SRs necessary to develop effective translational research programs in oncology.In fact, the physical build-up of SRs per se is not sufficient for the successful translation of biomedical research. Appropriate policies to improve the academic culture in collaboration, the availability of educational programs for translational investigators, the existence of administrative facilitations for translational research and an efficient organization supporting clinical trial recruitment

  11. Institutional shared resources and translational cancer research

    Directory of Open Access Journals (Sweden)

    De Paoli Paolo

    2009-06-01

    Full Text Available Abstract The development and maintenance of adequate shared infrastructures is considered a major goal for academic centers promoting translational research programs. Among infrastructures favoring translational research, centralized facilities characterized by shared, multidisciplinary use of expensive laboratory instrumentation, or by complex computer hardware and software and/or by high professional skills are necessary to maintain or improve institutional scientific competitiveness. The success or failure of a shared resource program also depends on the choice of appropriate institutional policies and requires an effective institutional governance regarding decisions on staffing, existence and composition of advisory committees, policies and of defined mechanisms of reporting, budgeting and financial support of each resource. Shared Resources represent a widely diffused model to sustain cancer research; in fact, web sites from an impressive number of research Institutes and Universities in the U.S. contain pages dedicated to the SR that have been established in each Center, making a complete view of the situation impossible. However, a nation-wide overview of how Cancer Centers develop SR programs is available on the web site for NCI-designated Cancer Centers in the U.S., while in Europe, information is available for individual Cancer centers. This article will briefly summarize the institutional policies, the organizational needs, the characteristics, scientific aims, and future developments of SRs necessary to develop effective translational research programs in oncology. In fact, the physical build-up of SRs per se is not sufficient for the successful translation of biomedical research. Appropriate policies to improve the academic culture in collaboration, the availability of educational programs for translational investigators, the existence of administrative facilitations for translational research and an efficient organization

  12. Cancer Survivor Eric Dishman Is On a Precision Medicine Mission | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... 19. That was the power of precision medicine.” PMI Cohort Program The PMI Cohort Program seeks to extend precision medicine to ... Thought Leader In naming Dishman director of the PMI Cohort Program, NIH Director Collins noted Dishman’s unique ...

  13. Prostate Cancer: Symptoms, Diagnosis and Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn Javascript on. Feature: Prostate Cancer Prostate Cancer: Symptoms, Diagnosis and Treatment Past Issues / Winter 2010 ... only way to confirm a diagnosis of prostate cancer. Treatment Prostate cancer treatment depends on how serious the cancer ...

  14. Lung Cancer:Symptoms, Diagnosis, Treatments & Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Lung Cancer: Symptoms, Diagnosis, Treatments & Research Past Issues / Winter 2013 ... lung cancer are given intravenously or by mouth. Lung Cancer Research The large-scale National Lung Screening Trial, ...

  15. Lung Cancer, Questions to Ask Your Health Professional | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Questions to Ask Your Health Professional Past Issues / ... answer questions about cancer at 1-800-4-CANCER. The NCI Lung Cancer Home Page provides up-to-date information ...

  16. Lung Cancer:Symptoms, Diagnosis, Treatments & Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn Javascript on. Feature: Lung Cancer Lung Cancer: Symptoms, Diagnosis, Treatments & Research Past Issues / Winter 2013 ... lung cancer are given intravenously or by mouth. Lung Cancer Research The large-scale National Lung Screening Trial, ...

  17. Lung Cancer, Questions to Ask Your Health Professional | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Questions to Ask Your Health Professional Past Issues / ... 2013 Table of Contents Tests What type of lung cancer do I have? Has the cancer spread from ...

  18. Breast Cancer Basics and You: Introduction | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Introduction Past Issues / Spring - Summer ... were more than 194,000 new cases of breast cancer in the United States in 2009. More than ...

  19. Breast Cancer Basics and You: Staging and Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Staging and Treatment Past Issues / ... Table of Contents Staging The extent (stage) of breast cancer needs to be determined to help choose the ...

  20. NIH Scientists Map Genetic Changes That Drive Tumors in a Common Pediatric Soft-Tissue Cancer

    Science.gov (United States)

    ... content 1-800-4-CANCER Live Chat Publications Dictionary Menu Contact Dictionary Search About Cancer Causes and Prevention Risk Factors ... Contacts Other Funding Find NCI funding for small business innovation, technology transfer, and contracts Training Cancer Training ...

  1. Breast Cancer Basics and You: Detection and Diagnosis | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Breast Cancer Breast Cancer Basics and You: Detection and Diagnosis Past Issues / ... regular clinical breast exams and mammograms to find breast cancer early, when treatment is more likely to work ...

  2. Smoking and Lung Cancer: It's Never Too Late To Quit | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn Javascript on. Feature: Lung Cancer Smoking and Lung Cancer: It's Never Too Late to ... getting another cancer. To get help with quitting smoking... Go online to www.smokefree.gov. (See this ...

  3. Skin Cancer Can Strike Anyone | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Skin Cancer Skin Cancer Can Strike Anyone Past Issues / Summer 2013 Table ... removed. That is the most common form of skin cancer and not as dangerous as melanoma. Photo: Corbis ...

  4. Skin Cancer Can Strike Anyone | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Skin Cancer Skin Cancer Can Strike Anyone Past Issues / Summer 2013 ... removed. That is the most common form of skin cancer and not as dangerous as melanoma. Photo: ...

  5. 78 FR 50064 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2013-08-16

    ...: 8:30 a.m. to 3:30 p.m. Agenda: Cancer Communication for Prevention: In the Digital Commons... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to... a meeting of the President's Cancer Panel. The meeting will be open to the public, with...

  6. 78 FR 69432 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2013-11-19

    ...:30 a.m. to 4:00 p.m. Agenda: Cancer Communication in the Digital Era: Opportunities and Challenges... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to... a meeting of the President's Cancer Panel. The meeting will be open to the public, with...

  7. 78 FR 53154 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-08-28

    ... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93... Emphasis Panel NCI Experimental Therapeutics--Clinical Trials Network with Phase 1 Emphasis. Date: November... HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed...

  8. Nutritional profile of pediatric cancer patients at Cancer Institute, Chennai

    Directory of Open Access Journals (Sweden)

    V Radhakrishnan

    2015-01-01

    Full Text Available Background: Malnutrition is widely prevalent in the pediatric population in India. There is paucity of data on the prevalence of malnutrition in pediatric cancer patients and the impact of cancer treatment on nutritional status of Indian children. Aims: The study was conducted to look at the prevalence of malnutrition and assess the impact of treatment on nutritional status of pediatric cancer patients. Settings And Design: This was a retrospective study. Materials And Methods: Data on the weight of pediatric cancer patients <16 years of age treated at Cancer Institute, Chennai, from January 2013 to May 2014 were analyzed at systematic time points in therapy. Patients' weight were plotted on the Centre for Disease Control (CDC growth charts. Patients were defined to be undernourished if their weight for age was ≤3rd centile in CDC growth charts and obese if their weight for age was ≥97th centile on CDC growth charts. RESULTS: A total of 295 patient case records were analyzed. Acute lymphoblastic leukemia was the most common malignancy. At diagnosis, under-nutrition was seen in 44% patients, this increased to 46% midway during treatment (end of induction in acute leukemia and completion of 50% of planned treatment in solid tumors and decreased to 27% at the end of treatment (beginning of maintenance in acute leukemia and completion of planned treatment in solid tumors (P = 0.0005. There was no significant difference in nutritional status between patients with hematological malignancies and solid tumors (P = 0.8. Conclusion: Under-nutrition is present in close to half of the pediatric cancer patients presenting to our institute. Active nutritional intervention and education were able to significantly reduce the prevalence of under-nutrition in patients at the end of treatment.

  9. Lung Cancer: Early Detection is the Key | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Lung Cancer Early Detection is the Key Past Issues / Winter 2013 Table of Contents Lung cancer survivor Dusty Donaldson helps to spread the word ...

  10. Breast Cancer:Detection and Diagnosis | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Screening For Breast Cancer Detection and Diagnosis Past Issues / Summer 2014 Table ... States Preventive Services Task Force updated recommendations on breast cancer screening, suggesting that women ages 50 to 74 ...

  11. Breast Cancer: Staging and Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Screening For Breast Cancer Staging and Treatment Past Issues / Summer 2014 Table of Contents Staging The extent (stage) of breast cancer needs to be determined to help choose the ...

  12. Skin Cancer: Biology, Risk Factors & Treatment | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Skin Cancer Skin Cancer: Biology, Risk Factors & Treatment Past Issues / Summer ... that make up tissues. Tissues make up the skin and other organs of the body. Normal cells ...

  13. Breast Cancer Basics and You | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Screening For Breast Cancer Breast Cancer Basics and You Past Issues / Summer 2014 Table ... more than 232,670 new cases of female breast cancer in the United States in 2014. More than ...

  14. 78 FR 36201 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-06-17

    ... new diagnostics for cancer. Place: National Cancer Institute, 9609 Medical Center Drive, Room 2W908... meeting is to evaluate requests for development resources for potential new cancer diagnostics. The... of the potential diagnostics to improve the treatment of cancer. The research proposals and...

  15. 77 FR 54584 - Final Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH...

    Science.gov (United States)

    2012-09-05

    ... HUMAN SERVICES National Institutes of Health Final Action Under the NIH Guidelines for Research... in the Federal Register (74 FR 9411) to revise the NIH Guidelines in two regards. The first was to..., NIH/OBA revised the proposal and published a notice for comment on April 22, 2010 (75 FR...

  16. NIH Precision Medicine Initiative: Implications for Diabetes Research.

    Science.gov (United States)

    Fradkin, Judith E; Hanlon, Mary C; Rodgers, Griffin P

    2016-07-01

    In his January 2015 State of the Union address, President Barack Obama announced a new Precision Medicine Initiative (PMI) to personalize approaches toward improving health and treating disease (www.whitehouse.gov/precision-medicine). He stated that the goal of such an initiative was "to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier." Since that time, the National Institutes of Health (NIH) has taken a leadership role in implementing the President's vision related to biomedical research (www.nih.gov/precisionmedicine). Here, we discuss the NIH component of the PMI, related ongoing diabetes research, and near-term research that could position the diabetes field to take full advantage of the opportunities that stem from the PMI. PMID:27289128

  17. Lung Cancer: Early Detection is the Key | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Past Issues For an enhanced version of this page please turn Javascript on. Feature: Lung Cancer Early Detection is the Key Past Issues / Winter ... don't have to consider themselves doomed to lung cancer. They can have early detection, get treated early, and hopefully live a ... Volume 7 Number 4 Page 5

  18. Basic Science and The NIH

    OpenAIRE

    Varmus, Harold

    1994-01-01

    The following is an edited version of the Keynote Speech delivered at the Annual Meeting of the American Society for Cell Biology by Harold Varmus, Director of the National Institutes of Health. The address, entitled Basic Science and the NIH, was given at the opening of the meeting in New Orleans on December 11, 1993. It was Varmus' first public policy talk as NIH Director.

  19. Quiz: How much do you know about breast cancer? | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... are often painful are often visible to the naked eye don't cause any symptoms What percent ... answer. Breast cancer is more common among older women than younger women. C is the correct answer. ...

  20. NIH study finds high cancer risk for U.S. organ transplant recipients

    Science.gov (United States)

    Organ transplant recipients in the United States have a high risk of developing 32 different types of cancer, according to a new study of transplant recipients which fully describes the range of malignancies that occur.

  1. 75 FR 16488 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-01

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  2. 75 FR 60132 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-09-29

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  3. 76 FR 42719 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-07-19

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics...

  4. 77 FR 43098 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-07-23

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  5. 76 FR 10381 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-02-24

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  6. 77 FR 15782 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2012-03-16

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research.... ] Name of Committee: National Cancer Institute Special Emphasis Panel NCI Experimental...

  7. 75 FR 33817 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-06-15

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel; NCI Experimental Therapeutics...

  8. 76 FR 66733 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-10-27

    ... the treatment of cancer. The outcome of the evaluation will provide information to internal NCI... development of the potential therapeutic to improve the treatment of various forms of cancer. The research... of Committee: National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics...

  9. Are meat and heme iron intake associated with pancreatic cancer? Results from the NIH-AARP diet and health cohort.

    Science.gov (United States)

    Taunk, Pulkit; Hecht, Eric; Stolzenberg-Solomon, Rachael

    2016-05-01

    Several studies on pancreatic cancer have reported significant positive associations for intake of red meat but null associations for heme iron. We assessed total, red, white and processed meat intake, meat cooking methods and doneness and heme iron and mutagen intake in relation to pancreatic cancer in the NIH-AARP Diet and Health Study cohort. A total of 322,846 participants (187,265 men and 135,581 women) successfully completed and returned the food frequency questionnaire between 1995 and 1996. After a mean follow-up of 9.2 years (up to 10.17 years), 1,417 individuals (895 men and 522 women) developed exocrine pancreatic cancer. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs), and trends were calculated using the median value of each quantile. Models incorporated age as the time metric and were adjusted for smoking history, body mass index, self-reported diabetes and energy-adjusted saturated fat. Pancreatic cancer risk significantly increased with intake of total meat (Q5 vs. Q1: HR = 1.20, 95% CI 1.02-1.42, p-trend = 0.03), red meat (HR = 1.22, 95% CI 1.01-1.48, p-trend = 0.02), high-temperature cooked meat (HR = 1.21, 95% CI 1.00-1.45, p-trend = 0.02), grilled/barbequed meat (HR = 1.24, 95% CI 1.03-1.50, p-trend = 0.007), well/very well done meat (HR = 1.32, 95% CI 1.10-1.58, p-trend = 0.005) and heme iron from red meat (Q4 vs. Q1: HR = 1.21, 95% CI 1.01-1.45, p-trend = 0.04). When stratified by sex, these associations remained significant in men but not women except for white meat intake in women (HR = 1.33, 95% CI 1.02-1.74, p-trend = 0.04). Additional studies should confirm our findings that consuming heme iron from red meat increases pancreatic cancer risk. PMID:26666579

  10. NIH MedlinePlus Advisory Group

    Science.gov (United States)

    ... nihadvisory.html National Institutes of Health MedlinePlus Advisory Group To use the sharing features on this page, please enable JavaScript. The NIH MedlinePlus Advisory Group fosters collaboration between Institutes to guide the general ...

  11. Meat Intake and Meat Preparation in Relation to Risk of Postmenopausal Breast Cancer in the NIH-AARP Diet and Health Study

    OpenAIRE

    Kabat, Geoffrey C; Cross, Amanda J; Park, Yikyung; Schatzkin, Arthur; Hollenbeck, Albert R; Rohan, Thomas E.; Sinha, Rashmi

    2009-01-01

    A number of studies have reported that intake of red meat or meat cooked at high temperatures is associated with increased risk of breast cancer, but other studies have shown no association. We assessed the association between meat, meat-cooking methods, meat-mutagen intake and postmenopausal breast cancer in the NIH-AARP Diet and Health Study cohort of 120,755 postmenopausal women who completed a food frequency questionnaire at baseline (1995-1996) as well as a detailed meat-cooking module w...

  12. NIH-supported trial drug shows benefit in children with previously treated cancers

    Science.gov (United States)

    Young patients with some types of advanced cancer, for whom standard treatment had failed, had their tumors disappear during treatment with a drug that both targets and blocks a protein associated with their disease. These findings are from a Phase I, mul

  13. Cell Biology and Cancer. Grades 9-12. NIH Curriculum Supplement Series.

    Science.gov (United States)

    Biological Sciences Curriculum Study, Colorado Springs.

    This curriculum supplement guide brings the latest medical discoveries to classrooms. This module focuses on the objectives of introducing students to major concepts related to the development of cancer and its impacts, and developing an understanding of the relationship between biomedical research and personal and public health. This module…

  14. NIH Peer Review

    Science.gov (United States)

    Vancea, Adrian; Chen, Mei-Ching; Chacko, George

    2015-01-01

    The National Institutes of Health (NIH) is the largest source of funding for biomedical research in the world. Funding decisions are made largely based on the outcome of a peer review process that is intended to provide a fair, equitable, timely, and unbiased review of the quality, scientific merit, and potential impact of the research. There have been concerns about the criteria reviewers are using, and recent changes in review procedures at the NIH now make it possible to conduct an analysis of how reviewers evaluate applications for funding. This study examined the criteria and overall impact scores recorded by assigned reviewers for R01 grant applications. The results suggest that all the scored review criteria, including innovation, are related to the overall impact score. Further, good scores are necessary on all five scored review criteria, not just the score for research methodology, in order to achieve a good overall impact score. PMID:27239158

  15. 76 FR 1625 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2011-01-11

    ... Committee: National Cancer Institute Initial Review Group; Subcommittee I--Career Development, Career Development. Date: February 22-23, 2011. Time: February 22, 2011, 8 a.m. to 6 p.m. Agenda: To review...

  16. 75 FR 48699 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-08-11

    ... Committee: National Cancer Institute Initial Review Group, Subcommittee I--Career Development, NCI-I Career Development. Date: September 21, 2010. Time: 8 a.m. to 6 p.m. Agenda: To review and evaluate...

  17. Dana-Farber Cancer Institute | Office of Cancer Genomics

    Science.gov (United States)

    Functional Annotation of Cancer Genomes Principal Investigator: William C. Hahn, M.D., Ph.D. The comprehensive characterization of cancer genomes has and will continue to provide an increasingly complete catalog of genetic alterations in specific cancers. However, most epithelial cancers harbor hundreds of genetic alterations as a consequence of genomic instability. Therefore, the functional consequences of the majority of mutations remain unclear.

  18. The association between selenium and other micronutrients and thyroid cancer incidence in the NIH-AARP Diet and Health Study.

    Directory of Open Access Journals (Sweden)

    Thomas J O'Grady

    Full Text Available BACKGROUND: Selenium is an essential trace element that is important for thyroid hormone metabolism and has antioxidant properties which protect the thyroid gland from oxidative stress. The association of selenium, as well as intake of other micronutrients, with thyroid cancer is unclear. METHODS: We evaluated associations of dietary selenium, beta-carotene, calcium, vitamin D, vitamin C, vitamin E, folate, magnesium, and zinc intake with thyroid cancer risk in the National Institutes of Health - American Association of Retired Persons Diet and Health Study, a large prospective cohort of 566,398 men and women aged 50-71 years in 1995-1996. Multivariable-adjusted Cox proportional hazards regression was used to examine associations between dietary intake of micronutrients, assessed using a food frequency questionnaire, and thyroid cancer cases, ascertained by linkage to state cancer registries and the National Death Index. RESULTS: With the exception of vitamin C, which was associated with an increased risk of thyroid cancer (HR(Q5 vs Q1, 1.34; 95% CI, 1.02-1.76; P(trend, <0.01, we observed no evidence of an association between quintile of selenium (HR(Q5 vs Q1, 1.23; 95% CI, 0.92-1.65; P(trend, 0.26 or other micronutrient intake and thyroid cancer. CONCLUSION: Our study does not suggest strong evidence for an association between dietary intake of selenium or other micronutrients and thyroid cancer risk. More studies are needed to clarify the role of selenium and other micronutrients in thyroid carcinogenesis.

  19. The Association between Selenium and Other Micronutrients and Thyroid Cancer Incidence in the NIH-AARP Diet and Health Study

    Science.gov (United States)

    O’Grady, Thomas J.; Kitahara, Cari M.; DiRienzo, A. Gregory; Gates, Margaret A.

    2014-01-01

    Background Selenium is an essential trace element that is important for thyroid hormone metabolism and has antioxidant properties which protect the thyroid gland from oxidative stress. The association of selenium, as well as intake of other micronutrients, with thyroid cancer is unclear. Methods We evaluated associations of dietary selenium, beta-carotene, calcium, vitamin D, vitamin C, vitamin E, folate, magnesium, and zinc intake with thyroid cancer risk in the National Institutes of Health – American Association of Retired Persons Diet and Health Study, a large prospective cohort of 566,398 men and women aged 50–71 years in 1995–1996. Multivariable-adjusted Cox proportional hazards regression was used to examine associations between dietary intake of micronutrients, assessed using a food frequency questionnaire, and thyroid cancer cases, ascertained by linkage to state cancer registries and the National Death Index. Results With the exception of vitamin C, which was associated with an increased risk of thyroid cancer (HRQ5 vs Q1, 1.34; 95% CI, 1.02–1.76; Ptrend, <0.01), we observed no evidence of an association between quintile of selenium (HRQ5 vs Q1, 1.23; 95% CI, 0.92–1.65; Ptrend, 0.26) or other micronutrient intake and thyroid cancer. Conclusion Our study does not suggest strong evidence for an association between dietary intake of selenium or other micronutrients and thyroid cancer risk. More studies are needed to clarify the role of selenium and other micronutrients in thyroid carcinogenesis. PMID:25329812

  20. Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-associated cancers: NIH-AARP study.

    Directory of Open Access Journals (Sweden)

    Fatma M Shebl

    Full Text Available BACKGROUND: Chronic inflammation has been linked to cancers, and use of non-steroidal anti-inflammatory drugs (NSAIDs has been associated with reduced risk of several cancers. To further refine the magnitude of NSAID-related associations, in particular for cancers related to inflammation, such as alcohol-, infection-, obesity-, and smoking-related cancers, as well as for less common cancers, we evaluated the use of NSAIDs and cancer risk in a very large cohort. We used propensity scores to account for potential selection bias and hypothesized that NSAID use is associated with decreased cancer incidence. METHODS: We conducted a prospective study among 314,522 participants in the NIH-AARP Diet and Health Study. Individuals who completed the lifestyle questionnaire, which included NSAID use, in 1996-1997 were followed through 2006. Information on cancer incidence was ascertained by linking to cancer registries and vital status databases. FINDINGS: During 2,715,994 person-years of follow-up (median 10.1 person-years, there were 51,894 incident cancers. Compared with non-users of NSAIDs, individuals who reported use in the 12 months prior to interview had a significantly lower risk of all inflammation-related cancer, alcohol-related, infection-related, obesity-related, and smoking-related cancers [hazard ratio (HR (95% CI 0.90 (0.87-0.93, 0.80 (0.74-0.85, 0.82 (0.78-0.87, 0.88 (0.84-0.92, and 0.88 (0.85-0.92 respectively]. CONCLUSIONS: After accounting for potential selection bias, our data showed an inverse association between NSAID use and alcohol-related, infection-related, obesity-related, and smoking-related cancers and support the hypothesis that inflammation is related to an increased risk of certain cancers.

  1. How to Write an NIH R13 Conference Grant Application

    Science.gov (United States)

    Sonis, Jeffrey H.; Triffleman, Elisa; King, Lynda; King, Daniel

    2009-01-01

    Objective: The purpose of this article is to provide recommendations for writing a successful R13 conference grant proposal for the National Institutes of Health (NIH). Methods: The authors reviewed successful NIH conference grant proposal abstracts. They also reflect on their own experience in writing an NIH conference grant proposal and…

  2. Commentary on "Reproductive factors and kidney cancer risk in 2 US cohort studies, 1993-2010." Karami S, Daugherty SE, Schonfeld SJ, Park Y, Hollenbeck AR, Grubb RL 3rd, Hofmann JN, Chow WH, Purdue MP, Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD. Am J Epidemiol 2013; 177(12):1368-77. [Epub 2013 Apr 26]. doi: 10.1093/aje/kws406.

    Science.gov (United States)

    Boorjian, Stephen

    2014-08-01

    Clinical and experimental findings suggest that female hormonal and reproductive factors could influence kidney cancer development. To evaluate this association, we conducted analyses in 2 large prospective cohorts (the National Institutes of Health-AARP Diet and Health Study (NIH-AARP), 1995-2006, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), 1993-2010). Cohort-specific and aggregated hazard ratios and 95% confidence intervals relating reproductive factors and kidney cancer risk were computed by Cox regression. The analysis included 792 incident kidney cancer cases among 283,952 postmenopausal women. Women who had undergone a hysterectomy were at a significantly elevated kidney cancer risk in both NIH-AARP (hazard ratio = 1.28, 95% confidence interval: 1.09, 1.50) and PLCO (hazard ratio = 1.41, 95% confidence interval: 1.06, 1.88). Similar results were observed for both cohorts after analyses were restricted to women who had undergone a hysterectomy with or without an oophorectomy. For the NIH-AARP cohort, an inverse association was observed with increasing age at menarche (P for trend= 0.02) and increasing years of oral contraceptive use (P for trend = 0.02). No clear evidence of an association with parity or other reproductive factors was found. Our results suggest that hysterectomy is associated with increased risk of kidney cancer. The observed associations with age at menarche and oral contraceptive use warrant further investigation. PMID:25087669

  3. Institutional shared resources and translational cancer research

    OpenAIRE

    De Paoli Paolo

    2009-01-01

    Abstract The development and maintenance of adequate shared infrastructures is considered a major goal for academic centers promoting translational research programs. Among infrastructures favoring translational research, centralized facilities characterized by shared, multidisciplinary use of expensive laboratory instrumentation, or by complex computer hardware and software and/or by high professional skills are necessary to maintain or improve institutional scientific competitiveness. The s...

  4. Survey of Community Engagement in NIH-Funded Research

    OpenAIRE

    Hood, Nancy E.; Brewer, Tracy; Jackson, Rebecca; Wewers, Mary Ellen

    2010-01-01

    Community engagement is an innovative and required component for Clinical and Translational Science Awards (CTSAs) funded by the National Institutes of Health (NIH). However, the extent of community engagement in NIH-funded research has not been previously examined. This study assessed baseline prevalence of community engagement activities among NIH-funded studies at a large Midwestern university with a CTSA. An online survey was e-mailed to principal investigators of recent NIH-funded studie...

  5. 78 FR 27974 - Proposed Collection; 60-Day Comment Request: National Cancer Institute (NCI) Alliance for...

    Science.gov (United States)

    2013-05-13

    ... Cancer Institute (NCI) Alliance for Nanotechnology in Cancer Platform Partnership Scientific Progress... Partnerships (CNPP) awarded by the National Cancer Institute (NCI). The CNPPs are part of the Alliance for... trans-Alliance collaboration, scientific milestones, progress towards clinical translation...

  6. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... you can visit the NIHSeniorHealth website. A new topic page, "Healthy Eyes," offers a variety of tips. For ... expect when you get there. The "Healthy Eyes" topic page was developed by NIH's National Eye Institute. The ...

  7. NIH/NSF accelerate biomedical research innovations

    Science.gov (United States)

    A collaboration between the National Science Foundation and the National Institutes of Health will give NIH-funded researchers training to help them evaluate their scientific discoveries for commercial potential, with the aim of accelerating biomedical in

  8. Licensing Opportunities for NIH, CDC & FDA Technologies

    Data.gov (United States)

    U.S. Department of Health & Human Services — This dataset represents all technologies available for licensing from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the...

  9. New Hires at the National Cancer Institute at Frederick | Poster

    Science.gov (United States)

    Fifty-one people joined the facility in November and December 2013. The National Cancer Institute welcomes… Emily Boward Emad Darvishi Shuo Gu Sanath Kumar Janaka Robert Kortum Yasmin Lachir Jinbian Liu Yang Liu Eric Ramirez Salazar Brett Shelley Li Xia Jaeho Yoon

  10. The Regina Elena National Cancer Institute process of accreditation according to the standards of the Organisation of European Cancer Institutes.

    Science.gov (United States)

    Canitano, Stefano; Di Turi, Annunziata; Caolo, Giuseppina; Pignatelli, Adriana C; Papa, Elena; Branca, Marta; Cerimele, Marina; De Maria, Ruggero

    2015-12-31

    The accreditation process is, on the one hand, a tool used to homogenize procedures, rendering comparable and standardized processes of care, and on the other, a methodology employed to develop a culture of quality improvement. Although not yet proven by evidence-based studies that health outcomes improve as a result of an accreditation to excellence, it is undeniable that better control of healthcare processes results in better quality and safety of diagnostic and therapeutic pathways. The Regina Elena National Cancer Institute underwent the accreditation process in accordance with the standards criteria set by the Organisation of European Cancer Institutes (OECI), and it has recently completed the process, acquiring its designation as a Comprehensive Cancer Center (CCC). This was an invaluable opportunity for the Regina Elena Institute to create a more cohesive environment, to widely establish a culture of quality, to implement an institutional information system, and to accelerate the process of patient involvement in strategic decisions. The steps of the process allowed us to evaluate the performance and the organization of the institute and put amendments in place designed to be adopted through 26 improvement actions. These actions regarded several aspects of the institute, including quality culture, information communication technology system, care, clinical trials unit, disease management team, nursing, and patient empowerment and involvement. Each area has a timeline. We chose to present the following 3 improvement actions: clinical trial center, computerized ambulatory medical record, and centrality of patient and humanization of clinical pathway. PMID:27096274

  11. Red and processed meat, nitrite, and heme iron intakes and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study.

    Science.gov (United States)

    Inoue-Choi, Maki; Sinha, Rashmi; Gierach, Gretchen L; Ward, Mary H

    2016-04-01

    Previous studies have shown inconsistent associations between red and processed meat intake and breast cancer risk. N-nitroso compounds and heme iron have been hypothesized as contributing factors. We followed 193,742 postmenopausal women in the NIH-AARP Diet and Health Study and identified 9,305 incident breast cancers (1995-2006). Dietary intake was assessed using a food frequency questionnaire at baseline. We adjusted daily intakes of meat, nitrite and heme iron for energy intake using the nutrient density method. We estimated multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) by quintiles of dietary exposures for all breast cancer, by stage (in-situ, localized, regional/distant) and by estrogen/progesterone receptor (ER/PR) status using Cox proportional hazards regression. Total red meat intake was positively associated with risk of regional/distant cancer (p-trend = 0.02). The risk was 25% higher in the highest vs. lowest intake quintile (95% CI = 1.03-1.52). Higher processed red meat intake (Q5 vs. Q1) was associated with 27% higher risk of localized breast cancer (95% CI = 1.01-1.27, p-trend = 0.03) and a 19% higher risk of regional/distant cancer (95% CI = 0.98-1.44, p-trend = 0.10). In addition, higher nitrite intake from processed red meat was positively associated with localized cancer (HR for Q5 vs. Q1 = 1.23, 95% CI = 1.09-1.39, p-trend red meat and processed meat may increase risk of postmenopausal breast cancer. Added nitrite and heme iron may partly contribute to these observed associations. PMID:26505173

  12. Gastrointestinal Tumor Board: An Evolving Experience in Tehran Cancer Institute

    Directory of Open Access Journals (Sweden)

    Peiman Haddad

    2013-04-01

    Full Text Available Gastrointestinal (GI cancers are a significant source of morbidity and mortality in Iran, with stomach adenocarcinoma as the most common cancer in men and the second common cancer in women. Also, some parts of Northern Iran have one of the highest incidences of esophageal cancer in the world. Multi-disciplinary organ-based joint clinics and tumor boards are a well-recognized necessity for modern treatment of cancer and are routinely utilized in developed countries, especially in major academic centres. But this concept is relatively new in developing countries, where cancer treatment centres are burdened by huge loads of patients and have to cope with a suboptimum availability of resources and facilities. Cancer Institute of Tehran University of Medical Sciences is the oldest and the only comprehensive cancer treatment centre in Iran, with a long tradition of a general tumor board for all cancers. But with the requirements of modern oncology, there has been a very welcome attention to sub-specialized organ-based tumor boards and joint clinics here in the past few years. Considering this, we started a multi-disciplinary tumor board for GI cancers in our institute in early 2010 as the first such endeavor here. We hereby review this 2-year evolving experience. The process of establishment of a GI tumor board, participations from different oncology disciplines and related specialties, the cancers presented and discussed in the 2 years of this tumor board, the general intents of treatment for the decisions made and the development of interest in this tumor board among the Tehran oncology community will be reviewed. The GI tumor board of Tehran Cancer Institute started its work in January 2010, with routine weekly sessions. A core group of 2 physicians from each surgical, radiation and medical oncology departments plus one gastroenterologist, GI pathologist and radiologist was formed, but participation from all interested physicians was encouraged. An

  13. Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study

    International Nuclear Information System (INIS)

    Despite strong evidence of an inverse association of physical activity with postmenopausal breast cancer risk, whether a certain intensity or time of life of physical activity is most effective for lowering breast cancer risk is not known. In 118,899 postmenopausal women in the prospective NIH-AARP Diet and Health Study, we examined the relations of light and moderate-to-vigorous intensity physical activity during four periods of life ('historical': ages 15-18, 19-29, 35-39 years; 'recent': past 10 years) to postmenopausal breast cancer risk. Physical activity was assessed by self-report at baseline, and 4287 incident breast cancers were identified over 6.6 years of follow-up. In age-adjusted and multivariate Cox regression models, >7 hours/week of moderate-to-vigorous activity during the past 10 years was associated with 16% reduced risk of postmenopausal breast cancer (RR:0.84; 95%CI:0.76,0.93) compared with inactivity. The association remained statistically significant after adjustment for BMI (RR:0.87; 95%CI:0.78,0.96). Neither moderate-to-vigorous activity during other periods of life nor light intensity activity during any period of life was related to breast cancer risk, and associations did not vary by tumor characteristics. A high level of recent, but not historical, physical activity of moderate-to-vigorous intensity is associated with reduced postmenopausal breast cancer risk. More precise recall of recent physical activity than activity in the distant past is one possible explanation for our findings

  14. NIH Quickfinder and NIH MedlinePlus Advisory Group - Summer 2009

    Science.gov (United States)

    ... Current Issue Past Issues NIH Quickfinder Past Issues / Summer 2009 Table of Contents For an enhanced version ... Institute of Arthritis and Musculoskeletal and Skin Diseases Summer 2009 Issue: Volume 4 Number 3 Page 29

  15. From the NIH Director: The Importance of Clinical Trials | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. From the NIH Director: The Importance of Clinical Trials Past Issues / Summer 2011 ... Francis S. Collins, M.D., Ph.D., Director of the National Institutes of Health, led the successful effort ...

  16. 75 FR 63494 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-10-15

    ... Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentations; Reports... entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will...

  17. New Cancer Prevention and Control Central Institutional Review Board Established | Division of Cancer Prevention

    Science.gov (United States)

    The NCI Central Institutional Review Board (CIRB) Initiative announced the establishment of the Cancer Prevention and Control (CPC) CIRB January 14, extending the benefits of centralized review to investigators participating in clinical trials sponsored by the Division of Cancer Prevention (DCP). |

  18. Understanding and Reducing Obstacles in a Collaboration between a Minority Institution and a Cancer Center

    OpenAIRE

    Thompson, Beti; O’Connell, Mary; Löest, Helena; Anderson, Jennifer; Westcott, Rick

    2013-01-01

    Reducing the cancer incidence and mortality rates of underserved populations will require multidisciplinary efforts involving teams of diverse investigators. We describe a collaborative program between a National Cancer Institute-designated cancer center and a minority-serving institution. The organizations worked together to discover institutional and cultural barriers and facilitators to productive collaboration.

  19. Epithelial ovarian cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study

    OpenAIRE

    Aschebrook-Kilfoy, Briseis; Ward, Mary H.; Gierach, Gretchen L; Schatzkin, Arthur; Hollenbeck, Albert R; Sinha, Rashmi; Cross, Amanda J

    2012-01-01

    Ovarian cancer is a leading cause of cancer death among women in the United States and it has the highest mortality rate of all gynecologic cancers. Internationally, there is a five-fold variation in incidence and mortality of ovarian cancer, which suggests a role for environmental factors, including diet. Nitrate and nitrite are found in various food items and they are precursors of N-nitroso compounds, which are known carcinogens in animal models. We evaluated dietary nitrate and nitrite in...

  20. Northeast Regional Cancer Institute's Cancer Surveillance and Risk Factor Program

    Energy Technology Data Exchange (ETDEWEB)

    Lesko, Samuel M.

    2007-07-31

    OBJECTIVES The Northeast Regional Cancer Institute is conducting a program of ongoing epidemiologic research to address cancer disparities in northeast Pennsylvania. Of particular concern are disparities in the incidence of, stage at diagnosis, and mortality from colorectal cancer. In northeast Pennsylvania, age-adjusted incidence and mortality rates for colorectal cancer are higher, and a significantly smaller proportion of new colorectal cancer cases are diagnosed with local stage disease than is observed in comparable national data. Further, estimates of the prevalence of colorectal cancer screening in northeast Pennsylvania are lower than the US average. The Northeast Regional Cancer Institute’s research program supports surveillance of common cancers, investigations of cancer risk factors and screening behaviors, and the development of resources to further cancer research in this community. This project has the following specific objectives: I. To conduct cancer surveillance in northeast Pennsylvania. a. To monitor incidence and mortality for all common cancers, and colorectal cancer, in particular, and b. To document changes in the stage at diagnosis of colorectal cancer in this high-risk, underserved community. II. To conduct a population-based study of cancer risk factors and screening behavior in a six county region of northeast Pennsylvania. a. To monitor and document changes in colorectal cancer screening rates, and b. To document the prevalence of cancer risk factors (especially factors that increase the risk of colorectal cancer) and to identify those risk factors that are unusually common in this community. APPROACH Cancer surveillance was conducted using data from the Northeast Regional Cancer Institute’s population-based Regional Cancer Registry, the Pennsylvania Cancer Registry, and NCI’s SEER program. For common cancers, incidence and mortality were examined by county within the region and compared to data for similar populations in the US

  1. Cooperative research and development opportunities with the National Cancer Institute

    Science.gov (United States)

    Sybert, Kathleen

    1991-01-01

    The Office of Technology Development (OTD) of the National Cancer Institute (NCI) is responsible for negotiating Cooperative Research and Development Agreements (CRADAs), whereby the knowledge resulting from NCI investigators' government-sponsored research is developed in collaboration with universities and/or industry into new products of importance for the diagnosis and treatment of cancer and acquired immunodeficiency syndrome (AIDS). The NCI has recently executed a unique 'clinical trials' CRADA and is developing a model agreement based upon it for the development and commercialization of products for the diagnosis and treatment of cancer and AIDS. NCI drug screening, preclinical testing, clinical trials, and AIDS program capabilities form the basis for this new technology development/technology transfer vehicle. NCI's extensive drug screening program and 'designer foods' program serve as potential sources of investigational new drugs (INDs) and cancer preventatives. Collaborations between NCI and pharmaceutical companies having the facilities, experience, and expertise necessary to develop INDs into approved drugs available to the public are being encouraged where the companies have proprietary rights to INDs, or where NCI has proprietary rights to INDs and invites companies to respond to a collaborator announcement published in the Federal Register. The joint efforts of the NCI and the chosen collaborator are designed to generate the data necessary to obtain pharmaceutic regulatory approval from the Food and Drug Administration (FDA) to market the drugs developed, and thereby make them available to health care providers for the diagnosis and treatment of cancer and AIDS.

  2. Virginia Tech receives NIH funds brucellosis research

    OpenAIRE

    Trulove, Susan

    2004-01-01

    Virginia Tech researchers from Virginia Bioinformatics Institute (VBI) and Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) have received $300,000 from the National Institutes of Health (NIH) to study brucellosis. Caused by Brucella bacteria, a potential bioterrorism agent, brucellosis is common to animals and some strains infect humans.

  3. Cancer Genome Anatomy Project | Office of Cancer Genomics

    Science.gov (United States)

    The National Cancer Institute (NCI) Cancer Genome Anatomy Project (CGAP) is an online resource designed to provide the research community access to biological tissue characterization data. Request a free copy of the CGAP Website Virtual Tour CD from ocg@mail.nih.gov.

  4. Cancer complementary and alternative medicine research at the US National Cancer Institute.

    Science.gov (United States)

    Jia, Libin

    2012-05-01

    The United States National Cancer Institute (NCI) supports complementary and alternative medicine (CAM) research which includes different methods and practices (such as nutrition therapies) and other medical systems (such as Chinese medicine). In recent years, NCI has spent around $120 million each year on various CAM-related research projects on cancer prevention, treatment, symptom/side effect management and epidemiology. The categories of CAM research involved include nutritional therapeutics, pharmacological and biological treatments, mind-body interventions, manipulative and body based methods, alternative medical systems, exercise therapies, spiritual therapies and energy therapies on a range of types of cancer. The NCI Office of Cancer Complementary and Alternative Medicine (OCCAM) supports various intramural and extramural cancer CAM research projects. Examples of these cancer CAM projects are presented and discussed. In addition, OCCAM also supports international research projects. PMID:22241505

  5. Implementation of NIH Inclusion Guidelines: Survey of NIH Study Section Members

    OpenAIRE

    Taylor, Holly A.

    2008-01-01

    In March of 1994, the National Institutes of Health (NIH) released guidelines mandating the inclusion of women and minorities in clinical research. Four years later, the NIH released similar guidelines mandating the inclusion of children. These “inclusion guidelines” were created to increase the representation of women, minorities and children in clinical research to address potential harms (real and perceived) created by their exclusion or omission. As designated in the guidelines, Instituti...

  6. Demographic pattern of male breast cancer: an institutional based study

    International Nuclear Information System (INIS)

    Background: Male breast cancer incidence rises with age with peak in the sixth and seventh decade. It is one of the rare diseases and accounts for less than 1% of all malignancies worldwide. It is usually diagnosed in the late stage with poor prognosis. Objective: The purpose of this study was to know the demographic pattern and tumour characteristic of breast cancer in men reported at Institute of Radiotherapy and Nuclear Medicine (IRNUM), Peshawar. Methods: Retrospective data was collected from the (IRNUM), Peshawar for a period of three years (2006-2008). The evaluation was done from the histopathological reports of mastectomy and biopsy specimens. All male patients in the age group 26 -86 year with breast cancer were included in the study. The age of the patients and tumour characteristics recorded were size, grade, type, skin involvement and stage. Results: Total number of male patients with breast cancer were 31 (2.1%) out of the total patients with breast malignancy during the study period with the mean age of 58.3 years. Tumour size ranged from 2 to 12 Cm. with average of 3.6 Cm. Invasive ductal carcinoma was found in 87% , papillary carcinoma in 6.5%, each of malignant fibrous histocytoma and sarcoma in 3.2% cases. Maximum number of patients was of grade II (41%). Patients in whom stage of the disease was know n were 22 cases with 45.5% had stage III disease and 32% had stage IV disease. Skin involvement was found positive in 8 (25.8%). Conclusion: Due to poor health care system breast cancer is diagnosed in a late stage of the disease and prognosis is poor. (author)

  7. 75 FR 51830 - National Cancer Institute's Best Practices for Biospecimen Resources

    Science.gov (United States)

    2010-08-23

    ... HUMAN SERVICES National Institutes of Health National Cancer Institute's Best Practices for Biospecimen... best practices, the National Cancer Institute (NCI) is seeking public comment on a revised version of the NCI Best Practices for Biospecimen Resources. This revised version of the NCI Best Practices...

  8. CPTAC Establishes Formal Relationships with Two Academic Institutions in Taiwan - Office of Cancer Clinical Proteomics Research

    Science.gov (United States)

    The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) has entered into memorandum of understandings (MOUs) with Chang Gung University and Academia Sinica, in Taipei, Taiwan.

  9. NIH Clinical Centers

    Data.gov (United States)

    Federal Laboratory Consortium — The NIH Clinical Center consists of two main facilities: The Mark O. Hatfield Clinical Research Center, which opened in 2005, houses inpatient units, day hospitals,...

  10. NIH Data Sharing Repositories

    Data.gov (United States)

    U.S. Department of Health & Human Services — A list of NIH-supported repositories that accept submissions of appropriate scientific research data from biomedical researchers. It includes resources that...

  11. HealthLines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... exams. The National Eye Institute supported the study. Depression High For Victims of Cyberbullying Young people who ... at http://www.nih.gov/Subscriptions.htm . Newsletters Facebook pages Twitter feeds YouTube channels Podcasts Vodcasts (video ...

  12. Cooperative Research and Development Agreement (CRADA) Opportunities from NIH

    Data.gov (United States)

    U.S. Department of Health & Human Services — This RSS Feed represents all Collaborative Research and Development (CRADA) opportunities available from the National Institutes of Health (NIH).The intent of...

  13. The national cancer institute (NCI) and cancer biology in a 'post genome world'

    International Nuclear Information System (INIS)

    The National Cancer Institute (NCI) exists to reduce the burden of all cancers through research and discovery. Extensive restructuring of the NCI over the past year has been aimed at assuring that the institution functions in all ways to promote opportunities for discovery in the laboratory, in the clinic, and in the community. To do this well requires the difficult and almost paradoxical problem of planning for scientific discovery which, in turn is based on the freedom to pursue the unanticipated. The intellectual and structural landscape of science is changing and it places new challenges, new demands and new opportunities for facilitating discovery. The nature of cancer as a disease of genomic instability and of accumulated genetic change, coupled with a possibility of the development of new technologies for reading, utilizing, interpreting and manipulating the genome of single cells, provides unprecedented opportunities for a new type of high through-put biology that will change the nature of discovery, cancer detection, diagnosis, prognosis, therapeutic decision-making and therapeutic discovery. To capture these new opportunities will require attention to be paid to integrate the development of technology and new scientific discoveries with the ability to apply advances rapidly and efficiently through clinical trials

  14. 75 FR 15710 - Submission for OMB Review; Comment Request; Process Evaluation of the NIH's Roadmap...

    Science.gov (United States)

    2010-03-30

    ... control number. Proposed Collection: The National Institute of Dental and Craniofacial Research of the National Institutes of Heath requests a two-year clearance for Title: ``Process Evaluation of the NIH... Institute of Dental and Craniofacial Research (NIDCR), NIH. You may reach Dr. Hamann by telephone on...

  15. 75 FR 992 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-01-07

    ... personal privacy. Name of Committee: National Cancer Advisory Board; Ad Hoc Subcommittee on Experimental Therapeutics. Open: February 8, 2010, 6:30 p.m. to 8 p.m. Agenda: Discussion on cancer experimental... Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research;...

  16. Contact | Office of Cancer Genomics

    Science.gov (United States)

    For more information about the Office of Cancer Genomics, please contact: Office of Cancer Genomics National Cancer Institute 31 Center Drive, 10A07 Bethesda, Maryland 20892-2580 Phone: (301) 451-8027 Fax: (301) 480-4368 Email: ocg@mail.nih.gov *Please note that this site will not function properly in Internet Explorer unless you completely turn off the Compatibility View*

  17. 78 FR 28235 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-14

    ... Toolkit for Cancer Diagnosis, Staging, and Treatment. Date: May 29, 2013. Time: 12:00 p.m. to 2:00 p.m... Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research... Diagnostic Assay to Detect Basal- like Breast Cancer. Date: June 13, 2013. Time: 12:00 p.m. to 1:00...

  18. ISS-NIH Collaborative Programme: final report of the projects

    International Nuclear Information System (INIS)

    In July 2003, the National Institutes of Health (NIH) of the United States of America and the Istituto Superiore di Sanita (ISS) of Italy signed an agreement aimed at strengthening the ongoing research cooperation between USA and Italy. Over the years, the programme was able to create new partnerships and to foster the establishment of innovative synergies, the exchange of young researcher, and the merging of the best available skills, talents and know-how in different fields of biomedical sciences. This book contains the final report of the projects of the scientific cooperation between the two Countries. The report consists of two parts (in Italian and English) divided into four sections: Cancer, Neuroscience, Cardiovascular diseases, Infectious diseases

  19. Prevalence of bone marrow necrosis in Egyptian cancer patients referring to the National Cancer Institute

    International Nuclear Information System (INIS)

    Bone marrow necrosis; Egyptian cancer patients Abstract Background: Bone marrow necrosis is a relatively rare entity which has been associated with a poor prognosis. It is most commonly found in patients with neoplastic disorders and severe infections. Methods: study comprised examination of 5043 bone marrow biopsy specimens performed at the National Cancer Institute, Cairo University, over 7 years period (March 2004-March 2011). It included 5 years retrospective (2867 archived samples) and 2 years prospective (2176 samples). Results: Bone marrow necrosis was diagnosed in fifteen out of 5043 examined specimens with a percentage of 0.3% and ranged from mild to massive according to semiquantitative estimation. Prognosis of all patients was poor with survival not exceeding 6 months from the date of marrow necrosis diagnosis. Conclusion: In Egyptian patients, bone marrow necrosis in association with malignancy is a rare disorder which is accompanied by a poor outcome

  20. Clinicopathological Characteristics of Colon Cancer Diagnosed at Primary Health Care Institutions

    OpenAIRE

    Park, Sang Hyun; Song, Chi Wook; Kim, Yun Bae; Kim, Young Sun; Chun, Hwang Rae; Lee, Jung Hyun; Seol, Won Jong; Yoon, Hyung Sun; Lee, Myung Kwon; Lee, Jong Hyup; Bhang, Choon Sang; Park, Jae Hyung; Park, Ji Young; Do, Byung Hun; Park, Young Dae

    2014-01-01

    Background/Aims The purpose of this study was to evaluate the clinicopathologic characteristics of colon cancers detected at the SOK Sokpeynhan Internal Medical Network, a nationwide system of primary health care institutions. Methods We analyzed 579 colon cancer patients diagnosed using colonoscopy at the SOK network from January 2011 through December 2012. Cancers from the rectum to the splenic flexure were classified as left colon cancer. Patients over 65 were classified as senior. Results...

  1. 75 FR 26267 - National Cancer Institute; Notice of Meeting

    Science.gov (United States)

    2010-05-11

    ... personal privacy. Name of Committee: National Cancer Advisory Board Ad hoc Subcommittee on Experimental Therapeutics. Open: June 21, 2010, 6:30 p.m. to 8 p.m. Agenda: Discussion on Experimental Therapeutics. Place... Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research;...

  2. NIH Research to Results

    Science.gov (United States)

    ... Home Current Issue Past Issues Cover Story: Traumatic Brain Injury NIH Research to Results Past Issues / Fall 2008 Table of ... of stem cells to repair or replace damaged brain tissue is also a new avenue of research. Another important area of research involves the development ...

  3. Cancer in human immunodeficiency virus-infected children : A case series from the Children's Cancer Group and the National Cancer Institute

    NARCIS (Netherlands)

    Granovsky, MO; Mueller, BU; Nicholson, HS; Rosenberg, PS; Rabkin, CS

    1998-01-01

    Purpose: To describe the spectrum of malignancies in human immunodeficiency virus (HIV)-infected children and the clinical outcome of patients with these tumors. Methods: We retrospectively surveyed the Children's Cancer Group (CCG) and the National Cancer institute (NCI) for cases of cancer that oc

  4. Adherence to the World Cancer Research Fund/American Institute for Cancer Research lifestyle recommendations in colorectal cancer survivors : Results of the PROFILES registry

    NARCIS (Netherlands)

    Winkels, Renate M; van Lee, Linde; Beijer, Sandra; Bours, Martijn J; van Duijnhoven, Fränzel J B; Geelen, Anouk; Hoedjes, Meeke; Mols, F.; de Vries, Jeanne; Weijenberg, Matty P; Kampman, Ellen

    2016-01-01

    We examined adherence to the eight The World Cancer Research Foundation/American Institute for Cancer Research (WCRF/AICR) recommendations on diet, physical activity, and body weight among colorectal cancer survivors, and whether adherence was associated with intention to eat healthy and with the ne

  5. 77 FR 51032 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-08-23

    ... patentable material, and personal information concerning individuals associated with the grant applications... & Conference Center 5701 Marinelli Road Bethesda, MD 20852. Contact Person: Jeannette F. Korczak, Ph.D... Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394,...

  6. 77 FR 29674 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-05-18

    ... property such as patentable material, and personal information concerning individuals associated with the... evaluate grant applications. Place: Bethesda North Marriott Hotel Conference & Center, 5701 Marinelli Road.... (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause...

  7. 77 FR 56215 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-12

    ... patentable material, and personal information concerning individuals associated with the grant applications.... Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852... Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and...

  8. 76 FR 64090 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2011-10-17

    ... commercial property such as patentable material, and personal information concerning individuals associated... Conference & Center Hotel, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Clifford W Schweinfest... Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394,...

  9. 75 FR 66770 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2010-10-29

    ... patentable material, and personal information concerning individuals associated with the grant applications... applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852... Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394,...

  10. 78 FR 66373 - National Cancer Institute; Notice of Closed Meeting

    Science.gov (United States)

    2013-11-05

    ... new diagnostics for cancer. Place: NCI Shady Grove, 9609 Medical Center Drive, Room 3W030, Rockville... diagnostics. The outcome of the evaluation will be information for consideration by an internal NCI committee... development of the potential diagnostics to improve the treatment of cancer. The research proposals and...

  11. A clinicoepidemiological study of esophageal cancer patients at the National Cancer Institute, Cairo University, Egypt

    Institute of Scientific and Technical Information of China (English)

    Soumaya Ezzat; Hisham El Hossieny; Mohamed Abd Alla; Azza Nasr; Nagwan Anter; Ahmed Adel

    2016-01-01

    Objective The purposes of this study were to (1) assess the clinicoepidemiological characteristics of esopha-geal cancer patients, (2) analyze the prognostic factors determining treatment failure and survival, and (3) evaluate the results of various treatment modalities for locoregional and disseminated disease and their ef ect on disease-free survival and overal survival (OS). Methods Clinicoepidemiological retrospective data from 81 esophageal cancer patients treated at the Na-tional Cancer Institute of Cairo between 2007 and 2011 were evaluated. Results The study showed that patients with esophageal cancer commonly present with local y advanced disease (87.7% had T-stage 3 and 12.3% had T-stage 4). There was a significant correlation between surgery and survival; patients who received radical surgery and postoperative radiation had a better median survival than patients who received radical radiotherapy (20 months vs. 16 months, respectively; P = 0.04). There was also a significant statistical correlation between radical concomitant chemoradiotherapy (NCRT) and pal iative treatment. Patients who received radical NCRT had a better median survival than patients who received pal-liative radiotherapy (16 months vs. 10 months, respectively; P = 0.001). The median fol ow-up period for al patients was 7 months. The median OS of the whole group was 12 months. The OS after 1 and 2 years was 57.8% and 15%, respectively. Conclusion High-dose NCRT is an acceptable alternative for patients unfit for surgery or with inoperable disease. High-dose radiation is more ef ective than low-dose radiation in terms of local control, time to relapse, and OS. Further study using a larger series of patients and introducing new treatment protocols is necessary for a final evaluation.

  12. Learning about Prostate Cancer

    Science.gov (United States)

    ... of Information on Prostate Cancer What is prostate cancer? Prostate cancer is the most common cancer in American ... of page Additional Resources of Information on Prostate Cancer Prostate Cancer [nlm.nih.gov] From Medline Plus Medical ...

  13. Intake of Fruits and Vegetables, and Risk of Endometrial Cancer in Women in the NIH-AARP Diet and Health Study

    OpenAIRE

    Kabat, Geoffrey C; Park, Yikyung; Hollenbeck, Albert R.; Schatzkin, Arthur; Rohan, Thomas E.

    2010-01-01

    Fruits and vegetables contain a wide variety of phytochemicals which may have anti-carcinogenic effects. Although the results of case-control studies have suggested a possible protective effect of fruit and vegetable intake on the risk of endometrial carcinoma, few cohort studies have examined this association. We used data from the NIH-AARP Diet and Health Study to assess the association of fruit and vegetable consumption, as well as intake of specific botanical groupings of fruits and veget...

  14. 76 FR 44339 - Office of Biotechnology Activities; Recombinant DNA Research: Action Under the NIH Guidelines for...

    Science.gov (United States)

    2011-07-25

    ... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... Minor Action under the NIH Guidelines. SUMMARY: The Office of Biotechnology Activities (OBA) is updating... Biotechnology Activities, National Institutes of Health, 6705 Rockledge Drive, Suite 750, Bethesda,...

  15. NIH Exported Research Portfolio Online Reporting Tools: Expenditures and Results (ExPORTER)

    Data.gov (United States)

    National Institutes of Health, Department of Health and Human Services — Research projects funded by the National Institutes of Health (NIH), other DHHS Operating Divisions (AHRQ, CDC, FDA, HRSA, SAMHSA), and the Department of Veterans...

  16. 77 FR 12600 - National Cancer Institute; Notice of Closed Meetings

    Science.gov (United States)

    2012-03-01

    ...; Quantitative Imaging for Evaluation of Responses to Cancer Therapies. Date: March 8, 2012. Time: 1 p.m. to 5 p... Emphasis Panel Cancer Imaging. Date: March 6, 2012. Time: 11 a.m. to 3 p.m. Agenda: To review and evaluate... Phase IIB Bridge Awards. Date: March 20, 2012. Time: 11 a.m. to 4 p.m. Agenda: To review and...

  17. The National Cancer Institute's Physical Sciences - Oncology Network

    Science.gov (United States)

    Espey, Michael Graham

    In 2009, the NCI launched the Physical Sciences - Oncology Centers (PS-OC) initiative with 12 Centers (U54) funded through 2014. The current phase of the Program includes U54 funded Centers with the added feature of soliciting new Physical Science - Oncology Projects (PS-OP) U01 grant applications through 2017; see NCI PAR-15-021. The PS-OPs, individually and along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OCs), comprise the Physical Sciences-Oncology Network (PS-ON). The foundation of the Physical Sciences-Oncology initiative is a high-risk, high-reward program that promotes a `physical sciences perspective' of cancer and fosters the convergence of physical science and cancer research by forming transdisciplinary teams of physical scientists (e.g., physicists, mathematicians, chemists, engineers, computer scientists) and cancer researchers (e.g., cancer biologists, oncologists, pathologists) who work closely together to advance our understanding of cancer. The collaborative PS-ON structure catalyzes transformative science through increased exchange of people, ideas, and approaches. PS-ON resources are leveraged to fund Trans-Network pilot projects to enable synergy and cross-testing of experimental and/or theoretical concepts. This session will include a brief PS-ON overview followed by a strategic discussion with the APS community to exchange perspectives on the progression of trans-disciplinary physical sciences in cancer research.

  18. The relationship between National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI)and serum high sensitivity C-reactive protein (Hs-CRP) level in Fangchengang area male residents%广西防城港地区男性居民慢性前列腺炎症状指数和血清 Hs-CRP 的关系

    Institute of Scientific and Technical Information of China (English)

    牛得草; 米华; 陶佳意; 余小祥; 莫曾南

    2016-01-01

    目的:探讨广西防城港地区男性居民的美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)和血清超敏C 反应蛋白(Hs-CRP)水平的关系。方法对广西防城港地区男性居民进行大型横断面健康调查。采用标准设计生活方式的调查问卷采集试验数据,包括 NIH-CPSI 总评分、社会人口学资料、生活方式等基本信息。并采集静脉血标本进行 Hs-CRP 检测。根据 NIH-CPSI 评分将参与者分为前列腺炎样症状组和正常组。结果前列腺炎样症状患病率为6.69%。血清 Hs-CRP 水平在前列腺炎样症状组和正常组的均值分别是(1.38±2.78)mg/L 和(1.60±4.27)mg/L,差异无统计学意义。Logistic 回归模型提示血清 Hs-CRP 水平与前列腺炎样症状的发生、NIH-CPSI 评分中的疼痛评分和 CPSI 总评分无相关性。结论血清 Hs-CRP 与 CPSI 评分无关系。慢性前列腺炎的诊断和疗效评估应采用其它方法。%Objective To investigate the relationship between National Institute of Health Chronic Prosta-titis Symptom Index (NIH - CPSI)and serum high sensitivity C - reactive protein (Hs - CRP )level in Fangchengang area male residents. Methods A large cross sectional study was performed for Fangchengang area male residents.A standard questionnaire and basic data were collected including total score of NIH-CP-SI,demographic information and lifestyle risk factors.The vein blood was drawn to measure the serum Hs-CRP level.According to the NIH-CPSI score,the participants were divided into a prostatitis-like symptoms group and a healthy group. Results According to NIH-CPSI total score,the prevalence of prostatitis-like symptoms was 6.70%.The mean values of serum Hs-CRP were (1.38 ±2.78)mg/L and (1.604±4.274) mg/L in the prostatitis-like symptom group and the healthy group respectively,and there was no statistically significant difference.By applying Logistic regression model,we found that there was no significant

  19. NIH Health Disparities Strategic Plan, Fiscal Years 2004-2008

    Science.gov (United States)

    National Human Genome Research Institute, 2008

    2008-01-01

    The National Human Genome Research Institute (NHGRI) led the National Institutes of Health's (NIH) contribution to the International Human Genome Project, whose primary goal was the sequencing of the human genome. This project was successfully completed in April 2003. Now, the NHGRI's mission is focused on a broad range of studies aimed at…

  20. Validation of Cancer Institute Quality of Life Questionnaire Version II for cancer patients in India

    Directory of Open Access Journals (Sweden)

    E Vidhubala

    2011-01-01

    Full Text Available Background: The Quality of Life (QOL questionnaire version I consisted of 38 items that were validated using 392 patients. The experiences gained through the interaction with the patients during the administration of the questionnaire provided a lot of inputs for the improvization of the tool. Aim: The current study is aimed at certain modifications of the QOL questionnaire version I and standardization of the same. Materials and Methods: The modifications of version I QOL scale included the change of verbatim, splitting, deleting, and adding of new items. Finally, version II included 42 items. It was administered to 183 cancer patients irrespective of their demographic details for further standardization. Statistics: The principal component method with varimax rotation was used. Spearman′s product moment correlation and Cronbach′s alpha coefficient were used for reliability analysis. Results: The data were subjected to factor analysis to explore the factors. Eleven factors emerged with the eigenvalue ranging from 8.03 to 1.10 and accounted for 66.7% variance. The first factor contributed maximally, 19.5%, and the remaining 10 factors contributed a total of 46.2% variance on QOL. They are general well-being, physical well-being, psychological well-being, familial relationship, sexual and personal ability, cognitive well-being, optimism and belief, economical well-being, information support, patient-physician relationship, and body image. The Cronbach alpha of 0.90 and split-half reliability of 0.80 indicated a high reliability of the tool. Conclusion: The factor structure showed that QOL is a multidimensional concept having different aspects. The Cancer Institute QOL Questionnaire version II for cancer patients is found to be a valid and reliable tool and feasible to administer at the clinical settings.

  1. 76 FR 11801 - National Institute of Mental Health; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-03

    ... of Committee: National Institute of Mental Health Special Emphasis Panel; Behavioral Mechanisms In..., Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001..., National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6142, MSC...

  2. Treatment of Prostate Cancer using Anti-androgen Small Molecules | NCI Technology Transfer Center | TTC

    Science.gov (United States)

    The National Cancer Institute seeks parties interested in collaborative research to co-develop and commercialize a new class of small molecules for the treatment of prostate cancer. General information on co-development research collaborations, can be found on our web site (http://ttc.nci.nih.gov/forms).

  3. Gazelles, unicorns, and dragons battle cancer through the Nanotechnology Startup Challenge

    OpenAIRE

    Truman, Rosemarie; Locke, Cody J.

    2016-01-01

    On March 4th, 2016, Springer’s Cancer Nanotechnology office promoted the launch of the Nanotechnology Startup Challenge in Cancer (NSC 2 ). This innovation-development model is a partnership among our company, the Center for Advancing Innovation (CAI), MedImmune, the global biologics arm of AstraZeneca, and multiple institutes at the National Institutes of Health (NIH). NSC 2 “crowdsources” talent from around the world to launch startups with near-term, commercially viable cancer nanotechnolo...

  4. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... NIH researchers report promising results in prevention and treatment of Ebola virus disease (from left) NIH Director Dr. Francis Collins, NIAID Director Dr. Anthony Fauci, and NIH Clinical Center Director Dr. John Gallin exit the Clinical Center ...

  5. Challenges in DCIS Risk Communication and Decision-Making: Report from an American Cancer Society and National Cancer Institute Workshop

    OpenAIRE

    Partridge, Ann H.; Elmore, Joann G.; Saslow, Debbie; McCaskill-Stevens, Worta; Schnitt, Stuart J.

    2012-01-01

    In September 2010, the American Cancer Society and National Cancer Institute convened a conference to review current issues in DCIS risk communication and decision-making and to identify directions for future research. Specific topics included patient and healthcare provider knowledge and attitudes about DCIS and its treatment, how to explain DCIS to patients given the heterogeneity of the disease, consideration of nomenclature changes, and the utility of decision tools/aids. This report desc...

  6. Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study

    OpenAIRE

    Adela Castelló; Miguel Martín; Amparo Ruiz; Casas, Ana M.; Baena-Cañada, Jose M; Virginia Lope; Silvia Antolín; Pedro Sánchez; Manuel Ramos; Antonio Antón; Montserrat Muñoz; Begoña Bermejo; Ana De Juan-Ferré; Carlos Jara; José I Chacón

    2015-01-01

    Background According to the “World Cancer Research Fund” and the “American Institute of Cancer Research” (WCRF/AICR) one in four cancer cases could be prevented through a healthy diet, weight control and physical activity. Objective To explore the association between the WCRF/AICR recommendations and risk of breast cancer. Methods During the period 2006 to 2011 we recruited 973 incident cases of breast cancer and 973 controls from 17 Spanish Regions. We constructed a score based on 9 of the W...

  7. Intraoperative Radiotherapy for Parotid Cancer: A Single-Institution Experience

    International Nuclear Information System (INIS)

    Purpose: Our practice policy has been to provide intraoperative radiotherapy (IORT) at resection to patients with head-and-neck malignancies considered to be at high risk of recurrence. The purpose of the present study was to review our experience with the use of IORT for primary or recurrent cancer of the parotid gland. Methods and Materials: Between 1982 and 2007, 96 patients were treated with gross total resection and IORT for primary or recurrent cancer of the parotid gland. The median age was 62.9 years (range, 14.3–88.1). Of the 96 patients, 33 had previously undergone external beam radiotherapy as a component of definitive therapy. Also, 34 patients had positive margins after surgery, and 40 had perineural invasion. IORT was administered as a single fraction of 15 or 20 Gy with 4–6-MeV electrons. The median follow-up period was 5.6 years. Results: Only 1 patient experienced local recurrence, 19 developed regional recurrence, and 12 distant recurrence. The recurrence-free survival rate at 1, 3, and 5 years was 82.0%, 68.5%, and 65.2%, respectively. The 1-, 3-, and 5-year overall survival rate after surgery and IORT was 88.4%, 66.1%, and 56.2%, respectively. No perioperative fatalities occurred. Complications developed in 26 patients and included vascular complications in 7, trismus in 6, fistulas in 4, radiation osteonecrosis in 4, flap necrosis in 2, wound dehiscence in 2, and neuropathy in 1. Of these 26 patients, 12 had recurrent disease, and 8 had undergone external beam radiotherapy before IORT. Conclusions: IORT results in effective local disease control at acceptable levels of toxicity and should be considered for patients with primary or recurrent cancer of the parotid gland.

  8. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience

    Science.gov (United States)

    Coelho, Rafael Corrêa; Reinert, Tomás; Campos, Franz; Peixoto, Fábio Affonso; de Andrade, Carlos Augusto; Castro, Thalita; Herchenhorn, Daniel

    2016-01-01

    ABSTRACT Purpose: The aim of this study was to assess the impact of sunitinib treatment in a non-screened group of patients with metastatic renal cell cancer (mRCC) treated by the Brazilian Unified Health System (SUS) at a single reference institution. Material and Methods: Retrospective cohort study, which evaluated patients with mRCC who received sunitinib between May 2010 and December 2013. Results: Fifty-eight patients were eligible. Most patients were male 41 (71%), with a median age of 58 years. Nephrectomy was performed in 41 (71%) patients with a median interval of 16 months between the surgery and initiation of sunitinib. The most prevalent histological subtype was clear cell carcinoma, present in 52 (91.2%) patients. In 50 patients (86%), sunitinib was the first line of systemic treatment. The main adverse effects were fatigue (57%), hypothyroidism (43%), mucositis (33%) and diarrhea (29%). Grade 3 and 4 adverse effects were infrequent: fatigue (12%), hypertension (12%), thrombocytopenia (7%), neutropenia (5%) and hand-foot syndrome (5%). Forty percent of patients achieved a partial response and 35% stable disease, with a disease control rate of 75%. Median progression free survival was 7.6 months and median overall survival was 14.1 months. Conclusion: Sunitinib treatment was active in the majority of patients, especially those with low and intermediate risk by MSKCC score, with manageable toxicity. Survival rates were inferior in this non-screened population with mRCC treated in the SUS. PMID:27564279

  9. 77 FR 59625 - NIH Evidence-Based Methodology Workshop on Polycystic Ovary; Syndrome

    Science.gov (United States)

    2012-09-28

    ... HUMAN SERVICES National Institutes of Health NIH Evidence-Based Methodology Workshop on Polycystic Ovary... Methodology Workshop on Polycystic Ovary Syndrome, to be held December 3-5, 2012. The workshop's opening... definition of the disorder and diagnostic criteria. The outcome of this conference, the NIH Criteria,...

  10. 76 FR 3150 - Office of Biotechnology Activities; Recombinant DNA Research: Action Under the NIH Guidelines for...

    Science.gov (United States)

    2011-01-19

    ...). On July 20, 2010 the NIH Office of Biotechnology Activities (OBA) published a proposed action (75 FR... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... contact OBA by e- mail at oba@od.nih.gov , telephone, 301-496-9838 or mail to the Office of...

  11. 76 FR 62816 - Office of Biotechnology Activities; Recombinant DNA Research: Action Under the NIH Guidelines for...

    Science.gov (United States)

    2011-10-11

    ... experts from NIH, CDC, and academia. These proposed changes were published in the Federal Register (76 FR... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... Biotechnology Activities (OBA) is updating Appendix B of the NIH Guidelines to specify the risk group...

  12. 77 FR 38844 - Notice of NIH Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus

    Science.gov (United States)

    2012-06-29

    ... Gestational Diabetes Mellitus SUMMARY: The National Institutes of Health (NIH) is holding a conference titled ``Consensus Development Conference: Diagnosing Gestational Diabetes Mellitus.'' The conference will be open to... http://prevention.nih.gov/cdp . SUPPLEMENTARY INFORMATION: Gestational diabetes mellitus (GDM) is...

  13. 77 FR 41191 - Proposed Collection; Comment Request: Effectiveness of the NIH Curriculum Supplements Programs

    Science.gov (United States)

    2012-07-12

    ... HUMAN SERVICES National Institutes of Health Proposed Collection; Comment Request: Effectiveness of the... review and approval. Proposed Collection: Title: The Effectiveness of the NIH Curriculum Supplements... teach science by featuring the latest NIH research and utilized research-based instructional methods....

  14. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    OpenAIRE

    Zuber, Simon; Weiß, Susan; Baaske, Dieter; Schöpe, Michael; Stevens, Simon; Bodis, Stephan; Zwahlen, Daniel R.

    2015-01-01

    Purpose We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. Material and methods Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexual fu...

  15. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    OpenAIRE

    Zuber, Simon; Weiß, Susan; Baaske, Dieter; Schöpe, Michael; Stevens, Simon; Bodis, Stephan; Zwahlen, Daniel R.

    2015-01-01

    PURPOSE: We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. MATERIAL AND METHODS: Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexu...

  16. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    OpenAIRE

    Hirasawa Naoki; Itoh Yoshiyuki; Naganawa Shinji; Ishihara Shunichi; Suzuki Kazunori; Koyama Kazuyuki; Murao Takayuki; Asano Akiko; Nomoto Yoshihito; Horikawa Yoshimi; Sasaoka Masahiro; Obata Yasunori

    2012-01-01

    Abstract Background The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan. Methods Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplet...

  17. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.

    OpenAIRE

    Desai, S J; Barr, R D; Andrew, M.; deVeber, L L; Pai, M K

    1989-01-01

    There is ample evidence of the value of intensive therapeutic strategies in the management of acute lymphoblastic leukemia (ALL), the commonest form of malignant disease in children. Such a program, devised at the Dana-Farber Cancer Institute (DFCI), Boston, and incorporating high-dose L-asparaginase, was adopted in 1984 by the Children's Hospital at Chedoke-McMaster, Hamilton, Ont., and the Children's Hospital of Western Ontario, London. We describe the experience of these institutions in th...

  18. NIH disease funding levels and burden of disease.

    Directory of Open Access Journals (Sweden)

    Leslie A Gillum

    Full Text Available BACKGROUND: An analysis of NIH funding in 1996 found that the strongest predictor of funding, disability-adjusted life-years (DALYs, explained only 39% of the variance in funding. In 1998, Congress requested that the Institute of Medicine (IOM evaluate priority-setting criteria for NIH funding; the IOM recommended greater consideration of disease burden. We examined whether the association between current burden and funding has changed since that time. METHODS: We analyzed public data on 2006 NIH funding for 29 common conditions. Measures of US disease burden in 2004 were obtained from the World Health Organization's Global Burden of Disease study and national databases. We assessed the relationship between disease burden and NIH funding dollars in univariate and multivariable log-linear models that evaluated all measures of disease burden. Sensitivity analyses examined associations with future US burden, current and future measures of world disease burden, and a newly standardized NIH accounting method. RESULTS: In univariate and multivariable analyses, disease-specific NIH funding levels increased with burden of disease measured in DALYs (p = 0.001, which accounted for 33% of funding level variation. No other factor predicted funding in multivariable models. Conditions receiving the most funding greater than expected based on disease burden were AIDS ($2474 M, diabetes mellitus ($390 M, and perinatal conditions ($297 M. Depression ($719 M, injuries ($691 M, and chronic obstructive pulmonary disease ($613 M were the most underfunded. Results were similar using estimates of future US burden, current and future world disease burden, and alternate NIH accounting methods. CONCLUSIONS: Current levels of NIH disease-specific research funding correlate modestly with US disease burden, and correlation has not improved in the last decade.

  19. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.

    Science.gov (United States)

    Robison, Leslie L; Armstrong, Gregory T; Boice, John D; Chow, Eric J; Davies, Stella M; Donaldson, Sarah S; Green, Daniel M; Hammond, Sue; Meadows, Anna T; Mertens, Ann C; Mulvihill, John J; Nathan, Paul C; Neglia, Joseph P; Packer, Roger J; Rajaraman, Preetha; Sklar, Charles A; Stovall, Marilyn; Strong, Louise C; Yasui, Yutaka; Zeltzer, Lonnie K

    2009-05-10

    Survival for childhood cancer has increased dramatically over the last 40 years with 5-year survival rates now approaching 80%. For many diagnostic groups, rapid increases in survival began in the 1970s with the broader introduction of multimodality approaches, often including combination chemotherapy with or without radiation therapy. With this increase in rates of survivorship has come the recognition that survivors are at risk for adverse health and quality-of-life outcomes, with risk being influenced by host-, disease-, and treatment-related factors. In 1994, the US National Cancer Institute funded the Childhood Cancer Survivor Study, a multi-institutional research initiative designed to establish a large and extensively characterized cohort of more than 14,000 5-year survivors of childhood and adolescent cancer diagnosed between 1970 and 1986. This ongoing study, which reflects the single most comprehensive body of information ever assembled on childhood and adolescent cancer survivors, provides a dynamic framework and resource to investigate current and future questions about childhood cancer survivors. PMID:19364948

  20. Outcome and treatment strategy in female lung cancer: a single institution experience

    International Nuclear Information System (INIS)

    Purpose: To assess the survival rate of female lung cancer treated at the Institute of Oncology of the Vilnius University, Lithuania during the period between 1996-2005. Materials and Methods: During the period between 1996-2005, 471 women diagnosed with lung cancer were treated at the Department of Thoracic Surgery and Oncology of the Institute of Oncology, Vilnius University. Data on morphology, stage and treatment was collected from the medical records. All lung cancer cases by histology were classified in two groups: non-small cell lung cancer (includes squamous cell carcinoma, large cell carcinoma, adenocarcinoma and other less common types) and small cell lung cancer. The vital status of the study group was assessed as of December 31, 2007, by passive follow-up, using data from the population registry. It was found that 411 (87.3%) of the patients had died. Survival was estimated according to the Kaplan-Meier method. Results: The median survival of female lung cancer diagnosed during 1996-2005 in Lithuania show to be 8.7 months (8.4 (95% CI 7.2-10.8) months with non-small cell lung cancer and 9.3 (95% CI 6.3-13.0) months with small-cell lung cancer). Survival was more than 20 months in resectable non-small cell lung cancer (stages I, II, IIIA). Non-small cell lung cancer survival in advanced stages was less than 7 months. Small-cell lung cancer patients median survival at limited and extended stages of the disease were 9.5 (95% CI 2.9-18.4) compared to 9.2 (95% CI 6.2-13.7) months. Non-small cell lung cancer patients most frequently were treated by surgery (27.0%), surgery and chemotherapy or radiotherapy (19.6%). Small cell lung cancer patient treatment included chemo and radiotherapy (27.0%), chemotherapy (19.0%), radiotherapy (17.5%), surgery (27.9%). Conclusions: The single center study of female lung cancer diagnosed during 1996-2005 in Lithuania show a significantly better chance of survival in resectable non-small cell lung cancer. Advanced stages of

  1. Epidemiology of epithelial ovarian cancer, a single institution-based study in India

    Directory of Open Access Journals (Sweden)

    Surendra Kumar Saini

    2016-01-01

    Full Text Available Background: Ovarian cancer is the leading cause of mortality among all cancers of female genital tract in countries where effective cervical cancer screening program exists. As the world's population ages, remarkable increase in the total number of ovarian cancer cases are expected. This is preliminary epidemiological study to decide priorities in ovarian cancer research. Materials and Methods: A retrospective study was conducted with primary epithelial ovarian cancer cases registered in J. K. Cancer Institute, Kanpur (Uttar Pradesh, from 2007 to 2009. Patients' age at diagnosis, clinical feature, parity of patients, tumor histological type, Federation of Gynecology and Obstetrics stage, chemotherapy regimens, and overall survival data were collected and analyzed. Results: One hundred and sixty-three cases of primary ovarian epithelial cancer were analyzed. Patients' mean age at diagnosis was 55.98 ± 9.24 (median = 55. Serous adenocarcinoma (49.69% was the most prevalent type of histopathology followed by endometroid (19.1%, mucinous (10.42% and clear cell (4.29%. Combination of taxane and platin was most commonly used first line regimen in newly diagnosed as well as in relapsed patients post 1 year. Survival was not significantly different in various histopathology (log-rank P = 0.7406, but advancing stage demonstrated gradually poor survival (log-rank P < 0.05 when compared with early stage disease. Conclusion: Research efforts should be in the direction to find early diagnostic and effective screening tools as well as better therapeutic approaches for advanced epithelial ovarian cancer.

  2. A multi-institute case-control study on the risk factors of developing pancreatic cancer.

    Science.gov (United States)

    Mizuno, S; Watanabe, S; Nakamura, K; Omata, M; Oguchi, H; Ohashi, K; Ohyanagi, H; Fujiki, T; Motojima, K

    1992-08-01

    A multi-institute, hospital-based, case-control study on pancreatic cancer was carried out to examine its association with preceding diseases, cigarette smoking, alcohol drinking and dietary factors. Analyses were based on 124 newly diagnosed exocrine pancreatic cancer cases and sex-, age- and institute-matched hospital controls in seven hospitals in Japan. Cigarette smoking showed a positive association with the risk of developing pancreatic cancer. Especially among smokers, a risk enhancing effect of involuntary/passive smoking prior to twenty years of age was observed (P tea or alcohol consumption. Among dietary factors, favoring food of a salty taste and drinking green tea five cups per day or more were positively associated with the risk. Drinking milk and eating fish everyday were inversely associated with the risk. PMID:1434027

  3. The challenge for NIH ethics policies: preserving public trust and biomedical progress.

    Science.gov (United States)

    Bravo, Norka Ruiz

    2007-03-01

    Recently updated ethics rules for employees of the National Institutes of Health (NIH) aim to prevent inappropriate influences on research decisions while preserving employees' professional and scientific interactions. Specific provisions require NIH employees to report their financial holdings in "substantially affected organizations" and require senior employees to divest all holdings greater than $15,000 in any single such organization. Outside institutions that receive NIH grants are bound by separate disclosure requirements. Public-private partnerships have become more important to NIH efforts to advance biomedical research in light of flat NIH budgets in recent years. Such partnerships open the door, however, to financial conflicts that must be prevented or managed in order to maintain scientific integrity and public trust. PMID:17469471

  4. NIH Turns Blind Eye to Academics' Financial Conflicts, Audit Says

    Science.gov (United States)

    Brainard, Jeffrey

    2008-01-01

    Hundreds of financial conflicts of interest among university researchers have not been investigated by the National Institutes of Health, an agency that should police them, according to a new audit report. The report, by the inspector general of the Department of Health and Human Services--NIH's parent agency--describes a dysfunctional system that…

  5. Keep Gum Disease Away! | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... possible." And he's become a stickler for good dental hygiene. "People need to brush and floss every day, and see the dentist regularly. No lapses," he urges. To Find Out More ... National Institute of Dental and Craniofacial Research (NIDCR): www.nidcr.nih.gov ; ...

  6. NIH Mulls Ways to Lure Back Veteran Peer Reviewers

    Science.gov (United States)

    Brainard, Jeffrey

    2008-01-01

    Not long ago, academic scientists welcomed calls from the National Institutes of Health (NIH) asking them to volunteer as peer reviewers. Many were glad for the opportunity to help distribute billions of dollars in federal biomedical-research grants even though the service required a big time commitment--the equivalent of one month a year to…

  7. NIH Peer Review: Scored Review Criteria and Overall Impact

    Science.gov (United States)

    Lindner, Mark D.; Vancea, Adrian; Chen, Mei-Ching; Chacko, George

    2016-01-01

    The National Institutes of Health (NIH) is the largest source of funding for biomedical research in the world. Funding decisions are made largely based on the outcome of a peer review process that is intended to provide a fair, equitable, timely, and unbiased review of the quality, scientific merit, and potential impact of the research. There have…

  8. How Is Psoriasis Treated? | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Javascript on. Feature: Living with Psoriasis How Is Psoriasis Treated? Past Issues / Fall 2013 Table of Contents Find Out More MedlinePlus — www.medlineplus.gov National Institute of Arthritis and Musculoskeletal and Skin Diseases — www.niams.nih. ...

  9. Profile of patients with lung cancer assisted at the National Cancer Institute, according to their smoking status, from 2000 to 2007

    OpenAIRE

    Mirian Carvalho de Souza; Ana Glória Godoi Vasconcelos; Marise Souto Rebelo; Paulo Antonio de Paiva Rebelo; Oswaldo Gonçalves Cruz

    2014-01-01

    INTRODUCTION: Tobacco use is directly related to the future incidence of lung cancer. In Brazil, a growing tendency in age-adjusted lung cancer mortality rates was observed in recent years. OBJECTIVE: To describe the profile of patients with lung cancer diagnosed and treated at the National Cancer Institute (INCA) in Rio de Janeiro, Brazil, between 2000 and 2007 according to their smoking status. METHODS: An observational study was conducted using INCA's database of cancer cases. To ...

  10. NIH Common Data Elements Repository

    Data.gov (United States)

    U.S. Department of Health & Human Services — The NIH Common Data Elements (CDE) Repository has been designed to provide access to structured human and machine-readable definitions of data elements that have...

  11. Memory and Forgetfulness: NIH Research

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Memory & Forgetfulness NIH Research Past Issues / Summer 2013 Table ... agency for research on Alzheimer's disease and related memory research. An analysis funded by the NIA finds ...

  12. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3

    Directory of Open Access Journals (Sweden)

    Lund Eiliv

    2009-07-01

    Full Text Available Abstract Background Gonadotropin releasing hormone (GNRH1 triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3. Methods We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs were genotyped and used to identify haplotype-tagging SNPs (htSNPS in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II, European Prospective Investigation on Cancer and Nutrition (EPIC, Multiethnic Cohort (MEC, Nurses' Health Study (NHS, and Women's Health Study (WHS. Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone were also measured in 4713 study subjects. Results Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Conclusion Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians.

  13. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

    International Nuclear Information System (INIS)

    Gonadotropin releasing hormone (GNRH1) triggers the release of follicle stimulating hormone and luteinizing hormone from the pituitary. Genetic variants in the gene encoding GNRH1 or its receptor may influence breast cancer risk by modulating production of ovarian steroid hormones. We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3). We sequenced exons of GNRH1 and GNRHR in 95 invasive breast cancer cases. Resulting single nucleotide polymorphisms (SNPs) were genotyped and used to identify haplotype-tagging SNPs (htSNPS) in a panel of 349 healthy women. The htSNPs were genotyped in 5,603 invasive breast cancer cases and 7,480 controls from the Cancer Prevention Study-II (CPS-II), European Prospective Investigation on Cancer and Nutrition (EPIC), Multiethnic Cohort (MEC), Nurses' Health Study (NHS), and Women's Health Study (WHS). Circulating levels of sex steroids (androstenedione, estradiol, estrone and testosterone) were also measured in 4713 study subjects. Breast cancer risk was not associated with any polymorphism or haplotype in the GNRH1 and GNRHR genes, nor were there any statistically significant interactions with known breast cancer risk factors. Polymorphisms in these two genes were not strongly associated with circulating hormone levels. Common variants of the GNRH1 and GNRHR genes are not associated with risk of invasive breast cancer in Caucasians

  14. Cisplatin-based chemotherapy: the only alternative in chemoradiation of head and neck cancer? Experience of the Institute of Oncology, Ljubljana, Slovenia

    International Nuclear Information System (INIS)

    Background: Concomitant chemoradiation is a widely used therapeutic concept in intensified locoregional treatment of high risk head and neck cancer patients. In this context, cisplatin monotherapy or in combination with other chemotherapeutics is recognized as the most effective drug to be added to radiotherapy. Aim: The aim of this review is to present the rationale for combining radiotherapy with cisplatin in the treatment of head and neck cancer and to summarize the experience of the Institute of Oncology Ljubljana, Slovenia, gained through two prospective randomized trials on chemoradiation with mitomycin C and bleomycin in operable as well as inoperable head and neck cancer patients. Furthermore, recent developments in technology and biological drug modeling are discussed, which are considered to have a potential to add significantly to the locoregional effectiveness of radiotherapy. Materials/Methods: References were retrieved using the online data base of the National Library of Medicine (PubMed: http://www.ncbi.nlm.nih.gov/PubMed). Terms used included: head and neck carcinoma, squamous cell carcinoma, concomitant chemoradiotherapy, cisplatin, mitomycin C, bleomycin. The results of studies using cisplatin- based chemoradiation regimens in the treatment of patients with inoperable tumors and on postoperative stetting were compared with the results of the studies, conducted at the Institute of Oncology and ENT Department at the Clinical Center Ljubljana, Slovenia. Results; When comparing mitomycin C-bleomycin chemotherapy with other comparable series on exclusively inoperable oropharyngeal cancer, but with cisplatin (or carboplatin) and 5-fluorouracil chemotherapy, and to standard dose cisplatin regimen used in postoperative setting, the effectiveness of our unconventional drug combination appeared to be at least equivalent to the well established platinum based chemotherapy standard. Conclusions: At the moment, concomitant chemoradiation with cisplatin

  15. NIH Exported Research Portfolio Online Reporting Tools: Expenditures and Results (ExPORTER)

    Data.gov (United States)

    U.S. Department of Health & Human Services — Research projects funded by the National Institutes of Health (NIH), other DHHS Operating Divisions (AHRQ, CDC, FDA, HRSA, SAMHSA), and the Department of Veterans...

  16. A comparative study of breast cancer mass screening using ultrasonography and mammography at a single institution

    International Nuclear Information System (INIS)

    In order to evaluate the effectiveness of ultrasonic screening for breast cancer (US group) in comparison with mammographic screening (MMG group), we analyzed 78,214 breast screening examinees presenting between 2007 and 2008 at our institution. The cancer detection rate in the US group was lower than that in the MMG group. However, the average age in the US group was significantly younger than that in the MMG group, and the rate of annual screening was significantly higher in the former than in the latter. In the US subgroup who underwent annual screening, the recall rate and the cancer detection rate were significantly lower, and the rate of detection of early breast cancers was significantly higher than that in the subgroup who underwent screening biennially or at longer intervals, and there was no significant inter-group difference in the cancer detection rate between women in their 40s and those aged 50 or above who underwent annual screening. The proportion of early breast cancers detected was almost the same in the both groups. In summary, US screening as well as MMG screening seems to be useful for detection of early breast cancer. Although a high recall rate for US screening has been reported previously, annual screening and sufficient quality control based on the guidelines proposed by the Japan Association of Breast and Thyroid Sonology (JABTS) are considered to reduce the recall rate. (author)

  17. National Institutes of Health Funding in Radiation Oncology: A Snapshot

    International Nuclear Information System (INIS)

    Currently, pay lines for National Institutes of Health (NIH) grants are at a historical low. In this climate of fierce competition, knowledge about the funding situation in a small field like radiation oncology becomes very important for career planning and recruitment of faculty. Unfortunately, these data cannot be easily extracted from the NIH's database because it does not discriminate between radiology and radiation oncology departments. At the start of fiscal year 2013 we extracted records for 952 individual grants, which were active at the time of analysis from the NIH database. Proposals originating from radiation oncology departments were identified manually. Descriptive statistics were generated using the JMP statistical software package. Our analysis identified 197 grants in radiation oncology. These proposals came from 134 individual investigators in 43 academic institutions. The majority of the grants (118) were awarded to principal investigators at the full professor level, and 122 principal investigators held a PhD degree. In 79% of the grants, the research topic fell into the field of biology, 13% in the field of medical physics. Only 7.6% of the proposals were clinical investigations. Our data suggest that the field of radiation oncology is underfunded by the NIH and that the current level of support does not match the relevance of radiation oncology for cancer patients or the potential of its academic work force

  18. Some radiation protection problems in a cancer hospital and associated research institute

    International Nuclear Information System (INIS)

    Experience gained at the Royal Marsden Hospital and Institute of Cancer Research has shown that with attention to the design of facilities and procedures and an active personnel monitoring policy, relatively large scale radiation commitments can proceed with individual whole body doses to staff being held well below 15 mSv/annum. In spite of detailed attention to control of radiation work, traumatic radiation incidents may still occur. (H.K.)

  19. Architectural and engineering design work for the Nevada Cancer Institute facility

    International Nuclear Information System (INIS)

    The purpose of this project was to complete the architectural and engineering design, program planning, and other preliminary work necessary to construct the new Nevada Cancer Institute facility. These goals were accomplished with the construction of a new building of approximately 119,000 gross square feet. The facility houses the diagnostic and radio therapeutic treatment laboratories, radiation oncology treatment facility, physician offices, and clinical research areas

  20. Treatment outcomes of female germ cell tumors: The Egyptian National Cancer Institute experience

    OpenAIRE

    Saber, Magdy M; Zeeneldin, Ahmed A.; Mosaad M. El Gammal; Salem E. Salem; Amira D. Darweesh; Alshaymaa A. Abdelaziz; Manar Monir

    2014-01-01

    Introduction: Female germ cell tumors (GCTS) are rare tumors that carry a good prognosis. Aim: To report the experience of the Egyptian National Cancer Institute (ENCI) in managing female GCTs. Methods: This retrospective study included 19 females with ovarian GCTs presenting to the ENCI between 2006 and 2010. Results: The median age was 23 years. Ovaries were the primary site in all patients. Dysgerminoma and teratoma were the predominant pathologies followed by mixed GCT in females...

  1. Treatment Option Overview (Breast Cancer)

    Science.gov (United States)

    ... trials is available from the NCI website . Locally Advanced or Inflammatory Breast Cancer Treatment of locally advanced ... NIH). NIH is the federal government’s center of biomedical research. The PDQ summaries are based on an ...

  2. NAČRTOVANJE FOTOVOLTAIČNIH SONČNIH ELEKTRARN

    OpenAIRE

    Dragovan, Luka

    2011-01-01

    V preteklosti se je zaradi slabih izkoristkov, visokih cen fotovoltaičnih modulov ter ostalih gradnikov, povezanih s fotovoltaiko, le-ta večinoma uporabljala predvsem v vesoljski tehnologiji in za raziskovalne namene. H komercializaciji fotovoltaike so sčasoma pripomogle nižje cene, boljši izkoristki fotovoltaičnih modulov, pa tudi podražitve ostalih energentov, svoje pa so dodale tudi državne subvencije v obliki javnih razpisov. V okviru fotovoltaične tehnologije obravnamo v diplomskem delu ...

  3. Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute.

    Directory of Open Access Journals (Sweden)

    Edamura,Kohei

    2005-10-01

    Full Text Available

    This study was undertaken to reveal the trends of prostate cancer and the outcome of treatment modalities for each disease stage in patients in a single institute over a 10-year period. From January 1994 through December 2003, 420 consecutive patients with previously untreated and histologically confirmed prostate cancer were analyzed for annual distributions of disease stages and treatment modalities and for long-term clinical progression-free survival, prostate cancer-specific survival, and prostate-specific antigen (PSA failure-free survival rates for each stage and treatment modality. Annual trends showed that the number of patients, especially those with clinically localized cancer, increased dramatically. The 5-year disease-specific survival rates for patients with clinically localized disease were 100 percent for all treatment modalities, including hormonal therapy alone. Patients with PSA levels less than 10 ng/ml showed an 81 percent 5-year PSA failure-free survival rate with radical prostatectomy. Stage C patients treated by surgery or radiation-based therapy with concomitant hormonal therapy obtained 93 percent and 100 percent cause-specific survival rates, respectively, and those treated by hormonal therapy alone showed a 79 percent rate. The number of patients with localized prostate cancer was increasing in this decade. While long-term hormonal therapy alone was highly efficient in controlling localized prostate cancer, radical therapies in conjunction with neo-adjuvant hormonal therapy produced better survival rates in cases of locally advanced disease.

  4. The National Cancer Informatics Program (NCIP) Annotation and Image Markup (AIM) Foundation Model

    OpenAIRE

    Mongkolwat, Pattanasak; Kleper, Vladimir; Talbot, Skip; Rubin, Daniel

    2014-01-01

    Knowledge contained within in vivo imaging annotated by human experts or computer programs is typically stored as unstructured text and separated from other associated information. The National Cancer Informatics Program (NCIP) Annotation and Image Markup (AIM) Foundation information model is an evolution of the National Institute of Health’s (NIH) National Cancer Institute’s (NCI) Cancer Bioinformatics Grid (caBIG®) AIM model. The model applies to various image types created by various techn...

  5. Back Cover: NIH MedlinePlus Salud

    Science.gov (United States)

    ... Bar Home Current Issue Past Issues NIH MedlinePlus Salud Past Issues / Winter 2009 Table of Contents For ... this page please turn Javascript on. ¡A su salud! Los Institutos Nacionales de la Salud (NIH, por ...

  6. NIH Researchers Identify OCD Risk Gene

    Science.gov (United States)

    ... News From NIH NIH Researchers Identify OCD Risk Gene Past Issues / Summer 2006 Table of Contents For ... and Alcoholism (NIAAA) have identified a previously unknown gene variant that doubles an individual's risk for obsessive- ...

  7. I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data.

    Science.gov (United States)

    Weintraub, Sandra; Bauer, Patricia J; Zelazo, Philip David; Wallner-Allen, Kathleen; Dikmen, Sureyya S; Heaton, Robert K; Tulsky, David S; Slotkin, Jerry; Blitz, David L; Carlozzi, Noelle E; Havlik, Richard J; Beaumont, Jennifer L; Mungas, Dan; Manly, Jennifer J; Borosh, Beth G; Nowinski, Cindy J; Gershon, Richard C

    2013-08-01

    This monograph presents the pediatric portion of the National Institutes of Health (NIH) Toolbox Cognition Battery (CB) of the NIH Toolbox for the Assessment of Neurological and Behavioral Function. The NIH Toolbox is an initiative of the Neuroscience Blueprint, a collaborative framework through which 16 NIH Institutes, Centers, and Offices jointly support neuroscience-related research, to accelerate discoveries and reduce the burden of nervous system disorders. The CB is one of four modules that measure cognitive, emotional, sensory, and motor health across the lifespan. The CB is unique in its continuity across childhood, adolescence, early adulthood, and old age, and in order to help create a common currency among disparate studies, it is also available at low cost to researchers for use in large-scale longitudinal and epidemiologic studies. This chapter describes the evolution of the CB; methods for selecting cognitive subdomains and instruments; the rationale for test design; and a validation study in children and adolescents, ages 3-15 years. Subsequent chapters feature detailed discussions of each test measure and its psychometric properties (Chapters 2-6), the factor structure of the test battery (Chapter 7), the effects of age and education on composite test scores (Chapter 8), and a final summary and discussion (Chapter 9). As the chapters in this monograph demonstrate, the CB has excellent psychometric properties, and the validation study provided evidence for the increasing differentiation of cognitive abilities with age. PMID:23952199

  8. ZADOVOLJSTVO UPORABNIKOV TURISTIČNIH STORITEV

    OpenAIRE

    Stanonik, Tana

    2015-01-01

    Zadovoljstvo uporabnikov turističnih storitev je eden ključnih dejavnikov za uspešno poslovanje ponudnikov turističnih storitev. V teoretičnem delu diplomske naloge smo na kratko razjasnili glavna pojma turizem ter zadovoljstvo. Opisali smo nekaj dejavnikov, ki vplivajo na zadovoljstvo uporabnikov turističnih storitev. Govorimo o kakovosti storitev v turizmu, nakupnem vedenju turistov ter o lojalnosti turistov. Opisali smo tudi samo merjenje zadovoljstva turistov ter razjasnili kako se v ...

  9. NIH Pathways to Prevention (P2P) Workshop: Role of Opioids in the Treatment of Chronic Pain | Division of Cancer Prevention

    Science.gov (United States)

    Chronic pain is a major public health problem, which is estimated to affect more than 100 million people in the United States and about 20–30% of the population worldwide. The prevalence of persistent pain is expected to rise in the near future as the incidence of associated diseases (including diabetes, obesity, cardiovascular disorders, arthritis, and cancer) increases in the aging U.S. population. |

  10. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations and breast cancer risk.

    Science.gov (United States)

    Harris, Holly R; Bergkvist, Leif; Wolk, Alicja

    2016-06-01

    The World Cancer Research Fund/American Association for Cancer Research (WCRF/AICR) has published eight nutrition-related recommendations for the prevention of cancer. However, few prospective studies have examined these recommendations by breast cancer hormone receptor subtype and only one case-control study has included the dietary supplements recommendation in their evaluation. We investigated whether adherence to the WCRF/AICR cancer prevention recommendations was associated with breast cancer incidence, overall and by hormone receptor subtype, in the Swedish Mammography Cohort. Among 31,514 primarily postmenopausal women diet and lifestyle factors were assessed with a self-administered food frequency questionnaire. A score was constructed based on adherence to the recommendations for body fatness, physical activity, energy density, plant foods, animal foods, alcoholic drinks and dietary supplements (score range 0-7). Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs). During 15 years of follow-up 1,388 cases of breast cancer were identified. Women who met six to seven recommendations had a 51% decreased risk of breast cancer compared to women meeting only zero to two recommendations (95% CI = 0.35-0.70). The association between each additional recommendation met and breast cancer risk was strongest for the ER-positive/PR-positive subtype (HR = 0.86; 95% CI = 0.79-0.94), while for the ER-negative/PR-negative subtype the individual recommendations regarding plant and animal foods were most strongly associated with reduced risk. Our findings support that adherence to the WCRF/AICR recommendations reduces breast cancer risk in a population of primarily postmenopausal women. Promoting these recommendations to the public could help reduce breast cancer incidence. PMID:26804371

  11. Plant collecting program in Southeast Asia under the sponsorship of the United States National Cancer Institute (NCI) (1986-1991)

    OpenAIRE

    Soejarto, D. D.

    1992-01-01

    Under the funding from the United States National Cancer Institute (NCI)¹, a program was undertaken to collect plant samples in Southeast Asia to be tested for their cancer- and AIDS-arresting properties, for the period of September 1, 1986 through August 31, 1991. The program was implemented with the collaboration of the Arnold Arboretum and the Bishop Museum. Botanists from these and other institutions collaborated in the field work operation for the program, among others: J.S. BURLEY (A), ...

  12. Parkinson's Disease Research at NIH

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Parkinson's Disease Parkinson's Disease Research at NIH Past Issues / Winter 2014 ... areas of its research: MedlinePlus . medlineplus.gov . Type "Parkinson's disease" in the Search box. NIHSeniorHealth —Parkinson's Disease ...

  13. Lumboaortic radiotherapy in patients with cervical cancer. Experience of the National Cancer Institute

    International Nuclear Information System (INIS)

    Background: Uterine cancer is still a prevalent disease in Chile. Is common to treat patients with tumors in stages IIB and IIIB where the risk of pelvic and paraortic limph node involvement is very high. Its treatment is radio-chemotherapy. Objective: To present a retrospective analysis of patients that suffered cervix-uterine cancer who were treated with radiotherapy including the aortic-lumbar area. Methods: From the revision of patients who were treated of cervix-uterine cancer between the years 1995 and 2007, 39 were treated including aortic-lumbar chains. Evolution and toxicity were analyzed. Two radiotherapy techniques were used. The first one, during the nineties, included two parallel previous and later and opposed fields, and a second technique, currently used, where pelvis and paraortic are radiated at the same time through four lateral (AP-PA) fields. Results: The dosimeter analysis of both techniques shows that there is a higher volume of radiated normal tissue with the two fields techniques, mainly in the small bowel. On the other hand, the toxicity was significantly different being today's technique less toxic and showing low gastrointestinal

  14. Plant collecting program in Southeast Asia under the sponsorship of the United States National Cancer Institute (NCI) (1986-1991)

    NARCIS (Netherlands)

    Soejarto, D.D.

    1992-01-01

    Under the funding from the United States National Cancer Institute (NCI)¹, a program was undertaken to collect plant samples in Southeast Asia to be tested for their cancer- and AIDS-arresting properties, for the period of September 1, 1986 through August 31, 1991. The program was implemented with t

  15. Patterns of care for ovarian cancer patients at Institute of Nuclear Medicine and Oncology (INMOL) Lahore

    International Nuclear Information System (INIS)

    The study was carried out to analyze the incidence of ovarian cancer and changing patterns of therapy during the last six years at INMOL (Institute of Nuclear Medicine and Oncology, Lahore Pakistan). Main objective was to review the results of treatment given and find out the causes of failure. Treatment and its outcome was also recorded to correlate the results with histological subtype and stage of diseases. It has been studied various factors like age of presentation, parity, social class, family history, method of surgery, stage of disease along with histologic type of the tumor. Epithelial ovarian cancer is not curable at advanced stages. Efforts should be made to find out some effective screening procedures for early detection. (Orig./A.B.)

  16. Male breast cancer: a report of 127 cases at a Moroccan institution

    Directory of Open Access Journals (Sweden)

    Tijami Fouad

    2011-06-01

    Full Text Available Abstract Background Male breast cancer (MBC is a rare disease representing less than 1% of all malignancies in men and only 1% of all incident breast cancers. Our study details clinico-pathological features, treatments and prognostic factors in a large Moroccan cohort. Findings One hundred and twenty-seven patients were collected from 1985 to 2007 at the National Institute of Oncology in Rabat, Morocco. Median age was 62 years and median time for consultation 28 months. The main clinical complaint was a mass beneath the areola in 93, 5% of the cases. Most patients have an advanced disease. Ninety-one percent of tumors were ductal carcinomas. Management consisted especially of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy with or without chemotherapy. The median of follow-up was 30 months. The evolution has been characterized by local recurrence; in twenty two cases (17% of all patients. Metastasis occurred in 41 cases (32% of all patients. The site of metastasis was the bone in twenty cases; lung in twelve cases; liver in seven case; liver and skin in one case and pleura and skin in one case. Conclusion Male breast cancer has many similarities to breast cancer in women, but there are distinct features that should be appreciated. Future research for better understanding of this disease at national or international level are needed to improve the management and prognosis of male patients.

  17. [The (German) Center for Cancer Registry Data (ZfKD) at the Robert Koch Institute (RKI) in Berlin].

    Science.gov (United States)

    Wolf, U; Barnes, B; Bertz, J; Haberland, J; Laudi, A; Stöcker, M; Schönfeld, I; Kraywinkel, K; Kurth, B-M

    2011-11-01

    Cancer represents the second most common cause of death in Germany. The country's federal states operate regional population-based cancer registries that collect and analyze data on cancer patients. This provides an essential basis for describing the cancer burden in the German population. In order to obtain valid and reliable information on cancer incidence at the national level, the Robert Koch Institute (RKI) set up the Federal Cancer Surveillance Unit in 1983 as a central institution for evaluating this cancer registry data. In August 2009, when the Federal Cancer Registry Data Act (BKRG) came into force, the Center for Cancer Registry Data (ZfKD) at the RKI took over the work of the Cancer Surveillance Unit with a broader remit. In the future, it will also regularly publish findings on survival, prevalence, and tumor stage distribution. A newly established record linkage process will help identify multiple submissions from the federal states. Further innovations and new tasks of the ZfKD include expanding an interactive Internet platform and encouraging a more intensive use of cancer registry data for epidemiological research by providing datasets to external scientists. The range of information available to the interested public is also to be expanded. PMID:22015795

  18. Preliminary Analysis of Difficulty of Importing Pattern-Based Concepts into the National Cancer Institute Thesaurus.

    Science.gov (United States)

    He, Zhe; Geller, James

    2016-01-01

    Maintenance of biomedical ontologies is difficult. We have developed a pattern-based method for dealing with the problem of identifying missing concepts in the National Cancer Institute thesaurus (NCIt). Specifically, we are mining patterns connecting NCIt concepts with concepts in other ontologies to identify candidate missing concepts. However, the final decision about a concept insertion is always up to a human ontology curator. In this paper, we are estimating the difficulty of this task for a domain expert by counting possible choices for a pattern-based insertion. We conclude that even with support of our mining algorithm, the insertion task is challenging. PMID:27577410

  19. Quality of life among young women with breast cancer: Study from a tertiary cancer institute in south India

    Directory of Open Access Journals (Sweden)

    B Dubashi

    2010-01-01

    Full Text Available Background : The incidence of breast cancer in young patients less than 35 years is less than 1%. The physical and psychosocial morbidity may affect their ability to successfully function in their social roles. Hence we studied the quality of life (QOL issues in this subset. Materials and Methods :Younger women with age less than 35 years, diagnosed with non-metastatic breast cancer at our Institute, from 1995 to 2005, were included in the study. Quality of life issues were studied during the follow-up using EORTC QOL C30 and BR23. Descriptive and inferential statistics were used in order to analyze the data. Results : A total of 51 patients were included for the study. The mean age at diagnosis was 30 years. The effect of breast cancer on the occupation and marital status was minimal. The global health status and the functional scores were high, while the overall sexual function was lower. The global health status was higher in the mastectomy group. The arm symptoms (P = 0.027 and pain were higher in the Breast conservation surgery (BCS group. The sexual symptoms appeared to be higher in the ovary ablated group when compared to the ovary preserved group. The sexual functional scores (P = 0.02 and sexual enjoyment scores (P = 0.003 were better in the mastectomy group. Conclusion : The overall QOL in younger patients with breast cancer appeared to be good. The QOL and sexual function were marginally worse in the breast conservation group when compared to mastectomy group.

  20. Endobronchial Ultrasound Changed the World of Lung Cancer Patients: A 11-Year Institutional Experience.

    Directory of Open Access Journals (Sweden)

    Chia-Hung Chen

    Full Text Available The role of advanced bronchoscopic diagnostic techniques in the detection and staging of lung cancer has increased sharply in recent years. The development of endobronchial ultrasound (EBUS improved minimally invasive mediastinal staging and diagnosis of peripheral lung lesions (PLLs. We investigated the impact of using EBUS as a diagnostic method for tissue acquisition in lung cancer patients.In a single center observational retrospective study, 3712 subjects were diagnosed with lung cancer from 2003 to 2013 (EBUS was introduced in 2008. Thus, we divided the data into two periods: the conventional bronchoscopy period (2003 to 2007 and the EBUS period (2008 to 2013.A total of 3712 patients were included in the analysis. Comparing the conventional bronchoscopy period with the EBUS period data, there has been a significant reduction in the use of diagnostic modalities: CT-guided biopsy (P < 0.0001 and pleural effusion cytology (P < 0.0001. The proportion of subjects diagnosed using bronchoscopy significantly increased from 39.4% in the conventional period to 47.4% in the EBUS period (P < 0.0001. In the EBUS period, there has also been a significant increase in the proportion of patients proceeding directly to diagnostic surgery (P < 0.0001. Compared to bronchoscopy, the incidence of complications was higher in those who underwent CT guide biopsy. The incidence of iatrogenic pneumothorax significantly decreased in the EBUS period.Advanced bronchoscopic techniques are widely used in the diagnosis of lung cancer. At our institution, the increasing use of EBUS for providing lung cancer diagnosis has led to a significant reduction in other diagnostic modalities, namely CT-guided biopsy and pleural effusion cytology. These changes in practice also led to a reduction in the incidence of complications.

  1. Environmental dose in the Nuclear Medicine Department of the National Institute of Cancer

    International Nuclear Information System (INIS)

    The dosimeters TLD-100 and TLD-900 were used to know the levels of environmental dose in areas of the Nuclear Medicine Department of the National Institute of Cancer. The dosimeters calibration was carried out in the Metrology Department of the National Institute of Nuclear Research. The radioisotopes used in the studied areas are 131I, 18F, 67Ga, 99mTc, 111In, 201Tl and 137Cs with gamma energies between 93 and 662 KeV. Dosimeters were placed during five months in the diagnostic, injection, waiting and PET rooms as well as hot room, waste room, enclosed corridors to patient rooms treated with 131I and 137Cs and witness dosimeters to know the bottom. The values found vary between 0.3 and 70 major times that those of bottom. The maximum doses were measured in the waste room and in the enclosed corridor to the patient rooms with cervical uterine cancer treated with 137Cs. (Author)

  2. Radiation therapy with or without primary limited surgery for operable breast cancer: A 20-year experience at the Marseilles Cancer Institute

    International Nuclear Information System (INIS)

    At the Marseilles Cancer Institute, the authors' first source of radioactive cesium was promptly applied to the treatment of breast cancer, to which it seemed ideally suited because of good superficial and intermediate penetration. Their favorable early experience led them to embark on a program of conservative treatment of operable breast cancer, which has supplanted the routine use of radical mastectomy at our institution. Since June 1960, more than 3000 consecutive operable breast cancers were treated primarily with radiation therapy with or without initial limited surgery. This paper presents the treatment results in 1440 cases eligible for five-year analysis, including 320 ten-year cases, thus representing the largest series of breast cancer patients treated with modern radiation therapy techniques thus far reported in the literature

  3. The research for mitochondrial DNA inducing the D-loop mutation of NIH3T3 cells in colorectal cancer%大肠癌线粒体DNA 诱导NIH3T3细胞D-环突变的作用与机制

    Institute of Scientific and Technical Information of China (English)

    姬宏莉; 姬宏娟; 马永全; 杜芳; 王辉

    2011-01-01

    目的 观察突变的大肠癌细胞线粒体DNA(mtDNA)转导NIH3T3细胞后转染细胞mtDNA D-环突变特性.方法 通过脂质体法(Lipofection2000TM)将大肠癌细胞突变的mtDNA真核表达载体转染NIH3T3细胞,利用G418抗性筛选克隆细胞;用PCR法检测转染细胞线粒体突变情况.结果 突变mtDNA导致转染细胞mtDNA 的突变和多态性变化.结论 突变的大肠癌mtDNA可致NIH3T3细胞mtDNA位点变化,但具体的机制和过程有待于进一步研究.

  4. Cost comparison of curative therapies for localized prostate cancer in Japan. A single-institution experience

    International Nuclear Information System (INIS)

    In addition to open surgery, curative therapies for prostate cancer now include endoscopic surgery and radiation therapies. Because of the expansion and subdivision of treatment methods for prostate cancer, the medical fee point schedule in Japan was revised in fiscal year 2006. We examined changes in medical income and expenditure after this revision of the medical fee system. We studied income and expenditure, after institution of the new medical fee schedule, for the five types of therapies for prostate cancer performed at our hospital: two surgical therapies (radical retropubic prostatectomy and laparoscopic prostatectomy) and three radiation therapies (three-dimensional conformal radiation therapy, 192Ir high-dose-rate brachytherapy, and 125I low-dose-rate brachytherapy). Low-dose-rate brachytherapy was found to be associated with a profit of 199 yen per patient. Laparoscopic prostatectomy, a highly advanced medical treatment that the fee revision changed from a partially insured to an insured procedure, yielded a profit of 75672 yen per patient. However, high-dose-rate brachytherapy was associated with a loss of 654016 yen per patient. Given the loss in hospital income per patient undergoing high-dose-rate brachytherapy, the medical fee point system for this procedure should be reassessed. (author)

  5. Altered plasma apolipoprotein modifications in patients with pancreatic cancer: protein characterization and multi-institutional validation.

    Directory of Open Access Journals (Sweden)

    Kazufumi Honda

    Full Text Available BACKGROUND: Among the more common human malignancies, invasive ductal carcinoma of the pancreas has the worst prognosis. The poor outcome seems to be attributable to difficulty in early detection. METHODS: We compared the plasma protein profiles of 112 pancreatic cancer patients with those of 103 sex- and age-matched healthy controls (Cohort 1 using a newly developed matrix-assisted laser desorption/ionization (oMALDI QqTOF (quadrupole time-of-flight mass spectrometry (MS system. RESULTS: We found that hemi-truncated apolipoprotein AII dimer (ApoAII-2; 17252 m/z, unglycosylated apolipoprotein CIII (ApoCIII-0; 8766 m/z, and their summed value were significantly decreased in the pancreatic cancer patients [P = 1.36×10(-21, P = 4.35×10(-14, and P = 1.83×10(-24 (Mann-Whitney U-test; area-under-curve values of 0.877, 0.798, and 0.903, respectively]. The significance was further validated in a total of 1099 plasma/serum samples, consisting of 2 retrospective cohorts [Cohort 2 (n = 103 and Cohort 3 (n = 163] and a prospective cohort [Cohort 4 (n = 833] collected from 8 medical institutions in Japan and Germany. CONCLUSIONS: We have constructed a robust quantitative MS profiling system and used it to validate alterations of modified apolipoproteins in multiple cohorts of patients with pancreatic cancer.

  6. Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution

    International Nuclear Information System (INIS)

    Pelvic exenteration (PE) continues to be the only curative option in selected patients with advanced or recurrent pelvic neoplasms. A current debate exists concerning the appropriate selection of patients for PE, with the most important factor being the absence of extrapelvic disease. To evaluate the outcome of patients submitted to exenterative surgery. A review of the clinical charts of patients with colorectal cancer who underwent PE between January 1994 and June 2010 at the Institute National of Cancerología in Mexico City was performed. We selected 59 patients, 53 of whom were females (90%), and six of whom were males (10%). Mean age at the time of diagnosis was 50 years (range, 21–77 years). A total of 51 patients underwent posterior PE (86%), and eight patients underwent total PE (14%). Operative mortality occurred in two cases (3%), and 29 patients developed complications (49%). Overall, 11 patients (19%) experienced local failure with mean disease-free survival time of 10.2 months. After a mean follow-up of 28.3 months, nine patients are still alive without evidence of the disease (15%). PE should be considered in advanced colorectal cancer without extrapelvic metastatic disease. PE is accompanied by considerable morbidity (49%) and mortality (3%), but local control is desirable. Overall survival justifies the use of this procedure in patients with primary or recurrent locally advanced rectal cancer

  7. The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

    Science.gov (United States)

    Shoemaker, Robert H; Suen, Chen S; Holmes, Cathy A; Fay, Judith R; Steele, Vernon E

    2016-02-01

    The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a National Cancer Institute, Division of Cancer Prevention (NCI, DCP)-supported program whose primary goal is to bring new cancer preventive interventions (small molecules and vaccines) and biomarkers through preclinical development towards clinical trials by creating partnerships between the public sector (eg, academia, industry) and DCP. PREVENT has a formalized structure for moving interventions forward in the prevention pipeline using a stage-gate process with go/no go decision points along the critical path for development. This review describes the structure of the program, its focus areas, and provides examples of projects currently in the pipeline. PMID:26970137

  8. Creating a “culture of research” in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program

    Science.gov (United States)

    St. Germain, Diane; Nacpil, Lianne M; Zaren, Howard A; Swanson, Sandra M; Minnick, Christopher; Carrigan, Angela; Denicoff, Andrea M; Igo, Kathleen E; Acoba, Jared D; Gonzalez, Maria M; McCaskill-Stevens, Worta

    2015-01-01

    Background The value of community-based cancer research has long been recognized. In addition to the National Cancer Institute’s Community Clinical and Minority-Based Oncology Programs established in 1983, and 1991 respectively, the National Cancer Institute established the National Cancer Institute Community Cancer Centers Program in 2007 with an aim of enhancing access to high-quality cancer care and clinical research in the community setting where most cancer patients receive their treatment. This article discusses strategies utilized by the National Cancer Institute Community Cancer Centers Program to build research capacity and create a more entrenched culture of research at the community hospitals participating in the program over a 7-year period. Methods To facilitate development of a research culture at the community hospitals, the National Cancer Institute Community Cancer Centers Program required leadership or chief executive officer engagement; utilized a collaborative learning structure where best practices, successes, and challenges could be shared; promoted site-to-site mentoring to foster faster learning within and between sites; required research program assessments that spanned clinical trial portfolio, accrual barriers, and outreach; increased identification and use of metrics; and, finally, encouraged research team engagement across hospital departments (navigation, multidisciplinary care, pathology, and disparities) to replace the traditionally siloed approach to clinical trials. Limitations The health-care environment is rapidly changing while complexity in research increases. Successful research efforts are impacted by numerous factors (e.g. institutional review board reviews, physician interest, and trial availability). The National Cancer Institute Community Cancer Centers Program sites, as program participants, had access to the required resources and support to develop and implement the strategies described. Metrics are an important

  9. A 20 years evaluation of cancer of the tongue at cancer institute Imam Khomeini Hospital, 1978-98

    Directory of Open Access Journals (Sweden)

    Mir M

    2001-08-01

    Full Text Available Informations regarding 152 patients of cancer of tongue in cancer institute from 1978 to 1998 was collected and analyzed. From these cases, 53.3 percent were male with a mean age of 54.49 years (SD=16.23 and the mean age of female was 2.5 years more than of male. Positive lymphadenopathy in men was positive and significantly more than that of female (P<0.05. The physical appearance of the tumor was ulcerative (66.7 percent. Most of the referrals were in the range of T1 (62.8 percent and were operated. Information from 88 patients was evaluated and it was found that 23.9 percent of the patients has died. One year survival was 92.05 percent and 3 years survival 83.3 percent and it was confirmed that advanced stage of the illness decreases the survival rate (P<0.001.      

  10. Locally advanced cervix cancer: chemotherapy prior to definitive surgery or radiotherapy. A single institutional experience

    International Nuclear Information System (INIS)

    Primary or neoadjuvant chemotherapy prior to definitive local therapy has potential advantages for locally advanced cervix cancer. It can down stage a cancer and allow definitive local therapy to be technically possible (surgery), or potentially more effective (radiotherapy). It can also eradicate subclinical systemic metastases. This report reviews a single institution's experience of neoadjuvant chemotherapy prior to definitive local therapy for cervix cancer over a 13-year period. One hundred and six patients were treated with this intent. The patients were analysed for their response to chemotherapy, treatment received, survival, relapse and toxicity. The chemotherapy was feasible and the majority of patients had a complete or partial response (58.5%). Eight patients did not proceed to local treatment. Forty-six patients had definitive surgery and 52 had definitive radiotherapy. The 5-year overall survival was 27% and the majority of patients died with disease. The first site of relapse was usually in the pelvis (46.2%). Late complications that required ongoing medical therapy (n = 6) or surgical intervention (n = 2) were recorded in eight patients (7.5%). On univariate analysis stage (P= 0.04), tumour size (P = 0.01), lymph node status (P=0.003), response to chemotherapy (P = 0.045) and treatment (P = 0.003) were all significant predictors of survival. On multivariate analysis, tumour size (P < 0.0001) and nodal status (P = 0.02) were significant predictors of survival. Despite the impressive responses to chemotherapy of advanced cervix cancer, there is evidence from randomized trials that it does not improve or compromise survival prior to radiotherapy. As its role prior to surgery remains unclear, it should not be used in this setting outside a prospective randomized trial. Copyright (2001) Blackwell Science Pty Ltd

  11. Seasonal Allergy Research at NIH | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn Javascript on. Feature: Managing Allergies Seasonal Allergy Research at NIH Past Issues / Spring 2013 Table of Contents To Find Out More MedlinePlus: Allergy www.nlm.nih.gov/medlineplus/allergy.html MedlinePlus: ...

  12. Asthma: NIH-Sponsored Research and Clinical Trials | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Asthma Asthma: NIH-Sponsored Research and Clinical Trials Past Issues / Fall 2011 Table of Contents NIH-Sponsored Research Asthma in the Inner City: Recognizing that asthma severity ...

  13. Nanoparticle-Based Drug Delivery for Therapy of Lung Cancer: Progress and Challenges

    OpenAIRE

    Anish Babu; Templeton, Amanda K.; Anupama Munshi; Rajagopal Ramesh

    2013-01-01

    The last decade has witnessed enormous advances in the development and application of nanotechnology in cancer detection, diagnosis, and therapy culminating in the development of the nascent field of “cancer nanomedicine.” A nanoparticle as per the National Institutes of Health (NIH) guidelines is any material that is used in the formulation of a drug resulting in a final product smaller than 1 micron in size. Nanoparticle-based therapeutic systems have gained immense popularity due to their ...

  14. Awareness and behavior of oncologists and support measures in medical institutions related to ongoing employment of cancer patients in Japan

    International Nuclear Information System (INIS)

    Improved outcomes of cancer treatment allow patients to undergo treatment while working. However, support from oncologists and medical institutions is essential for patients to continue working. This study aimed to clarify oncologists' awareness and behavior regarding patients who work during treatment, support in medical institutions and their association. A questionnaire was mailed to all 453 diplomates and faculty of the subspecialty board of medical oncology in the Japanese Society of Medical Oncology and all 1016 surgeons certified by the Japanese Board of Cancer Therapy living in the Kanto area. The questionnaire assessed demographics, oncologist awareness and behavior regarding patient employment and support measures at their medical institutions. Logistic regression analysis was used to examine the association of awareness and behavior of oncologists with support measures at their institutions. A total of 668 individuals participated. The overall response rate was 45.5%. Only 53.6% of respondents advised patients to tell their supervisors about prospects for treatment and ask for understanding. For medical institutions, 28.8% had a nurse-involved counseling program and adjustments in radiation therapy (28.0%) and chemotherapy (41.9%) schedules to accommodate patients' work. There was a significant correlation between awareness and behavior of oncologists and medical institutions' measures to support employed cancer patients. There is room for improvement in awareness and behavior of oncologists and support in medical institutions for cancer patients continuing to work. Oncologists could support working patients by exerting influence on their medical institutions. Conversely, proactive development of support measures by medical institutions could alter the awareness and behavior of oncologists. (author)

  15. Relationship of Internet health information use with patient behavior and self-efficacy: experiences of newly diagnosed cancer patients who contact the National Cancer Institute's Cancer Information Service.

    Science.gov (United States)

    Bass, Sarah Bauerle; Ruzek, Sheryl Burt; Gordon, Thomas F; Fleisher, Linda; McKeown-Conn, Nancy; Moore, Dirk

    2006-03-01

    This study examines the relationship of Internet health information use with patient behavior and self-efficacy among 498 newly diagnosed cancer patients. Subjects were classified by types of Internet use: direct use (used Internet health information themselves), indirect use (used information accessed by friends or family), and non-use (never accessing Internet information). Subjects were recruited from callers of the National Cancer Institute's (NCI's) Cancer Information Service, Atlantic Region. They were classified by type of Internet use at enrollment and interviewed by telephone after 8 weeks. There were significant relationships among Internet use and key study variables: subject characteristics, patient task behavior, and self-efficacy. Subjects' Internet use changed significantly from enrollment to 8 week follow-up; 19% of nonusers and indirect users moved to a higher level of Internet use. Significant relationships also were found among Internet use and perceived patient-provider relationship, question asking, and treatment compliance. Finally, Internet use was also significantly associated with self-efficacy variables (confidence in actively participating in treatment decisions, asking physicians questions, and sharing feelings of concern). The results of this study show that patients who are newly diagnosed with cancer perceive the Internet as a powerful tool, both for acquiring information and for enhancing confidence to make informed decisions. PMID:16537289

  16. Intraoperative radiation therapy at the National Cancer Institute: technical innovations and dosimetry

    International Nuclear Information System (INIS)

    The technical complexity of intraoperative radiotherapy (IORT) requires modification of the standard physical and dosimetric methods used in external electron beam therapy. At the National Cancer Institute, a number of technical innovations have been integrated into ongoing clinical studies of IORT. These include: (1) an electron beam applicator system that is significantly different from other IORT systems and includes customized squircle applicators; (2) peripheral dose shields; (3) a modified surgical table replacing the standard radiation treatment couch; and (4) routine use of multiple IORT fields that necessitates field matching. The IORT applicator system and related devices and techniques are dosimetrically characterized in detail both for use in the IORT program and in order to illustrate many useful facets of electron dosimetry

  17. Description of the National Institutes of Health

    Institute of Scientific and Technical Information of China (English)

    2011-01-01

    @@ Introduction The National Institutes of Health(NIH),apart of the U.S.Department of Health and Human Services,is the nation's medical research agency-making important discoveries that improve health and save lives.Thanks in large part to NIH-funded medical research,Americans today are living longer and healthier.

  18. Latest NIH Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Trials: Lung Cancer Prevention Check for trials about lung cancer prevention from NCI's List of Cancer Clinical Trials now accepting patients. http://www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid=475994 Winter 2011 Issue: Volume 5 Number 4 Page 9

  19. The Bone Marrow Transplantation Center of the National Cancer Institute - its resources to assist patients with bone marrow failure

    International Nuclear Information System (INIS)

    This paper describes the bone marrow transplantation center of the brazilian National Cancer Institute, which is responsible for the cancer control in Brazil. The document also describes the resources available in the Institute for assisting patients presenting bone marrow failures. The Center provides for allogeneic and autologous bone marrow transplants, peripheral stem cell transplants, umbilical cord collections and transplants, and a small experience with unrelated bone marrow transplants. The Center receives patient from all over the country and provides very sophisticated medical care at no direct cost to the patients

  20. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana:

    OpenAIRE

    Stanic, Karmen; Kovac, Viljem

    2010-01-01

    Background Prophylactic cranial irradiation (PCI) has been used in patients with small-cell lung cancer (SCLC) to reduce the incidence of brain metastases (BM) and thus increase overall survival. The aim of this retrospective study was to analyze the characteristics of patients with SCLC referred to the Institute of Oncology Ljubljana, their eligibility for PCI, patterns of dissemination, and survival. Patients and methods Medical charts of 357 patients with SCLC, referred to the Institute of...

  1. Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico

    OpenAIRE

    Arrieta, Oscar; Quintana-Carrillo, Roger Humberto; Ahumada-Curiel, Gabriel; Corona-Cruz, Jose Francisco; Correa-Acevedo, Elma; Zinser-Sierra, Juan; de la Mata-Moya, Dolores; Mohar-Betancourt, Alejandro; Morales-Oyarvide, Vicente; Reynales-Shigematsu, Luz Myriam

    2015-01-01

    Background Smoking is a public health problem in Mexico and worldwide; its economic impact on developing countries has not been well documented. The aim of this study was to assess the direct medical costs attributable to smoking incurred by lung cancer patients treated at the National Cancer Institute of Mexico (INCan). Methods The study was conducted at INCan in 2009. We carried out a cost of illness (COI) methodology, using data derived from an expert panel consensus and from medical chart...

  2. Zagotavljanje etičnih načel dobronamernosti in neškodljivosti v zdravstvenih ustanovah: Respecting ethical principles of beneficence and nonmaleficence in health care institutions:

    OpenAIRE

    Kadivec, Saša

    2004-01-01

    The article presents methods of ethical principles of beneficience and nonmaleficience assurance in health care institutions. The first part deals with the principles of beneficence and nonmaleficence, the occurence of unfavourable events and ways of their inclusion into the system of quality assurance. The purpose of the establishment of the system of monitoring of unfavourable events is preventions of them in the future and prevention of malpractice in nursing care. The second part of the a...

  3. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

    International Nuclear Information System (INIS)

    We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution. Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexual function, were measured, applying the International Prostate Symptom Score (IPSS), the 7-grade Quality of Life Scale (QoL) and medical status, the International Consultation on Incontinence Modular Questionnaire (ICIQ), the International Index of Erectile Function (IIEF-5) and the Common Terminology Criteria for Adverse Events (CTCAE v4.03). Seed migration and loss, dosimetric parameters and learning effects were also analyzed. Medium follow-up time was 50 months (range, 1–85 months). The five-year biochemical failure rate was 7%. Acute proctitis rates were 19% (grade 1) and 1% (grade 2), respectively. The overall incidence of incontinence was 19% (mild), 16% (moderate) and < 1% (severe). An increase in IPSS ≥ 5 points was detected in 59% of patients, with 38% regaining their baseline. Seed dislocation was found in 24% of patients and correlated with D90 and V100. A learning curve was found for seed migration, D90 and V100. QoL correlated with the general health condition of patient, incontinence symptoms and IPSS. BT for early stage prostate cancer offers excellent five-year biochemical control with low toxicities. QoL aspects are favorable. A learning curve was detected for procedural aspects but its impact on patient relevant endpoints remains inconclusive

  4. SPAJANJE IN MERITVE ZRAČNIH OPTIČNIH KABLOV V PRENOSTNIH ELEKTROENERGETSKIH SISTEMIH

    OpenAIRE

    Horvat, Dominik

    2010-01-01

    V nalogi smo predstavili spajanje in meritve zračnih optičnih kablov posebej v elektroenergetskih sistemih, pri čemer smo upoštevali ITU-T standarde za enorodovna optična vlakna. Podali smo predstavitev optičnih komunikacij, pri kateri smo opisali pomembne sestavne dele optične trase, kot so viri, prenosni mediji in detektorji. Posebej smo podali tipe zračnih optičnih kablov in spojk, ki se jih največkrat uporablja v elektroenergetskih sistemih, s poudarkom na OPGW kablih in kabelskih s...

  5. Quality Improvement in the National Cancer Institute Community Cancer Centers Program: The Quality Oncology Practice Initiative Experience

    Science.gov (United States)

    Siegel, Robert D.; Castro, Kathleen M.; Eisenstein, Jana; Stallings, Holley; Hegedus, Patricia D.; Bryant, Donna M.; Kadlubek, Pam J.; Clauser, Steven B.

    2015-01-01

    Purpose: The National Cancer Institute (NCI) Community Cancer Centers Program (NCCCP) began in 2007; it is a network of community-based hospitals funded by the NCI. Quality of care is an NCCCP priority, with participation in the American Society of Clinical Oncology Quality Oncology Practice Initiative (QOPI) playing a fundamental role in quality assessment and quality improvement (QI) projects. Using QOPI methodology, performance on quality measures was analyzed two times per year over a 3-year period to enhance our implementation of quality standards at NCCCP hospitals. Methods: A data-sharing agreement allowed individual-practice QOPI data to be electronically sent to the NCI. Aggregated data with the other NCCCP QOPI participants were presented to the network via Webinars. The NCCCP Quality of Care Subcommittee selected areas in which to focus subsequent QI efforts, and high-performing practices shared voluntarily their QI best practices with the network. Results: QOPI results were compiled semiannually between fall 2010 and fall 2013. The network concentrated on measures with a quality score of ≤ 0.75 and planned voluntary group-wide QI interventions. We identified 13 measures in which the NCCCP fell at or below the designated quality score in fall 2010. After implementing a variety of QI initiatives, the network registered improvements in all parameters except one (use of treatment summaries). Conclusion: Using the NCCCP as a paradigm, QOPI metrics provide a useful platform for group-wide measurement of quality performance. In addition, these measurements can be used to assess the effectiveness of QI initiatives. PMID:25538082

  6. NIH Research: Advances in Parkinson's Disease Research

    Science.gov (United States)

    ... of this page please turn JavaScript on. NIH Research: Advances in Parkinson's Disease Research Past Issues / Winter 2014 Table of Contents Story ... Photo courtesy of NIH Advances in Parkinson's Disease Research Story Landis, Ph.D., has been Director of ...

  7. 75 FR 8372 - National Institute of Mental Health; Notice of Closed Meeting

    Science.gov (United States)

    2010-02-24

    ... HUMAN SERVICES National Institutes of Health National Institute of Mental Health; Notice of Closed... of Committee: National Institute of Mental Health Special Emphasis Panel, HIV AIDS Training. Date... Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001...

  8. 78 FR 40755 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Summer Research Experience Programs... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC...

  9. 78 FR 37835 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-06-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIH Summer Research Experience Programs... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  10. 77 FR 57570 - National Institute On Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-18

    ... HUMAN SERVICES National Institutes of Health National Institute On Deafness and Other Communication..., Bethesda, MD 20892, 301-496-8683, sullivas@mail.nih.gov . Name of Committee: National Institute on Deafness...-8683, singhs@nidcd.nih.gov . Name of Committee: National Institute on Deafness and Other...

  11. FDG-PET scanning in patients with differentiated thyroid cancers. Institutional experience

    International Nuclear Information System (INIS)

    Full text: Patient with detectable serum thyroglobulin (Tg) and negative radioiodine whole body (RAI-WB) scan should have FDG-PET scan to locate tumor tissue. Sometimes scan fail to detect any pathologic accumulation of FDG. Some well-differentiated thyroid cancers do not accumulate FDG. In addition, tumor burden could be so small that imaging becomes impossible. To explore this possibility, several studies explored relationship between serum Tg level and result of FDG-PET scans. Results were inconclusive and it is not clear if there is some low level of serum Tg below which PET scanning is not cost effective. We examined all cases of thyroid cancer patients who underwent FDG-PET scanning in our institution (N-33) for relationship between Tg level and results of the scan. There were 16 females, 17 males. Age was 19-81 years. Follicular cancer was present in 2 patients while 31 had papillary cancer. 14 patients had PET scan while withdrawn from T4 therapy, and 19 patients were scanned while TSH was suppressed. Overall, 20 scans were considered positive, while 12 were negative. One patient was considered to have positive scan but after scan was repeated interpretation was changed into - positive uptake due to inflammation. In patients whose PET scan was positive, Tg level was in a range 6.6-7,108 ng/ml, while those with negative scan had Tg level in 1.7-36.5 ng/ml range. In group withdrawn from T4 therapy and positive scan Tg level ranged from 13.8-7,108 ng/ml, and with negative scan 2.8-36.5 ng/ml. In PET positive patients in euthyroid group Tg ranged 6.6-432 ng/ml and in negative 1.7-13.3 ng/ml. Conclusion: These results suggest that patients who have negative RAI scan and low Tg level may not benefit from PET scanning. In our study Tg level less than 6.6 ng/ml for the whole group, and below 13.8 ng/ml for patient withdrawn from T4 therapy did not result in positive FDG-PET scan result. Our group is small and more data need to be collected to clarify these

  12. Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

    International Nuclear Information System (INIS)

    Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant

  13. 76 FR 66932 - The National Cancer Institute (NCI) Announces the Initiation of a Public Private Industry...

    Science.gov (United States)

    2011-10-28

    ... Initiation of a Public Private Industry Partnership on Translation of Nanotechnology in Cancer (TONIC) To Promote Translational Research and Development Opportunities of Nanotechnology-Based Cancer Solutions... industry partnership called TONIC (Translation Of Nanotechnology In Cancer) to promote...

  14. NIH Precision Medicine Initiative | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... for analyzing large sets of data. Two Main Components The PMI has two main components: a near-term focus on cancers and a ... cancer biology, and establishing a national "cancer knowledge network" that will generate and share new knowledge to ...

  15. Tumor induction following intraoperative radiotherapy: Late results of the National Cancer Institute canine trials

    Energy Technology Data Exchange (ETDEWEB)

    Barnes, M.; Duray, P.; DeLuca, A.; Anderson, W.; Sindelar, W.; Kinsella, T. (Fox Chase Cancer Center, Philadelphia, PA (USA))

    1990-09-01

    Intraoperative radiotherapy has been employed in human cancer research for over a decade. Since 1979, trials to assess the acute and late toxicity of IORT have been carried out at the National Cancer Institute in an adult dog model in an attempt to establish dose tolerance guidelines for a variety of organs. Of the 170 animals entered on 12 studies with a minimum follow-up of 2 years, 148 dogs received IORT; 22 control animals received only surgery. Animals were sacrificed at designated intervals following IORT, usually at 1, 6, 12, 24, and 60 month intervals. 102 of 148 irradiated dogs were sacrificed less than 24 months; 46 dogs were followed greater than or equal to 24 months after IORT. To date, 34 of the 46 animals have been sacrificed; the 12 remaining animals are to be followed to 5 years. These 12 animals have minimum follow-up of 30 months. In the irradiated group followed for greater than or equal to 24 months, 10 tumors have arisen in 9 animals. One animal developed an incidental spontaneous breast carcinoma outside the IORT port, discovered only at scheduled post-mortem exam. The remaining nine tumors arose within IORT ports. Two tumors were benign neural tumors--a neuroma and a neurofibroma. One animal had a collision tumor comprised of grade I chondrosarcoma adjacent to grade III osteosarcoma arising in lumbar vertebrae. Two other grade III osteosarcomas, one grade III fibrosarcoma, and one grade III malignant fibrous histiocytoma arose in retroperitoneal/paravertebral sites. An embryonal rhabdomyosarcoma (sarcoma botryoides) arose within the irradiated urinary bladder of one animal. No sham irradiated controls nor IORT animals sacrificed less than 24 months have developed any spontaneous or radiation-induced tumors. The time range of diagnoses of tumors was 24-58 months. The IORT dose range associated with tumor development was 20-35 Gy.

  16. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis

    International Nuclear Information System (INIS)

    To evaluate the role of intensity modulated radiotherapy (IMRT) for locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer (MPC), and the prognostic factors in the setting of multidisciplinary approach strategies. 63 patients with LAPC and MPC receiving IMRT in our institution were retrospectively identified. Information on patient baseline, treatment characteristics and overall survival (OS) time were collected. Data of pain relief and toxicity were evaluated. Univariate and multivariate analyses were conducted to investigate the prognostic factors. All patients received IMRT with a median dose of 46.0 Gy. The median OS for LAPC and MPC patients were 15.7 months and 8.0 months, respectively (p = 0.029). Symptomatic improvements were observed in the 44 patients with abdominal/back pain after radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), particularly in those with severe pain. Only 13.9% and 14.8% cases presented Grade ≥ 3 hematologic toxicities in RT and CCRT group, while no cases developed Grade ≥ 3 non-hematologic toxicities in both groups. Multivariate analysis indicated that tumors located in pancreas body/tail (HR 0.28, p = 0.008), pretreatment CA19-9 < 1000 U/mL (HR 0.36, p = 0.029) and concurrent chemotherapy (HR 0.37, p = 0.016) were independent favorable predictors for OS. CCRT further improved OS for LAPC and MPC with acceptable toxicities, and use of RT markedly alleviated pain. Tumors located in pancreas body/tail, pretreatment CA19-9 level of < 1000 U/mL and CCRT were associated with better OS. However, regional intra-arterial chemotherapy did not show any survival benefit in our study

  17. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    International Nuclear Information System (INIS)

    The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC) treated with radiotherapy (RT) with or without chemotherapy at 10 institutions in the Tokai District, Japan. Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p < 0.05. For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT) was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016). The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage. In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage

  18. Multi-Institutional Analysis of Early Glottic Cancer from 2000 to 2005

    Directory of Open Access Journals (Sweden)

    Hirasawa Naoki

    2012-08-01

    Full Text Available Abstract Background The purpose of this study is to analyze the outcome of patients with early glottic cancer (GC treated with radiotherapy (RT with or without chemotherapy at 10 institutions in the Tokai District, Japan. Methods Ten institutions combined data from 279 patients with T1-T2 GC treated with RT with or without chemotherapy between 2000 and 2005. The overall survival rate, disease-specific survival rate, and local control rate were evaluated in 270 patients, except for incomplete cases due to issues such as discontinuation, using the method of Kaplan-Meier and compared using the log-rank test. Results were considered statistically significant at the level of p  0.05. Results For 122 patients, the tumors were classified as T1a, while 64 patients had T1b tumors, and 84 patients had T2 tumors. In three cases of T1 tumors, the subtype was unknown. Combined chemoradiotherapy (CRT was administered during each stage, and various chemotherapy drugs and regimens were used. The median follow-up period was 55.4 months. The 5-year LC rates for T1a, Tb, and T2 tumors in all patients were 87.9%, 82.7%, and 74.1%, respectively. The difference between T1a and T2 was statistically significant (p = 0.016. The 5-year LC rates for T1a, Tb, and T2 with CRT were 92.7%, 78.6%, and 80.7%, respectively, while the rates with radiation alone were 86.5%, 83.8%, and 64.4%, respectively. The difference between CRT and RT alone was not statistically significant in each stage. Conclusions In this survey, CRT was performed for early GC at most institutions in clinical practice. Our data showed no statistical difference in the LC rates between CRT and RT alone in each stage. However, there was a tendency for the LCRs of the CRT group to be more favorable than those of the RT group in the T2-stage.

  19. Clinicopathological Spectrum Of Gall Bladder Cancer In Kashmir - An Institutional Study.

    Science.gov (United States)

    Makhdoomi, R; Bashir, N; Bhat, N; Bashir, S; Mustafa, F; Aiman, A; Charaki, A; Hussain, S; Shafi, S; Baht, S; Bashir, N; Zahir, Z; Shah, P

    2016-01-01

    Gallbladder cancer is a highly aggressive malignancy that usually presents at an advanced incurable stage. It is the fifth most common gastro-intestinal tumor and leads to approximately 2800 deaths in United States annually. This was a retrospective study carried out in the Department of Pathology, Sher-i-Kashmir Institute of Medical Sciences, a 650-bed super speciality hospital in Kashmir valley. We reviewed the histopathological records of all the patients who were diagnosed as carcinoma gallbladder from Dec 2009-Dec 2013. Gross findings and histopathological findings were noted from the departmental archival material and clinical records of the patients including the clinical presentation, laboratory investigations, radiological investigations, pre-operative diagnosis and intra-operative findings, were retrieved from the hospital records. We analyzed 57 cases of carcinoma gallbladder for their clinicopathological features It included 19 males and 37 females. In our study, adenocarcinomas accounted for 87.5% of total carcinomas. Incidentally, all but one patient where gall stones were found, adenocarcinomas were seen. We have 4 patients of squamous cell carcinoma. In our series we have a single case of small cell carcinoma which was positive for neuroendocrine markers. In our study, gall stones were seen only in 8 cases (14%) of the total cases. PMID:27050183

  20. Physical properties of a linear accelerator-based stereotactic installed at national cancer institute

    International Nuclear Information System (INIS)

    The purpose of this paper is to present the dosimetry and mechanical accuracy of the first dedicated Siemens PRIMUS M6/6ST linear accelerator-based Stereotactic installed in National Cancer Institute for stereotactic radiosurgery and radiotherapy (SRS/SRT). The data were obtained during the installation, acceptance test procedure, and commissioning of the unit. The Primus M6/6ST has a single 6-MV beam with the same beam characteristics as that of the mother unit, the Siemens. The dosimetric data were taken using pin point ion chamber. The cone sizes vary from 12.5 to 40.0 mm diameter. The mechanical stability of the entire system was verified. The variations in isocenter position with table, gantry, and collimator rotation were found to be < 0.5 mm with a compounded accuracy of < or = 1.0 mm. The beam profiles of all cones in the x and y directions were within +/- 0.5 mm and match with the physical size of the cone. The basic dosimetry parameters such as tissue maximum ratio (TMR), off-axis ratio (OAR) and cone factor needed for patient treatment were evaluated. The mechanical and dosimetric characteristics including dose linearity of this unit are presented and found to be suitable for SRS/SRT. The difficulty in absolute dose measurement for small cone is discussed

  1. Treatment outcomes of female germ cell tumors: The Egyptian National Cancer Institute experience

    International Nuclear Information System (INIS)

    Introduction: Female germ cell tumors (GCTS) are rare tumors that carry a good prognosis. Aim: To report the experience of the Egyptian National Cancer Institute (ENCI) in managing female GCTs. Methods: This retrospective study included 19 females with ovarian GCTs presenting to the ENCI between 2006 and 2010. Results: The median age was 23 years. Ovaries were the primary site in all patients. Dysgerminoma and teratoma were the predominant pathologies followed by mixed GCT in females. Unilateral ovariectomy or ovarian tumorectomy were the classic surgical procedures with R0 resection being feasible in most cases. Surveillance was adopted in six patients with stage I disease. Chemotherapy was administered in 63% of ovarian GCTs with BEP being the commonest regimen with reasonable tolerability and good response rates. The median OS and EFS were not reached. The projected 5-year OS rate was 93.8%. Both OS and EFS were better in patients responding to chemotherapy than non-responders (p< 0.002). Stage of disease did not significantly affect OS or EFS. Conclusions: Female GCTs rarely affect Egyptian females. They have good prognosis.

  2. Evaluation of leakage in cobalt-60 unit in National Cancer Institute (NCI) Wad Medani

    International Nuclear Information System (INIS)

    This study has been conducted primarily to evaluate the leakages radiation in cobalt-60 unit in National Cancer Institute Wad Medani, which represent the basic risky factor in this unit for the radio therapists who spend much time during patient set up, also they need to stand near the head of the machine to fix some accessories. The measurements which done using survey meter give normal level of occupational exposure compared with IAEA references except one situation that the radio therapist to be close contact to the head of unit for long time which may increase the received dose, in this situation. The radio therapist either not well trained, or there is insufficient accessories to reduce the time inside the room. Radiotherapy department need a special considerations from the beginning of construction till starting of treatment. It is important to contain separate rooms, for planning to determine treatment area, another one for molding to shape lead blocks to protect normal parts and an optimum designed room for treatment to enable workers to apply basic radiation protection principles. (Author)

  3. The Gray Cancer Institute X-ray microprobe and its radiobiological applications

    International Nuclear Information System (INIS)

    Radiation micro-beams represent a unique and powerful tool to study and quantify the effects of precise doses of radiation delivered with micron precision to selected biological samples. The Gray Cancer Institute has developed two independent but complementary micro-irradiation facilities, specifically developed for the targeted irradiation of cells and structured tissues; a charged-particle microbeam that uses collimated protons or helium ions and an ultra-soft X-ray microprobe. The ultra-soft X-ray facility employs a focused electron bombardments source to produce a near monochromatic CK X-ray beam. Highly efficient zone plates optimised for the appropriate wavelength are used to focus the characteristic X-rays into a sub-micron spot. The facility is also equipped with a three-axis micro-positioning stage, an epi-fluorescent UV microscope with intensified CCD camera coupled to a fast PC for a automatic, fast and accurate samples recognition and alignment with the probe. Recent experiments have been directed to investigate the bystander effect by irradiating only one cell within a population of V79 cells that are subsequently individually revisited for colony formation. A clear bystander effect has been detected (∼ 10 % reduction in survival) when a single cell has been irradiated. The effect is triggered by very low doses ((∼ 100 mGy) and it is largely dose independent. (authors)

  4. ANALIZA TRGA UPORABNIKOV KOZMETIČNIH STORITEV

    OpenAIRE

    Majcen, Maja

    2010-01-01

    Izhodiščni cilj diplomske naloge je raziskava in analiza trga uporabnikov kozmetičnih storitev. V uvodnem delu so podani opredelitev problema, metodologija ter hipoteze, kar je bilo v pomoč pri izvedbi tržne raziskave. V teoretičnem delu sta predstavljena kozmetična dejavnost skozi marketinški splet 7 x P ter ciljno trženje. Del naloge smo namenili tudi strategiji trženja kozmetičnih storitev ter kakovosti in ugotavljanju zadovoljstva uporabnikov kozmetičnih storitev. Prepoznavnost ...

  5. Clinical and epidemiological profile of cases of deaths from stomach cancer in the National Cancer Institute, Brazil

    OpenAIRE

    Guedes, Maria Teresa dos Santos; de Jesus, José Paulo; de Souza Filho, Odilon; Fontenele, Raquel Malta; Sousa, Ana Inês

    2014-01-01

    Introduction Stomach cancer is the third most common cause of death worldwide, mainly affecting people with low socioeconomic status. In Brazil, we expect 20,390 new cases of stomach cancer in 2014, in both sexes, and according to the proportional distribution of the ten most prevalent types of cancer (except non-melanoma skin cancer) expected for 2014, this type of cancer was estimated to be the fourth most common in men and sixth in women. Aim To investigate and analyse the clinical and epi...

  6. DEMOGRAPHIC AND CLINICOPATHOLOGIC FEATURES OF PATIENTS WITH PRIMARY BREAST CANCER TREATED BETWEEN 1997 AND 2010: A SINGLE INSTITUTION EXPERIENCE.

    Science.gov (United States)

    Žitnjak, Daniela; Soldić, Željko; Kust, Davor; Bolanća, Ante; Kusić, Zvonko

    2015-09-01

    Breast cancer accounted for 28% of all new cancers and 18% of female cancer deaths in Europe in 2010. It is the most common type of cancer in women in Croatia, with an incidence rate of 56.9/100 000 in the year 2010, and the highest number of newly diagnosed women aged between 60 and 64. Multiple factors are associated with an increased risk of breast cancer: advancing age, family history, exposure to endogenous and exogenous reproductive hormones, dietary factors, benign breast disease, and environmental factors. To assess demographic and clinicopathologic features of primary breast cancer, we retrospectively analyzed 870 patients treated in our institution between 1997 and 2010. Data were obtained from medical documentation and a printed questionnaire regarding life habits. Most of our patients presented with a breast lump and were self-diagnosed by breast examination. This fact highlights the need of regular breast self-examination, although it should also be taken into account that most of our patients did not attend regular mammography screening (only 31%). One of the most concerning facts is that the mean time from observing the first symptom to visiting a physician was 4 months. Previous studies have identified ignorance, fear and fatalistic attitudes, poor socioeconomic conditions, and illiteracy as important factors resulting in delay. Considering these facts, education and raising awareness about the disease in the general population is one of the key weapons for lowering breast cancer mortality. PMID:26666098

  7. Institutional Repository Bibliography, Version 1

    OpenAIRE

    Bailey, Jr., Charles W.

    2009-01-01

    The Institutional Repository Bibliography (IRB) presents selected English-language articles, books, and other scholarly textual sources that are useful in understanding institutional repositories. Although institutional repositories intersect with a number of open access and scholarly communication topics, this bibliography only includes works that are primarily about institutional repositories. For example, an article dealing with the NIH open access policy would not be included, but one dea...

  8. 76 FR 24896 - National Institute of Environmental Health Sciences; Notice of Meetings

    Science.gov (United States)

    2011-05-03

    ....), notice is hereby given of meetings of the Interagency Breast Cancer and Environmental Research... Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee (IBCERC) Research...@niehs.nih.gov . Name of Committee: Interagency Breast Cancer and Environmental Research...

  9. NIH Research to Results | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Results Past Issues / Summer 2013 Table of Contents Scientists are studying new ways of working with the immune system to fight cancer. This includes vaccines aimed at making a person immune to his or her skin cancer cells. Another method is to train a person's immune cells to ...

  10. Accelerating Research Productivity in Social Work Programs: Perspectives on NIH's Postdoctoral T32 Research Training Mechanism

    Science.gov (United States)

    Matthieu, Monica M.; Bellamy, Jennifer L.; Pena, Juan B.; Scott, Lionel D., Jr.

    2008-01-01

    This article describes the experiences of four social work researchers who pursued an alternative career path immediately following their doctorate in social work by accepting a postdoctoral training fellowship funded by the National Institutes of Health (NIH). As schools of social work look for creative ways to build research capacity, this…

  11. 75 FR 42114 - Office of Biotechnology Activities; Recombinant DNA Research: Proposed Action Under the NIH...

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... transgenic rodent and a non-transgenic rodent). The NIH Office of Biotechnology Activities (OBA) received a... to the same email address or by fax to 301-496-9839 or mail to the Office of Biotechnology...

  12. 78 FR 12074 - Office of Biotechnology Activities; Recombinant DNA Research: Actions Under the NIH Guidelines...

    Science.gov (United States)

    2013-02-21

    ... containing an HA from the Goose/Guangdong/1/96 lineage should become an HHS Select Agent (77 FR 63783... HUMAN SERVICES National Institutes of Health Office of Biotechnology Activities; Recombinant DNA... recommendations of the RAC, the NIH Office of Biotechnology Activities (OBA) concluded that more specific...

  13. Healthy Aging with Go4Life® | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn JavaScript on. Feature: Healthy Aging Healthy Aging with Go4Life ® Past Issues / Winter 2015 Table of Contents Go4Life from the National Institute on Aging at NIH is a national exercise and physical ...

  14. NIH funds Virginia Tech project to help senior citizens access health care

    OpenAIRE

    Benton, Netta

    2004-01-01

    The National Institutes of Health (NIH) has awarded funding to computer science researchers in the Virginia Tech College of Engineering for a project aimed at making it easier for senior citizens to access Virginia Department for the Aging (VDA) services on the World Wide Web.

  15. 76 FR 69743 - Proposed Collection; Comment Request; Application for Collaboration With the NIH Center for...

    Science.gov (United States)

    2011-11-09

    ... drug project starting points and ongoing biological/disease expertise throughout the project. Frequency... more information on the proposed project or to obtain a copy of the data collection plans and... Branch, NIH Center for Translational Therapeutics, National Human Genome Research Institute,...

  16. 75 FR 2551 - NIH Consensus Development Conference: Lactose Intolerance and Health; Notice

    Science.gov (United States)

    2010-01-15

    ... HUMAN SERVICES National Institutes of Health NIH Consensus Development Conference: Lactose Intolerance... Consensus Development Conference: Lactose Intolerance and Health'' to be held February 22-24, 2010, in the.... Lactose intolerance is the inability to digest significant amounts of lactose, a sugar found in milk...

  17. "Bionic Man" Showcases Medical Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... this page please turn JavaScript on. Feature: The Bionic Man Meet the Bionic Man Past Issues / Fall 2014 Table of Contents ... and medical imaging, visit www.nibib.nih.gov "Bionic Man" Showcases Medical Research The National Institute of ...

  18. Focus on Communication: NIH Research to Results

    Science.gov (United States)

    ... Current Issue Past Issues Special Section: Focus on Communication NIH Research to Results Past Issues / Fall 2008 ... grew new hair cells. Read More "Focus on Communication" Articles Living with Hearing Loss / Anatomy of the ...

  19. Bush favours research at Pentagon and NIH

    CERN Multimedia

    MacIlwain, C

    2001-01-01

    The first budget from George W. Bush increases funding for military research and the NIH, while environmental work is drastically cut. The rest of civilian science funding is essentially frozen (1 page).

  20. From The NIH Director - Envisioning the Future

    Science.gov (United States)

    ... Past Issues From The NIH Director Envisioning the Future Past Issues / Winter 2008 Table of Contents For ... of biomedical imaging—a science that uses advanced technologies to capture, store, analyze, and display images of ...

  1. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Sullivan of NIAID discussed Ebola research with President Barack Obama, as NIAID Director Dr. Anthony Fauci and HHS ... notch today." Two months later, in December, President Barack Obama visited the NIH campus to see the progress ...

  2. GENETIKA SINDROMA POLICISTIČNIH JAJNIKA

    OpenAIRE

    Geršak, Ksenija; Ferk, Polonca

    2007-01-01

    Prikazan je sindrom policističnih jajnika (PCOS) kao heterogena kompleksna bolest, uglavnom iz vidika njegove multifaktorske patogeneze. Genetska pozadina ovog sindroma i najvjerojatniji PCOS geni kandidati detaljno su obrazloženi.

  3. Results of treatment of differentiated thyroid cancers using Iodine-131 at Sri Lanka's first private institution

    International Nuclear Information System (INIS)

    Full text: This department was started in order to meet the urgent demand of iodine-131 treatment in differentiated thyroid cancer (DTC), as the waiting list in government hospitals was unduly long. Data obtained revealed that 52% of the patients had iodine-131 therapy within 4 months, 31% in 4 to 8 months and 17% over 8 months time. Institute received license to order, stock and administer iodine-131 from the AEA-Sri Lanka as its facilities were according to IAEA standards. Facility included three 'single bedded en-suit toilet rooms' with storage capacity for iodine-131 capsules. 115 cases (male: female ratio 1:4) of DTC were treated during the past one and half year and each received 100 GBq of radioactivity. 89 (77.3%) comprised papillary carcinoma, 25 (21.7%) follicular carcinoma and 1 case of mixed carcinoma. 52% of males and 60.8% of females were in the 26-45 years age group. Sixty cases of papillary carcinoma were sub-typed and grouped to observe the distribution of metastases and response to iodine-131. They were follicular variant (FV) in 28 (46%), micropaillary (MP) in 10 (20%), encapsulated (EP) in 8 (13.3%), tall cell (TC) in 3 (5%) and diffuse sclerosis (DS) in 9 (15%). TSH and Tg values were measured before therapy and four months afterwards. Activity readings were measured 30 min after ingestion and 4 days later and discharged when the values were less than 20 μSv / hour. Six of the nine (66%) DS cancer patients had metastasis in lymph nodes and lungs when referred for iodine-131 treatment. In 8 of these patients, Tg levels were raised. 36% (8/9) of the FC patients also had raised Tg levels indicating metastases and 4/5 were found to have bony metastases. In post iodine-131 therapy whole body scans, 3.3% had metastases in the lungs in PC and 20% of FC in skeleton. With a single dose of iodine-131 over 90% had drop in Tg levels to less than I ng/ml except in DS (23% drop) and TC (33% drop). The study shows that sub-typing of PC was useful and TC and

  4. 75 FR 3475 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2010-01-21

    ... Review Branch, NIH/NINDS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, Msc 9529, Bethesda, MD... the Neurosciences, National Institutes of Health, HHS) Dated: January 14, 2010. Jennifer...

  5. Gustation assessment using the NIH Toolbox

    OpenAIRE

    Coldwell, Susan E.; MENNELLA, JULIE A.; Duffy, Valerie B.; Pelchat, Marcia L.; Griffith, James W.; Smutzer, Gregory; Cowart, Beverly J.; Breslin, Paul A.S.; Bartoshuk, Linda M; Hastings, Lloyd; Victorson, David; Hoffman, Howard J.

    2013-01-01

    The NIH Toolbox for Assessment of Neurological and Behavioral Function (NIH Toolbox) is a set of brief measures for the assessment of cognitive function, emotional health, motor function, and sensory function for use in clinical trials and in epidemiologic and longitudinal studies. Gustatory perception is assessed as 1 of 6 areas of sensory function. A team of 11 scientists with expertise in taste perception selected 2 gustatory measures, 1 of which can be used in young pediatric populations....

  6. Cognition assessment using the NIH Toolbox

    OpenAIRE

    Weintraub, Sandra; Dikmen, Sureyya S.; Heaton, Robert K.; Tulsky, David S.; Zelazo, Philip D.; Bauer, Patricia J.; Carlozzi, Noelle E.; Slotkin, Jerry; Blitz, David; Wallner-Allen, Kathleen; Fox, Nathan A.; Beaumont, Jennifer L.; Mungas, Dan; Nowinski, Cindy J.; Richler, Jennifer

    2013-01-01

    Cognition is 1 of 4 domains measured by the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB), and complements modules testing motor function, sensation, and emotion. On the basis of expert panels, the cognition subdomains identified as most important for health, success in school and work, and independence in daily functioning were Executive Function, Episodic Memory, Language, Processing Speed, Working Memory, and Attention. Seven measures were designed to tap ...

  7. Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India

    OpenAIRE

    Georgeena, P; Rajanbabu, Anupama; Vijaykumar, DK; Pavithran, K.; Sundaram, KR; Deepak, KS; Sanal, MR

    2016-01-01

    Objective To evaluate the treatment and survival pattern of patients with advanced epithelial ovarian cancer. Methods and results Retrospective study of all advanced epithelial ovarian cancer patients treated in the department of gynaecologic oncology from an academic centre, in a four year period from 1 January 2008–31 December 2011. Selection criteria All patients with advanced epithelial ovarian cancer (stage III and IV) who underwent surgery from 2008–2011and had a follow-up of at least t...

  8. 78 FR 70309 - Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed...

    Science.gov (United States)

    2013-11-25

    ... Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Boulevard, Room 5B01... of Committee: National Institute of Child Health and Human Development Special Emphasis Panel... Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH,...

  9. Definitive Radiotherapy for T1-2 Hypopharyngeal Cancer: A Single-Institution Experience

    Energy Technology Data Exchange (ETDEWEB)

    Nakajima, Aya, E-mail: anakajima-kyt@umin.ac.jp [Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan); Nishiyama, Kinji; Morimoto, Masahiro; Nakamura, Satoaki; Suzuki, Osamu; Kawaguchi, Yoshifumi; Miyagi, Ken [Department of Radiation Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan); Fujii, Takashi; Yoshino, Kunitoshi [Department of Head and Neck Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka (Japan)

    2012-02-01

    Purpose: To analyze the outcome in T1-2 hypopharyngeal cancer (HPC) patients treated with definitive radiotherapy (RT). Patients and Methods: A total of 103 patients with T1-2 hypopharyngeal squamous cell carcinoma treated with radical RT between March 2000 and June 2008 at our institution were analyzed. Pre-RT neck dissection (ND) was performed in 26 patients with advanced neck disease. Chemotherapy was used concurrently with RT in 14 patients. Sixty patients were associated with synchronous or metachronous malignancies. The median follow-up for surviving patients was 41 months. Results: The 3-year overall and cause-specific survival rates were 70% and 79%, respectively. The 3-year local control rates were 87% for T1 and 83% for T2 disease. The ultimate local control rate was 89%, including 7 patients in whom salvage was successful. The ultimate local control rate with laryngeal preservation was 82%. Tumors of the medial wall of the pyriform sinus tended to have lower control rates compared with tumors of the lateral or posterior pharyngeal wall. Among patients with N2b-3 disease, the 3-year regional control rates were 74% for patients with pre-RT ND and 40% for patients without ND. The 3-year locoregional control rates were as follows: Stage I, 100%; Stage II, 84%; Stage III, 67%; Stage IVA, 43%; Stage IVB, 67%. Forty-two patients developed disease recurrence, with 29 (70%) patients developing recurrence within the first year. Of the 103 patients, 6 developed late complications higher than or equal to Grade 3. Conclusions: Definitive RT accomplished a satisfactory local control rate and contributed to organ preservation.

  10. Cryotherapy for Primary Treatment of Prostate Cancer: Intermediate Term Results of a Prospective Study from a Single Institution

    OpenAIRE

    S. Alvarez Rodríguez; Arias Fúnez, F.; Bueno Bravo, C.; Rodríguez-Patrón Rodríguez, R.; Sanz Mayayo, E.; V. Hevia Palacios; Burgos Revilla, F. J.

    2014-01-01

    Purpose. Published data about cryotherapy for prostate cancer (PC) treatment are based on case series with a lack of clinical trials and the inexistence of a validated definition of biochemical failure. A prospective study with standardized followup protocol was conducted in our institution. Material and Methods. Prospective study of a series of cases including 108 patients diagnosed with localized PC at clinical stage T1c-T2c treated by primary cryoablation and median followup of 61 months. ...

  11. A pilot study to assess the level of depression and the coping strategies adopted by cancer patients receiving treatment in Mizoram State Cancer Institute, Aizawl

    Directory of Open Access Journals (Sweden)

    Gitumoni Konwar

    2015-01-01

    Full Text Available Background: Cancer, the second most common cause of death, has become a major health problem. Depression is the most common psychological problem encountered in patients with cancer. The coping skills adopted may affect the mental health of patients. Therefore, this research is undertaken to assess the level of depression and coping strategy adopted by the patients diagnosed with cancer. Materials and methods: A descriptive study to assess the level of depression and coping strategy adopted by cancer patients receiving treatment in Mizoram State Cancer Institute, Aizawl was carried out from April to May 2014 with 30 convenient samples. Depression was assessed by using Hospital Anxiety and Depression Scale (HADS developed by Zigmond and Snaith in 1983. Coping strategy adopted by patients were assessed by revised version of the Ways of Coping Checklist developed by Folkman and Lazarus in 1985. Results: Findings of the study showed that depression was universal to all the cancer patients. Majority of cancer patients (66.5% had moderate depression while 13.26% of the cancer patients had severe depression, and only 6.7% of them reported to have low depression. The most effective coping strategy adopted was reappraisal, followed by distancing. There is significant correlation between depression and reappraisal (r=-0.538, p<0.002, and also with depression and acceptance (r=-0.415, p<0.022 strategies. Conclusion: As depression is universal to all cancer patients, use of appropriate coping strategy is very essential to improve their quality of life. The recognition of coping strategies by health team may enable appropriate information and interventions to be provided at optimal times for each individual.

  12. 77 FR 16247 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

    Science.gov (United States)

    2012-03-20

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... Allergy and Infectious Diseases, including consideration of personnel qualifications and performance, and... of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH, Building 31,...

  13. Screening mammography. A missed clinical opportunity? Results of the NCI [National Cancer Institute] Breast Cancer Screening Consortium and national health interview survey studies

    International Nuclear Information System (INIS)

    Data from seven studies sponsored by the National Cancer Institute (NCI) were used to determine current rates of breast cancer screening and to identify the characteristics of and reasons for women not being screened. All seven studies were population-based surveys of women aged 50 to 74 years without breast cancer. While over 90% of non-Hispanic white respondents had regular sources of medical care, 46% to 76% had a clinical breast examination within the previous year, and only 25% to 41% had a mammogram. Less educated and poorer women had fewer mammograms. The two most common reasons women gave for never having had a mammogram were that they did not known they needed it and that their physician had not recommended it. Many physicians may have overlooked the opportunity to recommend mammography for older women when performing a clinical breast examination and to educate their patients about the benefit of screening mammography

  14. Comparison of Serum Selenium Levels in Breast Cancer Patients and Healthy People at a Cancer Institute in 2004

    Directory of Open Access Journals (Sweden)

    M Maleki

    2007-01-01

    Full Text Available Introduction: Breast Cancer is one of the most important fatal cancers in women. The mean age of breast cancer in Iran is 48.8 years which is very lower than other countries. Selenium can play an important role in reduction of cancer in several ways, for example selenium increases immunity response and protects cells from oxidation of free radicals and also decreases carcinogenic metabolites. Breast cancer is one of the most important cancers in our country because its incidence is very high and the mean age of patients is very low. Different studies have shown the benefits of selenium in prevention of cancer and since many years selenium has been used as a dietary supplement in advanced countries. Several studies regarding relationship between selenium levels and breast cancer have been done in different countries. We therefore planned a study to evaluate serum selenium levels in breast cancer patients and compare them with a healthy control group. Methods: We selected 45 patients younger than 48 years old and 33 patients older than 48 years old who had not yet received any therapy (surgery, chemotherapy, etc for their cancer as a case group and 46 healthy people who were matched with the patients as a control group and included 23 persons younger and 23 persons older than 48 years old. From each participant, 5cc blood was derived and in several stages, serum selenium levels were evaluated using atomic absorption technology. Data about type of cancer, stage, grade, IHC and cigarette smoking were also collected. Results: The mean Se level was 161.20 μg/l (SD=46.27 μg/l in the patients and 189.13 μg/l (SD=48.75 μg/l in the control group that was statistically significant (P48 years old was 155.39 μg/l (SD=46.68 μg/l that was lower than the control groups. Difference in serum selenium levels between patients and controls in the older group was significant (P=0.007, but in the younger group, it was not statistically significant (P=0

  15. Is the NIH policy for sharing GWAS data running the risk of being counterproductive?

    Directory of Open Access Journals (Sweden)

    Krawczak Michael

    2010-09-01

    Full Text Available Abstract Through their current policy on data sharing, the National Institutes of Health (NIH are inadvertently placing a serious and potentially insuperable burden upon non-US researchers who perform patient-based genomics studies in collaboration with US institutions. Because this policy could adversely affect future transnational scientific collaborations, we explore some of its likely consequences and suggest possible courses of remedial action wherever feasible.

  16. NIH's National Institute of Nursing Research Is Changing Lives

    Science.gov (United States)

    ... center, from the school health office to the intensive care unit —we count on them to give the shot, hold the hand, manage the care, answer the questions, and give trusted advice. Nurses play a central role in nearly every aspect ...

  17. Retrospective assessment of occupational asbestos exposure among 220 patients with respiratory cancer hospitalized at Vilnius University Institute of Oncology

    International Nuclear Information System (INIS)

    No cases of lung cancer or mesothelioma have ever been diagnosed or compensated as asbestos-related in Lithuania. This paper attempts to estimate the proportion of those occupationally exposed to asbestos among respiratory cancer patients. Occupational exposure to asbestos was assessed retrospectively for 218 lung cancer and 2 mesothelioma patients admitted to Institute of Oncology, Vilnius University. The evaluation was based on personal interview data using an internationally established questionnaire. Cumulative exposure to asbestos at work was evaluated in fibre-years. A cumulative asbestos exposure of ≥25 fibre-years was found for 7 patients (3.2%), in further 135 (61.2%) a cumulative exposure from 0.01 to 24.99 fibre-years was assessed. The most common occupations among heavily (≥25 fibre-years) exposed patients were smith, welder or insulator in foundries, construction, shipyard as well as asbestos cement and glass industry. Preliminary findings indicate that a fraction (3.2%) of the respiratory cancer cases could be attributed to occupational exposure to asbestos. Since 1560 or more cases of lung cancer are registered every year in Lithuania, about 50 cases per year could be predicted to be asbestos-related. (author)

  18. Natural products against cancer: A comprehensive bibliometric study of the research projects, publications, patents and drugs

    OpenAIRE

    Jian Du; Xiaoli L Tang

    2014-01-01

    Objectives: To analyze multi-source data including awards, publications, patents and drugs, and try to draw the whole landscape of the research and development community in the area of natural products (NPs) against cancer. Materials and Methods: Awards, publications, patents and drugs data from National Institute of Health/Natural Science Foundation of China (NIH/NSFC), PubMed, Derwent Innovation Index and Cortellis were collected. Bibliometric methodologies and technology are used to in...

  19. Epidemiology and management of breast carcinoma in Egyptian males: Experience of a single Cancer Institute

    International Nuclear Information System (INIS)

    To assess the epidemiological and clinico-pathological features, surgical and reconstructive techniques, adjuvant treatments and clinical outcome of breast carcinoma in males (BCM) at the Egyptian National Cancer Institute (NCI). Patients and methods: Thirty-two males with breast carcinoma presented to NCI between January 2000 and December 2002. They were evaluated by complete history, physical examination, laboratory and radiological investigations. Results: Median age was 59 years. Left sided and retroareolar breast lumps were the commonest presentations. Grade 11 tumors positive for hormone receptors were very common. Stage I, II, 111 and IV disease were encountered in 6.2%, 34.4%, 34.4% and 25.0% of patients, respectively. Curative surgery was done in 22 patients; they received adjuvant hormonal therapy, chemotherapy and radiotherapy in 22,16 and 10 patients, respectively. Eight metastatic patients were treated with palliative measures. Surgery was done in 25 patients; the most common procedure was modified radical mastectomy (40.6%). Primary closure was feasible in 17 patients (68%), local flaps were needed in 4 cases (16%), while myocutaneous flap was done in 3 cases (12%). The commonest complication was development of seroma (9 cases). The overall survival (OS) at 5 years was 65.4%. The disease free survival (DPS) at 5 years was 53.9%. Stage and curative surgery significantly affected OS, while type of surgery was the only variable significantly affecting DPS. Conclusion: Male breast carcinoma occurs at older ages than females, usually in advanced stage. This necessitates directing attention of males and awareness on the prevalence and risk factors for this disease.needed in 4 cases (16%), while myocutaneous flap was done in 3 cases (12%). The commonest complication was development of seroma (9 cases). The overall survival (OS) at 5 years was 65.4%. The disease free survival (DPS) at 5 years was 53.9%. Stage and curative surgery significantly affected OS

  20. Reproductive Factors and Kidney Cancer Risk in 2 US Cohort Studies, 1993–2010

    Science.gov (United States)

    Karami, Sara; Daugherty, Sarah E.; Schonfeld, Sara J.; Park, Yikyung; Hollenbeck, Albert R.; Grubb, Robert L.; Hofmann, Jonathan N.; Chow, Wong-Ho; Purdue, Mark P.

    2013-01-01

    Clinical and experimental findings suggest that female hormonal and reproductive factors could influence kidney cancer development. To evaluate this association, we conducted analyses in 2 large prospective cohorts (the National Institutes of Health–AARP Diet and Health Study (NIH-AARP), 1995–2006, and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), 1993–2010). Cohort-specific and aggregated hazard ratios and 95% confidence intervals relating reproductive factors and kidney cancer risk were computed by Cox regression. The analysis included 792 incident kidney cancer cases among 283,952 postmenopausal women. Women who had undergone a hysterectomy were at a significantly elevated kidney cancer risk in both NIH-AARP (hazard ratio = 1.28, 95% confidence interval: 1.09, 1.50) and PLCO (hazard ratio = 1.41, 95% confidence interval: 1.06, 1.88). Similar results were observed for both cohorts after analyses were restricted to women who had undergone a hysterectomy with or without an oophorectomy. For the NIH-AARP cohort, an inverse association was observed with increasing age at menarche (P for trend = 0.02) and increasing years of oral contraceptive use (P for trend = 0.02). No clear evidence of an association with parity or other reproductive factors was found. Our results suggest that hysterectomy is associated with increased risk of kidney cancer. The observed associations with age at menarche and oral contraceptive use warrant further investigation. PMID:23624999

  1. Clinical features of esophageal cancer in the octogenarian treated by definitive radiotherapy. A multi-institutional retrospective survey

    International Nuclear Information System (INIS)

    As age-related infirmity often influences treatment options and outcome of esophageal cancer, the optimization of treatment for the elderly, especially in octogenarians, has been the subject of considerable debate. We performed a retrospective, multi-institutional survey to assess the effect of age on the outcome of definitive radiotherapy for esophageal cancer by a questionnaire sent to eight institutions in Japan. There were 362 evaluable replies. The patients included 317 males and 45 females, with a median age of 72 years (range 35-93 years), and 96% had squamous cell carcinoma. There were 30 clinical stage I, 71 stage IIA, 17 stage IIB, 113 stage III and 116 stage IV cases. The stage was not specified in 16 cases. Multiple co-morbidities existed in 40% of the patients who were 70 years of age or older. There was no statistically significant age-related difference in the incidence of adverse reactions to radiotherapy (p>0.05). Overall survival was more significantly affected by Karnofsky Performance Status than by the patient's age. The influence of performance status on cumulative survival for stage I and II disease was more pronounced in patients in their 80s. The safety of radiotherapy for esophageal carcinoma is not influenced by the patient's age. Because the performance status strongly influenced survival, the multi-disciplinary assessment of functional status is mandatory for optimizing the choice of treatment for patients in their 80s with esophageal cancer. (author)

  2. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health–AARP Diet and Health Study

    OpenAIRE

    Gierach, Gretchen L.; James V Lacey; Schatzkin, Arthur; Leitzmann, Michael F.; Richesson, Douglas; Hollenbeck, Albert R.; Brinton, Louise A.

    2008-01-01

    Introduction By inhibiting cyclooxygenase-2, nonsteroidal anti-inflammatory drugs (NSAIDs) decrease aromatase activity and might reduce breast cancer risk by suppressing estrogen synthesis. Epidemiologic evidence for a protective role of NSAIDs in breast cancer, however, is equivocal. Methods We tested NSAID use for its association with breast cancer incidence in the National Institutes of Health–AARP Diet and Health Study, where 127,383 female AARP (formerly known as the American Association...

  3. Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop.

    Science.gov (United States)

    Balogh, Erin P; Ganz, Patricia A; Murphy, Sharon B; Nass, Sharyl J; Ferrell, Betty R; Stovall, Ellen

    2011-01-01

    The Institute of Medicine's National Cancer Policy Forum recently convened a workshop on patient-centered cancer treatment planning, with the aim of raising awareness about this important but often overlooked aspect of cancer treatment. A primary goal of patient-centered treatment planning is to engage patients and their families in meaningful, thorough interactions with their health care providers to develop an accurate, well-conceived treatment plan, using all available medical information appropriately while also considering the medical, social, and cultural needs and desires of the patient and family. A cancer treatment plan can be shared among the patient, family, and care team in order to facilitate care coordination and provide a roadmap to help patients navigate the path of cancer treatment. There are numerous obstacles to achieving patient-centered cancer treatment planning in practice. Some of these challenges stem from the patient and include patients' lack of assertiveness, health literacy, and numeracy, and their emotional state and concurrent illnesses. Others are a result of physician limitations, such as a lack of time to explain complex information and a lack of tools to facilitate treatment planning, as well as insensitivity to patients' informational, cultural, and emotional needs. Potential solutions to address these obstacles include better training of health care providers and patients in optimal communication and shared decision making, and greater use of support services and tools such as patient navigation and electronic health records. Other options include greater use of quality metrics and reimbursement for the time it takes to develop, discuss, and document a treatment plan. PMID:22128118

  4. Determinants of quality of life in prostate cancer patients: A single institute analysis

    Directory of Open Access Journals (Sweden)

    Yao-Lin Kao

    2015-12-01

    Conclusion: Our data demonstrated that marital status is an important determinant of quality of life in prostate cancer patients besides other sociodemographic factors. Clinicians are advised to provide more social support recourses for patients who do not have a partner.

  5. Determinants of quality of life in prostate cancer patients: A single institute analysis

    OpenAIRE

    Yao-Lin Kao; Yuh-Shyan Tsai; Fat-Ya Ou; Ya-Jhu Syu; Chien-Hui Ou; Wen-Horng Yang; Hong-Lin Cheng; Tzong-Shin Tzai; Jung-Der Wang

    2015-01-01

    Objective: To determine factors that influence quality of life in prostate cancer patients. Patients and methods: Patients with pathologically verified prostate cancer and treated at the National Cheng Kung University Hospital were invited to fill out the World Health Organization Quality of Life-BREF questionnaires at the outpatient clinic. We explored the determinants of quality of life including age, education, income, marital status, disease stage, and treatment modality using a mixed-...

  6. Cryotherapy for primary treatment of prostate cancer: intermediate term results of a prospective study from a single institution.

    Science.gov (United States)

    Rodríguez, S Alvarez; Arias Fúnez, F; Bueno Bravo, C; Rodríguez-Patrón Rodríguez, R; Sanz Mayayo, E; Palacios, V Hevia; Burgos Revilla, F J

    2014-01-01

    Purpose. Published data about cryotherapy for prostate cancer (PC) treatment are based on case series with a lack of clinical trials and the inexistence of a validated definition of biochemical failure. A prospective study with standardized followup protocol was conducted in our institution. Material and Methods. Prospective study of a series of cases including 108 patients diagnosed with localized PC at clinical stage T1c-T2c treated by primary cryoablation and median followup of 61 months. Criteria of biochemical recurrence were unified according to the American Society for Therapeutic Radiology and Oncology (ASTRO). End points were biochemical progression-free survival (BPFS), cancer-specific survival, and overall survival. Rate of complications was reported. Results. The BPFS for low-, medium-, and high-risk patients was 96.4%, 91.2%, and 62.2%, respectively. Cancer-specific survival was 98.1%. Overall survival reached 94.4%. Complications included incontinence in 5.6%, urinary tract obstruction in 1.9%, urethral sloughing in 5.6%, haematuria in 1.9%, perineal pain in 11.1%, and prostatorectal fistula in 0.9%. Erectile disfunction was found in 98.1%. Conclusions. Cryotherapy is an effective and minimally invasive treatment for primary PC in well-selected cases, with low surgical risk and good results in terms of BPFS, cancer-specific survival, and overall survival. PMID:24693437

  7. NIH医学研究路线图(NIH roadmap)

    Institute of Scientific and Technical Information of China (English)

    徐高连; 赵冰海; 吕学诜

    2005-01-01

    多年来,国防和医疗领域一直是美国科技政策的重点。美国国立卫生研究院(national institutes of health,NIH)不仅是美国,也是世界上从事生命科学研究最重要的研究机构,它的一举一动无不对世界的科学研究,尤其是生命科学的发展有着巨大的影响。为提高医学研究能力,加速基础医学研究成果向临床应用的转化,NIH院长瑞尔霍尼(Elias A.Zerhouni)博士于2003年10月1日公布了NIH医学研究路线图(the NIH roadmap for medical research,NIH roadmap),这是一个通向生命科学未来的“中长期发展规划”,它将对21世纪全世界医学的发展产生重大影响。

  8. NIH study shows increased risk for two types of myotonic muscular dystrophy

    Science.gov (United States)

    Adults with a form of muscular dystrophy called myotonic muscular dystrophy (MMD) may be at increased risk of developing cancer, according to a study by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health.

  9. 76 FR 37358 - Office of the Director, National Institutes of Health; Notice of Meeting

    Science.gov (United States)

    2011-06-27

    ... p.m. Agenda: To review and evaluate second-level review of NIH Director's Early Independence Awards... HUMAN SERVICES National Institutes of Health Office of the Director, National Institutes of Health... Councils. Date: August 15, 2011. Open: 1 p.m. to 2: p.m. Agenda: Discussion of NIH Director's...

  10. NIH Research Addresses Aging Issues and Disparities in Oral Health | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... maintain oral health. The research is evaluating motivational interviewing, counseling, and oral hygiene skills-building to establish which approach(es) is most effective. We are also in active discussions with NIH ...

  11. The Children's Inn at NIH - Three Stories | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: The Children's Inn The Children's Inn at NIH - Three Stories Past Issues / Summer 2014 Table of Contents Kristal Nemeroff—The Patient Kristal Nemeroff, age 2, at the Children's ...

  12. 77 FR 68134 - Submission for OMB Review; Comment Request (30-day): National Institute of Nursing Research (NINR...

    Science.gov (United States)

    2012-11-15

    ...): National Institute of Nursing Research (NINR) Summer Genetics Institute Alumni Survey SUMMARY: Under the...: Dr. Amanda Greene, Office of Science Policy and Public Liaison, NINR, NIH, Democracy One, 6701... publication. Proposed Collection: National Institute of Nursing Research (NINR) Summer Genetics...

  13. Proposed NIH Budget Includes Mandatory Funding.

    Science.gov (United States)

    2016-05-01

    President Obama has proposed an overall budget increase of $825 million for the NIH in fiscal year 2017 compared with 2016. That money would be reserved for three efforts: the NCI's "moonshot" initiative, the Precision Medicine Initiative cohort program, and the BRAIN program. PMID:26984350

  14. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Insel. "The sooner we are able to identify early markers for autism, the more effective our treatment interventions can be." ... stage clinical trials. NIH scientists are starting an early-stage ... even when symptoms aren't showing. Researchers say a protective vaccine ...

  15. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Winter 2014 Table of Contents From DNA to Beer: Harnessing Nature in Medicine and Industry is an online exhibition created by the National ... consume. The exhibition is called From DNA to Beer: Harnessing Nature in Medicine and Industry. NIH's National Library of Medicine created it with ...

  16. 77 FR 10455 - National Institutes of Health Loan Repayment Programs

    Science.gov (United States)

    2012-02-22

    ... awards, e.g., NIH Intramural Research Training Awards (IRTA) or Cancer Research Training Awards (CRTA... nature, such as a physical or mental disability or terminal illness in the immediate family, which...

  17. A Novel Cross-Disciplinary Multi-Institute Approach to Translational Cancer Research: Lessons Learned from Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC

    Directory of Open Access Journals (Sweden)

    Ashokkumar A. Patel

    2007-01-01

    Full Text Available Background: The Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC, http://www.pcabc.upmc.edu is one of the first major project-based initiatives stemming from the Pennsylvania Cancer Alliance that was funded for four years by the Department of Health of the Commonwealth of Pennsylvania. The objective of this was to initiate a prototype biorepository and bioinformatics infrastructure with a robust data warehouse by developing a statewide data model (1 for bioinformatics and a repository of serum and tissue samples; (2 a data model for biomarker data storage; and (3 a public access website for disseminating research results and bioinformatics tools. The members of the Consortium cooperate closely, exploring the opportunity for sharing clinical, genomic and other bioinformatics data on patient samples in oncology, for the purpose of developing collaborative research programs across cancer research institutions in Pennsylvania. The Consortium’s intention was to establish a virtual repository of many clinical specimens residing in various centers across the state, in order to make them available for research. One of our primary goals was to facilitate the identification of cancer specific biomarkers and encourage collaborative research efforts among the participating centers.Methods: The PCABC has developed unique partnerships so that every region of the state can effectively contribute and participate. It includes over 80 individuals from 14 organizations, and plans to expand to partners outside the State. This has created a network of researchers, clinicians, bioinformaticians, cancer registrars, program directors, and executives from academic and community health systems, as well as external corporate partners - all working together to accomplish a common mission. The various sub-committees have developed a common IRB protocol template, common data elements for standardizing data collections for three organ sites, intellectual

  18. A long-term survival pattern for breast cancer treated in a single institution

    Directory of Open Access Journals (Sweden)

    T Gokce

    2011-01-01

    Full Text Available Aim: This paper presents a 14-year retrospective study evaluating the survival rates and prognostic factors of breast carcinoma patients treated in private treatment center in the west coast of Turkey. Materials and Methods: The survival rates of breast cancer patients (n = 1746 who have been treated from 1995 until 2008 were analyzed. The clinical data include age, menopausal stage, oestrogen (ER and progesterone (PR receptor status, and C-erbB-2 status as well as histopathological evaluation. AJCC (2002 was used for clinical tumor staging. Survival rates were computed using standard Kaplan-Meier methods, and the difference in survival curves was analyzed with the log-rank test. Results: The 14-year overall survival, disease-free survival, local failure-free survival, and distant failure-free survival rates were 77%, 95%, 77%, and 94%, respectively. Early-stage patients had higher overall survival rates compared to advanced-stage patients (stage IIIb and IIIc, AJCC 2002, and early-stage patients had higher survival rates than advanced-stage patients for disease-free survival, local failure-free survival, and distant failure-free survival. The risk for cancer development increases significantly for advanced-stage patients with positive ER and PR receptor as well as C-erbB-2 receptor. Conclusions: The incidence of breast cancer in Turkey is smaller compared to other European countries. Low advanced-stage patient numbers compared to high early-stage patient numbers; and very high median survival times could possibly be the result of the improvement of detection and treatment of breast cancer over the years.

  19. Radiotherapy in the cavum cancer: analysis of 30 cases treated in our institution in Beirut

    International Nuclear Information System (INIS)

    The authors describe the results obtained for nasopharyngeal cancers treated by irradiation, exclusively or in combination with chemotherapy. They also assess the impact of the different pathological and clinic variables on survival without relapse. The study is based on a sample of 30 patients treated between 1999 and 2009. Local control, metastatic dissemination, and toxicity are analysed and discussed. A ganglionary extension seems to be the worst prognostic factor. Short communication

  20. Intraoperative Radiotherapy for Pancreatic Cancer: 30-Year Experience in a Single Institution in Japan

    Energy Technology Data Exchange (ETDEWEB)

    Jingu, Keiichi, E-mail: kjingu-jr@rad.med.tohoku.ac.jp [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan); Tanabe, Takaya [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan); Nemoto, Kenji [Department of Radiation Oncology, Yamagata University School of Medicine, Yamagata (Japan); Ariga, Hisanori; Umezawa, Rei; Ogawa, Yoshihiro; Takeda, Ken; Koto, Masashi; Sugawara, Toshiyuki; Kubozono, Masaki; Shimizu, Eiji; Abe, Keiko; Yamada, Shogo [Department of Radiation Oncology, Tohoku University School of Medicine, Sendai (Japan)

    2012-07-15

    Purpose: To analyze retrospectively the results of intraoperative radiotherapy (IORT) with or without external beam radiotherapy ({+-} EBRT) for localized pancreatic cancer in the past three decades and to analyze prognostic factors by multivariate analysis. Methods and Materials: Records for 322 patients with pancreatic cancer treated by IORT {+-} EBRT in Tohoku University Hospital between 1980 and 2009 were reviewed. One hundred ninety-two patients who had no distant organ metastases or dissemination at the time of laparotomy were enrolled in the present study. Results: Eighty-three patients underwent gross total resection (R0: 48 patients, R1: 35 patients), and 109 patients underwent only biopsy or palliative resection. Fifty-five patients underwent adjuvant EBRT, and 124 underwent adjuvant chemotherapy. The median doses of IORT and EBRT were 25 and 40 Gy, respectively. The median follow-up period was 37.5 months. At the time of the analysis, 166 patients had disease recurrence, and 35 patients had local failure. The 2-year local control (LC) and overall survival (OS) rates were 71.0% and 16.9%, respectively. Comparison of the results for each decade showed that OS was significantly improved decade by decade (2-year: 25.0% vs. 18.8% vs. 4.2%, p < 0.001). Multivariate analysis showed that degree of resection (R0-1 vs. R2, hazard ratio = 1.97, p = 0.001) and adjuvant chemotherapy (yes vs. no, hazard ratio = 1.54, p = 0.028) had significant impacts on OS. Late gastrointestinal morbidity of Common Terminology Criteria for Adverse Events version 3.0 grade 4 or 5 was observed in four patients. Conclusion: Excellent local control for pancreatic cancer with few cases of severe late toxicity was achieved by using IORT. OS of patients with pancreatic cancer treated by IORT {+-} EBRT improved significantly decade by decade. Multivariate analysis showed that degree of resection and adjuvant chemotherapy had significant impacts on OS.

  1. The NIH Intramural Research Loan Repayment Program: Career Outcomes of Participants and Nonparticipants.

    OpenAIRE

    Steven Glazerman; Neil Seftor

    2005-01-01

    For over a decade, the National Institutes of Health has been using repayment of education loans as an incentive to attract and retain first-rate biomedical scientists in its labs and clinics. This report from an evaluation of the NIH Intramural Loan Repayment Programs uses new survey data on recruitment of biomedical researchers and career paths of program participants and nonparticipants to assess the role of these policies in recruiting and retention outcomes. The findings suggest that eli...

  2. Abbreviated report of the NIH/NINDS workshop on sudden unexpected death in epilepsy

    OpenAIRE

    Hirsch, L J; Donner, E.J.; So, E. L.; M. Jacobs; Nashef, L.; Noebels, J.L.; Buchhalter, J.R.

    2011-01-01

    Sudden unexpected death in epilepsy (SUDEP) is a devastating complication of epilepsy and is not rare. The NIH and National Institute of Neurological Disorders and Stroke sponsored a 3-day multidisciplinary workshop to advance research into SUDEP and its prevention. Parallel sessions were held: one with a focus on the science of SUDEP, and the other with a focus on issues related to the education of health care practitioners and people with epilepsy. This report summarizes the discussions and...

  3. 75 FR 28031 - National Institute of Dental & Craniofacial Research; Notice of Closed Meetings

    Science.gov (United States)

    2010-05-19

    ..., Scientific Review Officer, Scientific Review Branch, National Inst of Dental & Craniofacial Research, NIH...; Teleconference Review of Small Research Grants for Data Analysis and Statistical Methodology (R03) Applications... HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial...

  4. 75 FR 19979 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-16

    ... evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive... Review Administrator, Scientific Review Branch, NIH/NINDS/Neuroscience Center, 6001 Executive Blvd....854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated:...

  5. Cervical Lymph Node Metastases From Unknown Primary Cancer: A Single-Institution Experience With Intensity-Modulated Radiotherapy

    Energy Technology Data Exchange (ETDEWEB)

    Villeneuve, Hugo, E-mail: hugo.villeneuve@umontreal.ca [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Despres, Philippe; Fortin, Bernard; Filion, Edith; Donath, David [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Soulieres, Denis [Department of Medical Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Guertin, Louis; Ayad, Tarek; Christopoulos, Apostolos [Department of Head and Neck Surgery, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada); Nguyen-Tan, Phuc Felix [Department of Radiation Oncology, Centre hospitalier de l' Universite de Montreal, Montreal, QC (Canada)

    2012-04-01

    Purpose: To determine the effectiveness and rate of complications of intensity-modulated radiotherapy (IMRT) in the treatment of cervical lymph node metastases from unknown primary cancer. Methods and Materials: Between February 2005 and November 2008, 25 patients with an unknown primary cancer underwent IMRT, with a median radiation dose of 70 Gy. The bilateral neck and ipsilateral putative pharyngeal mucosa were included in the target volume. All patients had squamous cell carcinoma, except for 1 patient who had adenosquamous differentiation. They were all treated with curative intent. Of the 25 included patients, 20 were men and 5 were women, with a median age of 54 years. Of these patients, 3 had Stage III, 18 had Stage IVa, and 4 had Stage IVb. Of the 25 patients, 18 (72%) received platinum-based chemotherapy in a combined-modality setting. Neck dissection was reserved for residual disease after definitive IMRT. Overall survival, disease-free survival, and locoregional control were calculated using the Kaplan-Meier method. Results: With a median follow-up of 38 months, the overall survival, disease-free survival, and locoregional control rates were all 100% at 3 years. No occurrence of primary cancer was observed during the follow-up period. The reported rates of xerostomia reduced with the interval from the completion of treatment. Nine patients (36%) reported Grade 2 or greater xerostomia at 6 months, and only 2 (8%) of them reported the same grade of salivary function toxicity after 24 months of follow-up. Conclusion: In our institution, IMRT for unknown primary cancer has provided good overall and disease-free survival in all the patients with an acceptable rate of complications. IMRT allowed us to address the bilateral neck and ipsilateral putative pharyngeal mucosa with minimal late salivary function toxicity. The use of concurrent chemotherapy and IMRT for more advanced disease led to good clinical results with reasonable toxicities.

  6. Lung Cancer in Homeless People: Clinical Outcomes and Cost Analysis in a Single Institute

    Directory of Open Access Journals (Sweden)

    Koung Jin Suh

    2016-01-01

    Full Text Available Introduction. To characterize the demographic and clinical features, outcomes, and treatment costs of lung cancer in homeless people. Methods. Medical records of 22 homeless patients with lung cancer at Seoul National University Boramae Medical Center in Seoul, South Korea, were retrospectively analyzed. Results. All patients were men (median age, 62 years. Most patients (78% had advanced disease (stage IIIB, n=2; stage IV, n=15. Seven died during initial hospitalization (median survival, 1.5 months. Six were lost to follow-up after initial outpatient visits or discharges from initial admission (median follow-up, 13 days. Only 4 received appropriate treatment for their disease and survived for 1, 15, 19, and 28 months, respectively. Conversely, 4 of 5 patients with early stage disease (stage I, n=4; stage IIA, n=1 received curative surgery (median follow-up 25.5 months. The median treatment cost based on 29 days of hospitalization and 2 outpatient visits was $12,513, constituting 47.3% of the 2013 per capita income. Inpatient treatment accounted for 90% of the total costs. The National Health Insurance Service paid 82% of the costs. Conclusion. Among the homeless, lung cancer seems to be associated with poor prognosis and substantial costs during a relatively short follow-up and survival period.

  7. CPRIT/Johnson Space Center, September, 2011 (Cancer Prevention and Research Institute of Texas)

    Science.gov (United States)

    Davis, Jeffrey; Lane, Helen; Baker, Tracey; Cucinotta, Francis; Wu, Honglu

    2011-01-01

    JSC researchers study carcinogenesis, cancer prevention and treatment along with epidemiological (primarily retrospective and longitudinal) studies, modeling, and interactions with the environment such as radiation, nutritional, and endocrine changes related to space flight along with behaviors such as smoking. Cancer research is a major focus for human space flight due to the exposure to space radiation which consists of particles of varying charges and energies, and secondary neutrons. The JSC laboratories collaborate with investigators from the U.S. as well as our European and Japanese partners. We use accelerator facilities at the Brookhaven National Laboratory, Loma Linda University and Los Alamos National Laboratory that generate high energy charged particles and neutrons to simulate cosmic radiation and solar particle events. The research using cultured cells and animals concentrates on damage and repair from the level of DNA to organ tissues, due to exposure to simulated space radiation exposure, that contribute to the induction of leukemia and solid tumors in most major tissues such as lung, colon, liver and breast. The goal of the research is to develop a mathematical model that can predict cancer morbidity and mortality risks with sufficient accuracy for a given space mission.

  8. Lung Cancer Surgery Worthwhile for Older Patients

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158689.html Lung Cancer Surgery Worthwhile for Older Patients Study found those ... 2016 THURSDAY, May 5, 2016 (HealthDay News) -- Older lung cancer patients are surviving longer when they have lung ...

  9. Honoring Pioneers in Breast Cancer Research

    Science.gov (United States)

    ... Current Issue Past Issues Honoring Pioneers in Breast Cancer Research Past Issues / Spring 2007 Table of Contents For ... Distinguished Medical Service Award for their pioneering breast cancer research. Photo courtesy of Bill Branson, NIH In this ...

  10. Colon Cancer Rising in People Under 50

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_159004.html Colon Cancer Rising in People Under 50 Incidence up more ... TUESDAY, May 24, 2016 (HealthDay News) -- Although overall colon cancer rates are declining, the rates among Americans under ...

  11. 'Sunscreen' Gene May Guard Against Skin Cancer

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_158935.html 'Sunscreen' Gene May Guard Against Skin Cancer Researchers hope their ... say they've identified a so-called "sunscreen" gene that may help protect against skin cancer. They ...

  12. A simple technique for the generation of institution-specific nomograms for permanent prostate cancer brachytherapy

    OpenAIRE

    Lafata, Kyle J.; Bushe, Harry; Aronowitz, Jesse N.

    2014-01-01

    Purpose Nomograms once had a vital role in prostate brachytherapy practice. Although some of their functions have been assumed by computerized dosimetry, many programs still find them useful to determine the number and strength of seeds to be ordered in advance of the implant. As it has been demonstrated that brachytherapists differ in their implant practices and preferences (in regard to seed distribution and total implanted activity), we propose a simple technique for generating institution...

  13. 2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct metastatic organ-specific potentials: Comparison with parental cell line MDA-MB-231

    Czech Academy of Sciences Publication Activity Database

    Selicharová, Irena; Šanda, Miloslav; Mládková, Jana; Ohri, S. S.; Vashishta, A.; Fusek, M.; Jiráček, Jiří; Vetvicka, V.

    2008-01-01

    Roč. 19, č. 5 (2008), s. 1237-1244. ISSN 1021-335X R&D Projects: GA MZd NR8323 Grant ostatní: NIH(US) ROI CAA082159-03 Institutional research plan: CEZ:AV0Z40550506 Keywords : breast cancer * cell line * 2-DE * organ-specific metastases Subject RIV: CE - Biochemistry Impact factor: 1.524, year: 2008

  14. OBVLADOVANJE KONFLIKTOV V RAZLIČNIH ORGANIZACIJAH

    OpenAIRE

    Slemenšek, Nastja

    2015-01-01

    Ljudje se vsakodnevno spopadamo s konflikti na različnih mestih, z različnimi ljudmi. Redko kdo pa razmišlja o tem, kaj je konflikt, kako nastane, kakšne so posledice in kako jih je najlažje reševati. Ko govorimo o konfliktu, najprej pomislimo, da je to nekaj negativnega, nihče pa ne pomisli, da je lahko vsak najmanjši spor odlična priložnost za izboljšanje in razvoj. Izredno pomembno je, da se tega zavedajo tudi vsi zaposleni v podjetjih, od direktorja do podrejenih. Glede na to, da so nemot...

  15. Comparison of two different treatment regimens for cancer of uterine cervix as practised in our institute: a retrospective analysis

    International Nuclear Information System (INIS)

    Starting from the early days of radiotherapy practice till today, cancer of female uterine cervix is the most common malignant disease in India. A number of treatment modalities are being used for the treatment of this disease. Earlier, Wertheim's hysterectomy was the primary line of treatment. But due to poor cosmetic results and other complications, nowadays radiotherapy is the most preferred modality for the radical treatment of this commonest malignancy. Due to the lack of any universally accepted radiotherapy treatment regime, different oncology therapists within the same institute are practising different regimens derived from their own clinical practice experience. Majority of the patients are treated with two parallel opposed (AP-PA) portals up to 40 Gy, then 10 Gy dose is delivered using central shield to avoid overdose to bladder and rectum and to get dose uniformity caused by I/C application. External irradiation was delivered by a 60Co photon beam

  16. Cognition assessment using the NIH Toolbox.

    Science.gov (United States)

    Weintraub, Sandra; Dikmen, Sureyya S; Heaton, Robert K; Tulsky, David S; Zelazo, Philip D; Bauer, Patricia J; Carlozzi, Noelle E; Slotkin, Jerry; Blitz, David; Wallner-Allen, Kathleen; Fox, Nathan A; Beaumont, Jennifer L; Mungas, Dan; Nowinski, Cindy J; Richler, Jennifer; Deocampo, Joanne A; Anderson, Jacob E; Manly, Jennifer J; Borosh, Beth; Havlik, Richard; Conway, Kevin; Edwards, Emmeline; Freund, Lisa; King, Jonathan W; Moy, Claudia; Witt, Ellen; Gershon, Richard C

    2013-03-12

    Cognition is 1 of 4 domains measured by the NIH Toolbox for the Assessment of Neurological and Behavioral Function (NIH-TB), and complements modules testing motor function, sensation, and emotion. On the basis of expert panels, the cognition subdomains identified as most important for health, success in school and work, and independence in daily functioning were Executive Function, Episodic Memory, Language, Processing Speed, Working Memory, and Attention. Seven measures were designed to tap constructs within these subdomains. The instruments were validated in English, in a sample of 476 participants ranging in age from 3 to 85 years, with representation from both sexes, 3 racial/ethnic categories, and 3 levels of education. This report describes the development of the Cognition Battery and presents results on test-retest reliability, age effects on performance, and convergent and discriminant construct validity. The NIH-TB Cognition Battery is intended to serve as a brief, convenient set of measures to supplement other outcome measures in epidemiologic and longitudinal research and clinical trials. With a computerized format and national standardization, this battery will provide a "common currency" among researchers for comparisons across a wide range of studies and populations. PMID:23479546

  17. Multidisciplinary Service Utilization Pattern by Advanced Head and Neck Cancer Patients: A Single Institution Study

    Directory of Open Access Journals (Sweden)

    Jacqueline C. Junn

    2012-01-01

    Full Text Available Purpose. To analyze the patterns and associations of adjunctive service visits by head and neck cancer patients receiving primary, concurrent chemoradiation therapy. Methods. Retrospective chart review of patients receiving adjunctive support during a uniform chemoradiation regimen for stages III-IV head and neck squamous cell carcinoma. Univariate and multivariate models for each outcome were obtained from simple and multivariate linear regression analyses. Results. Fifty-two consecutive patients were assessed. Female gender, single marital status, and nonprivate insurance were factors associated with an increased number of social work visits. In a multivariate analysis, female gender and marital status were related to increased social work services. Female gender and stage IV disease were significant for increased nursing visits. In a multivariate analysis for nursing visits, living greater than 20 miles between home and hospital was a negative predictive factor. Conclusion. Treatment of advanced stage head and neck cancer with concurrent chemoradiation warrants a multidisciplinary approach. Female gender, single marital status, and stage IV disease were correlated with increased utilization of social work and nursing services. Distance over 20 miles from the center was a negative factor. This information may help guide the treatment team to allocate resources for the comprehensive care of patients.

  18. 76 FR 49778 - National Institutes of Health National Institute of Environmental Health Sciences; Notice of Meeting

    Science.gov (United States)

    2011-08-11

    ....), notice is hereby given of a meeting of the Interagency Breast Cancer and Environmental Research... Committee: Interagency Breast Cancer and Environmental Research Coordinating Committee. Date: September 26... NIH & other Federal agencies on how to improve existing research programs related to breast...

  19. Displacements of fiducial markers in patients with prostate cancer treated with image guided radiotherapy: A single-institution descriptive study

    Science.gov (United States)

    Cendales, Ricardo; Torres, Felipe; Arbelaez, Juan; Gaitan, Armando; Vasquez, Jaider; Bobadilla, Ivan

    2014-01-01

    Aim To describe daily displacements when using fiducial markers as surrogates for the target volume in patients with prostate cancer treated with IGRT. Background The higher grade of conformity achieved with the use of modern radiation technologies in prostate cancer can increase the risk of geographical miss; therefore, an associated protocol of IGRT is recommended. Materials and methods A single-institution, retrospective, consecutive study was designed. 128 prostate cancer patients treated with daily on-line IGRT based on 2D kV orthogonal images were included. Daily displacement of the fiducial markers was considered as the difference between the position of the patient when using skin tattoos and the position after being relocated using fiducial markers. Measures of central tendency and dispersion were used to describe fiducial displacements. Results The implant itself took a mean time of 15 min. We did not detect any complications derived from the implant. 4296 sets of orthogonal images were identified, 128 sets of images corresponding to treatment initiation were excluded; 91 (2.1%) sets of images were excluded from the analysis after having identified that these images contained extreme outlier values. If IGRT had not been performed 25%, 10% or 5% of the treatments would have had displacements superior to 4, 7 or 9 mm respectively in any axis. Conclusions Image guidance is required when using highly conformal techniques; otherwise, at least 10% of daily treatments could have significant displacements. IGRT based on fiducial markers, with 2D kV orthogonal images is a convenient and fast method for performing image guidance. PMID:25535583

  20. Patterns of Resection among Patients with Hepatic-Only Metastatic Colorectal Cancer a Single Institution Experience and Review

    Directory of Open Access Journals (Sweden)

    K. I. Quintyne

    2012-01-01

    Full Text Available Problem statement: Hepatic-only metastasis in colorectal cancer is not a rare clinical finding and can account for 30% of cases. However, only 10-25% of cases are suitable for hepatic resection as part of their treatment pathway. We sought to document our own findings by reviewing patients with hepatic-only disease. Approach: A retrospective analysis was designed to include all patients seen at our institution from 1st January 2000 until 30th June 2010 and information as derived from the patients� records. Results: Forty-four (44 patients were found, with an average age of 60.8 years and a male preponderance. The majority of patients (approximately 57% with hepatic-only metastases developed their disease following adjuvant therapy. Better overall survival was seen when a primary tumor had a low grade of histological differentiation and fewer than 3 hepatic lesions appreciated on conventional radiology. Better outcome was seen in patients who underwent hepatic resection. Conclusion: Patients with hepatic-only metastases are not uncommon within our institution. Hepatic resection afforded better outcome and compares favorably with published literature.

  1. The costs of breast cancer in a Mexican public health institution

    Directory of Open Access Journals (Sweden)

    Jacobo Alejandro Gómez-Rico

    2008-11-01

    Full Text Available Jacobo Alejandro Gómez-Rico1, Marina Altagracia-Martínez1, Jaime Kravzov-Jinich1, Rosario Cárdenas-Elizalde1, Consuelo Rubio-Poo21Universidad Autónoma Metropolitano–Xochimilco (UAM-X, Departments: Biological Systems and Healthcare, Biological and Health Sciences Division (DCBS; 2Universidad Nacional Autónoma de México (UNAM, Faculty of Professional Studies-Zaragoza (FES-ZaragozaAbstract: Breast cancer (BC is the second leading cause of death as a result of neoplasia in Mexico. This study aimed to identify the direct and indirect costs of treating female outpatients diagnosed with BC at a Mexican public hospital. A cross-sectional, observational, analytical study was conducted. A total of 506 medical records were analyzed and 102 were included in the cost analysis. The micro-costing process was used to estimate treatment costs. A 17-item questionnaire was used to obtain information on direct and indirect costs. Of the 102 women with BC included in the study, 92.2% (94 were at Stage II, and only 7.8% at Stage I. Total direct costs over six months for the 82 women who had modified radical mastectomy (MRM surgury were US$733,821.15. Total direct costs for the 15 patients with conservative surgery (CS were US$138,190.39. We found that the total economic burden in the study population was much higher for patients with MRM than for patients with CS.Keywords: breast cancer, Mexican women, direct and indirect costs

  2. 75 FR 33317 - Request for Information (RFI) on the National Institutes of Health Plan To Develop the Genetic...

    Science.gov (United States)

    2010-06-11

    ... HUMAN SERVICES National Institutes of Health Request for Information (RFI) on the National Institutes of... it would be creating the GTR (see http://www.nih.gov/news/health/mar2010/od-18.htm ). This RFI... to develop the GTR, as outlined in this RFI, may submit comments by e-mail to GTR@od.nih.gov or...

  3. PRIMERJAVA SPLETNIH STRANI SLOVENSKIH TURISTIČNIH AGENCIJ S SPLETNIMI STRANMI IRSKIH TURISTIČNIH AGENCIJ

    OpenAIRE

    Klokočovnik, Barbara

    2014-01-01

    V zadnjih dveh desetletjih se je elektronsko poslovanje bliskovito razširilo. Obvladanje elektronskega poslovanja in trženja podjetja preko spleta je danes postalo bistvenega pomena za preživetje podjetja. Še posebej je to vidno na področju turističnega sektorja. Pojav in razvoj interneta omogoča uporabnikom hiter dostop do vseh vrst turističnih informacij, ki jih potrebujejo za odločitev o nakupu turističnih storitev. Tudi podjetja se zavedajo, da s predstavitvijo na spletu izboljšujejo pogo...

  4. The Impact of NIH Postdoctoral Training Grants on Scientific Productivity

    OpenAIRE

    Jacob, Brian A.; Lefgren, Lars

    2011-01-01

    In this paper, we estimate the impact of receiving an NIH postdoctoral training grant on subsequent publications and citations. Our sample consists of all applications for NIH postdoctoral training grants (unsuccessful as well as successful) from 1980 to 2000. Both ordinary least squares and regression discontinuity estimates show that receipt of an NIH postdoctoral fellowship leads to about one additional publication over the next five years, which reflects a 20 percent increase in research ...

  5. Decade evaluation of management of differentiated thyroid cancer in National Anticancer Institute

    International Nuclear Information System (INIS)

    Full text: Although the differentiated thyroid cancer (DTC) has proven to have a good prognosis with significant decreases in mortality rates, many countries recently witnessed an increase in incidence of this pathology. In this respect, this study aims to assess 10 years of DTC management in the national cancer centre through a population survey. Materials and methods: 750 patients were referred to the department of endocrinology and nuclear medicine, Pierre and Marie curie centre for DTC management between 1996 and 2005. All patients have undergone a surgery with total thyroidectomy even for papillary microcarcinoma followed by an iodine 131 ablation (3.7 GBq). Results: This study confirms that the DTC incidence increased through the years, essentially from 2001(between 2 to 3 times).The incidence rate for the female sex is 6 times greater than that for males (86% vs. 14%) with a median age at diagnosis stage between 30 to 49 years in 49% of patients. In 64 % of the cases (33% for solitary nodule), the multinodular goiter is the principal reason for the first consultation. Even though the fine needle aspiration biopsy (FNA) was performed only in 30% of patients, 70% were malignant. The papillary histology type is 5 times more frequent than the follicular type (75% vs. 16%). The mean time for radioiodine therapy after surgery has decreased from 34 months in 1996 to 7 months in 2005. 86% of patients have received an activity of 3.7GBq of I-131, while 9% have received 7.4GBq and 5% received more than 7.4GBq. After a minimum follow-up of one year, 78% of patients have had an undetectable Tg. Conclusion: Although an increased incidence rate of DTC has been observed since 2001, the reasons, according to our understanding, are due to the early stage diagnosis using FNA, the frequent availability of ultrasonography neck and the multidisciplinary approach, rather than the fallout atmosphere of radioactive iodine or the population's exposure to thyroid radiation, for

  6. Security and privacy requirements for a multi-institutional cancer research data grid: an interview-based study

    Directory of Open Access Journals (Sweden)

    Weems William A

    2009-06-01

    Full Text Available Abstract Background Data protection is important for all information systems that deal with human-subjects data. Grid-based systems – such as the cancer Biomedical Informatics Grid (caBIG – seek to develop new mechanisms to facilitate real-time federation of cancer-relevant data sources, including sources protected under a variety of regulatory laws, such as HIPAA and 21CFR11. These systems embody new models for data sharing, and hence pose new challenges to the regulatory community, and to those who would develop or adopt them. These challenges must be understood by both systems developers and system adopters. In this paper, we describe our work collecting policy statements, expectations, and requirements from regulatory decision makers at academic cancer centers in the United States. We use these statements to examine fundamental assumptions regarding data sharing using data federations and grid computing. Methods An interview-based study of key stakeholders from a sample of US cancer centers. Interviews were structured, and used an instrument that was developed for the purpose of this study. The instrument included a set of problem scenarios – difficult policy situations that were derived during a full-day discussion of potentially problematic issues by a set of project participants with diverse expertise. Each problem scenario included a set of open-ended questions that were designed to elucidate stakeholder opinions and concerns. Interviews were transcribed verbatim and used for both qualitative and quantitative analysis. For quantitative analysis, data was aggregated at the individual or institutional unit of analysis, depending on the specific interview question. Results Thirty-one (31 individuals at six cancer centers were contacted to participate. Twenty-four out of thirty-one (24/31 individuals responded to our request- yielding a total response rate of 77%. Respondents included IRB directors and policy-makers, privacy and

  7. Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells

    International Nuclear Information System (INIS)

    A biological function for human papillomavirus 16 (HPV 16) DNA was demonstrated by transformation of NIH 3T3 cells. HPV 16 DNA has been found frequently in genital cancer and has been classified as a papillomavirus on the basis of DNA homology. A recombinant HPV 16 DNA (pSHPV16d), which contains a head-to-tail dimer of the full-length HPV 16 genome, induced morphologic transformation; the transformed cells were tumorigenic in nude mice. Expression of transforming activity was unique because of the long latency period (more than 4 weeks) required for induction of morphologic transformation and because the transfected DNA existed primarily in a multimeric form with some rearrangement. Furthermore, virus-specific RNAs were expressed in the transformants. The transformation of NIH 3T3 cells provides a model for analyzing the functions of HPV 16, which is associated with cervical carcinomas

  8. Author Disambiguation in PubMed: Evidence on the Precision and Recall of Author-ity among NIH-Funded Scientists.

    Science.gov (United States)

    Lerchenmueller, Marc J; Sorenson, Olav

    2016-01-01

    We examined the usefulness (precision) and completeness (recall) of the Author-ity author disambiguation for PubMed articles by associating articles with scientists funded by the National Institutes of Health (NIH). In doing so, we exploited established unique identifiers-Principal Investigator (PI) IDs-that the NIH assigns to funded scientists. Analyzing a set of 36,987 NIH scientists who received their first R01 grant between 1985 and 2009, we identified 355,921 articles appearing in PubMed that would allow us to evaluate the precision and recall of the Author-ity disambiguation. We found that Author-ity identified the NIH scientists with 99.51% precision across the articles. It had a corresponding recall of 99.64%. Precision and recall, moreover, appeared stable across common and uncommon last names, across ethnic backgrounds, and across levels of scientist productivity. PMID:27367860

  9. CYP17 genetic variation and risk of breast and prostate cancer from the national Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

    NARCIS (Netherlands)

    Setiawan, Veronica Wendy; Schumacher, Fredrick R.; Haiman, Christopher A.; Stram, Daniel O.; Albanes, Demetrius; Altshuler, David; Berglund, Gran; Buring, Julie; Calle, Eugenia E.; Clavel-Chapelon, Francoise; Cox, David G.; Gaziano, J. Michael; Hankinson, Susan E.; Hayes, Richard B.; Henderson, Brian E.; Hirschhorn, Joel; Hoover, Robert; Hunter, David J.; Kaaks, Rudolf; Kolonel, Laurence N.; Kraft, Peter; Ma, Jing; Le Marchand, Loic; Linseisen, Jakob; Lund, Eiliv; Navarro, Carmen; Overvad, Kim; Palli, Domenico; Peeters, Petra H. M.; Pike, Malcolm C.; Riboli, Elio; Stampfer, Meir J.; Thun, Michael J.; Travis, Ruth; Trichopoulos, Dimitrios; Yeager, Meredith; Ziegler, Regina G.; Feigelson, Heather Spencer; Chanock, Stephen J.

    2007-01-01

    CYP17 encodes cytochrome p450c17 alpha, which mediates activities essential for the production of sex steroids. Common germ line variation in the CYP17 gene has been related to inconsistent results in breast and prostate cancer, with most studies focusing on the nonsynonymous single nucleotide polym

  10. Lifestyle and cancer prevention in female employees at a health institution

    Directory of Open Access Journals (Sweden)

    Gladys Eugenia Canaval

    2011-06-01

    Full Text Available Objective: To establish the relationship between lifestyle for prevention of cervix and breast cancer and perceptual cognitive factors from the Pender model in working women. Materials and methods: Correlation and cross-sectional study with a random sample of 143 working women. The Lifestyle index is the total score of 5 variables: Papanicolau test, breast self-exam, physical activity, body mass index, and cigarette smoking. Results: The mean age for the sample was 44.4 + 6.2; 87% of the women had higher education and 85% were working in health care services. A total of 89% of the women had unhealthy lifestyles because of the lack of regular physical activity, not having a Papanicolau test according to the norm, not practicing breast self-exams, and having an altered body mass index. There was significant correlation between lifestyle and occupation, and also with self-efficacy perception for breast self-examination. Conclusion: The lifestyles for most of the women sampled were unhealthy. Recommendations: It is also recommend conducting culturally sensitive healthcare campaigns in addition to setting up flexible attention schedules for women.

  11. Lifestyle and cancer prevention in female employees at a health institution

    Directory of Open Access Journals (Sweden)

    Gladys Eugenia Canaval

    2011-06-01

    Full Text Available Objective: To establish the relationship between lifestyle for prevention of cervix and breast cancer and perceptual cognitive factors from the Pender model in working women.Materials and methods: Correlation and cross-sectional study with a random sample of 143 working women. The Lifestyle index is the total score of 5 variables: Papanicolau test, breast self-exam, physical activity, body mass index, and cigarette smoking.Results: The mean age for the sample was 44.4 + 6.2; 87% of the women had higher education and 85% were working in health care services. A total of 89% of the women had unhealthy lifestyles because of the lack of regular physical activity, not having a Papanicolau test according to the norm, not practicing breast self-exams, and having an altered body mass index. There was significant correlation between lifestyle and occupation, and also with self-efficacy perception for breast self-examination.Conclusion: The lifestyles for most of the women sampled were unhealthy.Recommendations: It is recommend the reorientation of health services based on health promotion, which permit planning and executing health care, health education and nursing care programs specifically for working women. It is also recommend conducting culturally sensitive.

  12. Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience

    Science.gov (United States)

    Nace, Gary W.; Steel, Jennifer L.; Amesur, Nikhil; Zajko, Albert; Nastasi, Bryon E.; Joyce, Judith; Sheetz, Michael; Gamblin, T. Clark

    2011-01-01

    Purpose. We sought to evaluate our experience using yttrium-90 (90Y) resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC). Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0). The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6), compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status. PMID:22312513

  13. Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience

    Directory of Open Access Journals (Sweden)

    Gary W. Nace

    2011-01-01

    Full Text Available Purpose. We sought to evaluate our experience using yttrium-90 (90Y resin microsphere hepatic radioembolization as salvage therapy for liver-dominant metastatic colorectal cancer (mCRC. Methods. A retrospective review of consecutive patients with unresectable mCRC who were treated with 90Y after failing first and second line systemic chemotherapy. Demographics, treatment dose, biochemical and radiographic response, toxicities, and survival were examined. Results. Fifty-one patients underwent 90Y treatments of which 69% were male. All patients had previously undergone extensive chemotherapy, 31% had undergone previous liver-directed therapy and 24% had a prior liver resection. Using RECIST criteria, either stable disease or a partial response was seen in 77% of patients. Overall median survival from the time of first 90Y treatment was 10.2 months (95% CI = 7.5–13.0. The absence of extrahepatic disease at the time of treatment with 90Y was associated with an improved survival, median survival of 17.0 months (95% CI = 6.4–27.6, compared to those with extrahepatic disease at the time of treatment with 90Y, 6.7 months (95% CI = 2.7–10.6 Conclusion: 90Y therapy is a safe locoregional therapy that provides an important therapeutic option to patients who have failed first and second line chemotherapy and have adequate liver function and performance status.

  14. From the NIH: A Systems Approach to Increasing the Diversity of the Biomedical Research Workforce.

    Science.gov (United States)

    Valantine, Hannah A; Lund, P Kay; Gammie, Alison E

    2016-01-01

    The National Institutes of Health (NIH) is committed to attracting, developing, and supporting the best scientists from all groups as an integral part of excellence in training. Biomedical research workforce diversity, capitalizing on the full spectrum of skills, talents, and viewpoints, is essential for solving complex human health challenges. Over the past few decades, the biomedical research workforce has benefited from NIH programs aimed at enhancing diversity. However, there is considerable room for improvement, particularly at the level of independent scientists and within scientific leadership. We provide a rationale and specific opportunities to develop and sustain a diverse biomedical research workforce through interventions that promote the successful transitions to different stages on the path toward completion of training and entry into the biomedical workforce. PMID:27587850

  15. 78 FR 24221 - National Institute of Neurological Disorders and Stroke

    Science.gov (United States)

    2013-04-24

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke... Advisor, Officer of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31...

  16. 78 FR 77475 - National Institute of Neurological Disorders and Stroke

    Science.gov (United States)

    2013-12-23

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke..., Officer of the Director, National Institute of Neurological Disorders and Stroke, NIH, 31 Center...

  17. 75 FR 74068 - National Eye Institute; Notice of Closed Meetings

    Science.gov (United States)

    2010-11-30

    ... Institute, 5635 Fishers Lane, Rockville, MD 20852. (Telephone Confence Call). Contact Person: Samuel..., National Institutes of Health, 5635 Fishers Lane, Suite 1300, MSC 9300. 301-451-2020. rawlings@nei.nih.gov... imposed by the review and funding cycle. Name of Committee: National Eye Institute Special Emphasis...

  18. Multi-institutional analysis of bioimpedance spectroscopy in the early detection of breast cancer related lymphedema

    Directory of Open Access Journals (Sweden)

    Vicini FA

    2013-03-01

    Full Text Available Background: The purpose of this study was to evaluate bioelectrical impedance spectroscopy’s (BIS ability to detect and monitor extracellular fluid accumulation of the upper limb as it relates to the extent of loco-regional therapy. Methods: A total of 125 patients with breast cancer from 4 clinical practices were evaluated with BIS at baseline and following loco-regional procedures. In order to assess the ability of BIS to detect subclinical changes by treatment modality, the change in L-Dex score from baseline to measurements taken within 180 days following surgery were calculated. Results: Mean age was 55 years with 68 patients (54.4% undergoing sentinel lymph node (SLN sampling while 57 (45.6% underwent an axillary dissection (ALND. Sixty-five patients (52% underwent radiation therapy (RT. Patients receiving RT had a significantly increased change in L-Dex score (0.8 v.-2.5, p=0.03 compared with those patients not receiving RT. For all patients, ALND was associated with a significantly increased change in L-Dex score (5.0 v. 0.3, p=0.003 compared with SLN. When stratifying by the number of nodes removed, a statistically significant increase in the change in L-Dex score was noted (0.4 v. 0.4 v. 4.3 v. 6.4, p=0.04 for 0-3, 4-6, 7-10 and greater than 10 lymph nodes removed. Conclusions: In this limited analysis, L-Dex scores paralleled the extent of axillary sampling and the addition of radiation therapy; these results demonstrate that BIS can be used to monitor patients for the early onset of edema as differences emerged within 180 days of surgery.

  19. Liver transplantation for patients with hepatocellular carcinoma at the Liver Cancer Institute of Fudan University, China

    Institute of Scientific and Technical Information of China (English)

    ZHOU Jian; HE Yi-feng; YANG Guo-huan; SONG Kang; YUAN Zhou; WANG Yu-qi; TANG Zhao-you; FAN Jia; WU Zhi-quan; QIU Shuang-jian; HUANG Xiao-wu; YU Yao; WANG Zheng; SUN Jian; XIAO Yong-sheng

    2005-01-01

    Background Selection of patients with hepatocellular carcinoma (HCC) for orthotopic liver transplantation (OLT) remains controversial. Since there is a trend to expand the transplant criteria for HCC patients, we reviewed the data of patients with HCC who had received OLT at our institute to determine their survival and prognostic factors.Methods A total of 67 patients with HCC who had undergone OLT from April 2001 through December 2003 were reviewed retrospectively. Selection OLT candidates with HCC was dependent on the anatomical characteristics and/or the severity of underlying liver cirrhosis. The 67 patients were followed up for more than 6 months after transplantation. Their survival rate was calculated by the Kaplan-Meier method. Univariate and multivariate analyses using the Cox proportional hazards regression model were performed to reveal the factors affecting the survival rate.Results No perioperative death occurred in this series. The 1- and 2-year cumulative survival rates were 90.0% and 65.6%, and the disease-free survival (DFS) rates were 77.5% and 62.5% respectively. Univariate analysis revealed the tumor size, portal vein tumor thrombus (PVTT), serum alpha-fetoprotein level, bilobular distribution of tumors, pTNM stage and histological differentiation were statistically significant factors affecting the DFS (P<0.05). Multivariate analysis showed tumor size and PVTT were independent and statistically significant factors affecting the DFS (P=0.005 and 0.010, respectively). In this series, all but 2 received systemic chemotherapy, among them 13 had tumor recurrence within 8 months after OLT.Conclusions OLT is indicated for patients with HCC, even for some patients with end-stage liver disease who may survive longer without tumor recurrence. Adjuvant chemotherapy may decrease the recurrence of HCC after OLT.

  20. Breast cancer therapies weighed

    International Nuclear Information System (INIS)

    Even as the National Institutes of Health came under fire last week for giving short shrift to women in the institute's basic and clinical research programs, the report of a recent NIH consensus conference points up the need for more research on how to treat early breast cancer. Although the experts were able to agree on the best surgical treatment for women with early breast cancer, they couldn't resolve the more controversial issue of whether the patients should subsequently receive systemic treatment - chemotherapy or hormone therapy - to prevent recurrence of their disease. The panel reaffirmed that the removal of the lump and nearby lymph nodes, followed by irradiation, is just as effective as a mastectomy. But then came the contentious question: should women with early breast cancer, especially those without detectable lymph node metastases, receive drug therapy to prevent recurrence of the disease? Currently, 70% of such cancers are successfully treated with surgery and radiation alone. For this reason, about 2 years ago, the National Cancer Institute issued a clinical alert saying that addition treatment with drugs or hormones is a credible therapeutic option worthy of careful attention for all early stage patients. This pronouncement engendered a storm of criticism. A consensus panel concluded that in cases where tumors are 1 centimeter or less in diameter and no lymph nodes are affected, the likelihood of recurrence is so small that the benefits of adjuvant therapy would be insignificant. But for the patients with larger tumors, the panel concluded that the decision is an individual one that depends on personal preferences and a variety of prognostic factors that can help to indicate whether a woman is at high risk of having a recurrence and should therefore have adjuvant therapy

  1. NIH Research on Concussion and the Brain | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: Concussion NIH Research on Concussion and the Brain Past Issues / Summer 2015 Table of Contents Dr. ... chronic traumatic encephalopathy (CTE). "Boxing, Football and the ... head trauma and CTE. The research is led by neuropathologist Ann McKee, M.D., ...

  2. Parkinson's Disease Research at NIH | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn JavaScript on. Feature: Parkinson's Disease Parkinson's Disease Research at NIH Past Issues / Winter 2014 ... of its research: MedlinePlus . www.medlineplus.gov . Type "Parkinson's disease" in the Search box. NIHSeniorHealth —Parkinson's Disease ...

  3. Precision Medicine: Healthcare Tailored to You | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: NIH Precision Medicine Initiative Precision Medicine: Healthcare Tailored to You Past Issues / Fall 2015 ... NIH researchers and fellow scientists working on precision medicine efforts gather on the NIH campus in Bethesda, ...

  4. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

    International Nuclear Information System (INIS)

    Purpose: The effectiveness of stereotactic body radiotherapy (SBRT) for localized prostate cancer is tested. Methods and materials: A total of 1100 patients with clinically localized prostate cancer were enrolled in separate prospective phase 2 clinical trials of SBRT from 8 institutions during 2003–11 and pooled for analysis. SBRT using the CyberKnife delivered a median dose of 36.25 Gy in 4–5 fractions. Patients were low-risk (58%), intermediate-risk (30%) and high-risk (11%). A short-course of androgen deprivation therapy (ADT) was given to 14%. PSA relapse defined as a rise >2 ng/ml above nadir was analyzed with the Kaplan Meier method. Results: With a median follow-up of 36 months there were 49 patients with PSA failure (4.5%), 9 of whom were subsequently determined to be benign PSA bounces. The 5-year biochemical relapse free survival (bRFS) rate was 93% for all patients; 95%, 83% and 78% for GS ⩽6, 7 and ⩾8, respectively (p = 0.001), and 95%, 84% and 81% for low-, intermediate- and high-risk patients, respectively (p 0.2 ng/ml was noted among 16% of patients. For 135 patients possessing a minimum of 5 years follow-up, the 5-year bRFS rate for low- and intermediate-risk patients was 99% and 93%, respectively. Conclusion: PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients. The current evidence supports consideration of SBRT among the therapeutic options for these patients

  5. Cancer risk among Italian veterans from the Balkans: the activities of the Italian National Institute of Health

    International Nuclear Information System (INIS)

    In recent years, cases of cancer have been reported among Italian troops involved in the peace-keeping mission in Bosnia and Kosovo. By the end of 2000, the Italian Minister of Defence appointed a Committee of Enquiry to gain a scientifically sound, reliable picture of the health consequences of the exposure of military personnel to Depleted Uranium (DU) and to assess the possible etiologic role DU may have played in the occurrence of specific pathologies. The Committee found a statistically significant excess of Hodgkin's lymphomas, but up to now the lack of thorough knowledge about internal uranium exposure and its potential effects has prevented us from determining whether lymphatic cancers are correlated with DU exposure. The Committee of Enquiry issued several recommendations, in particular: 1) to follow up the cohort of military personnel deployed in Bosnia and Kosovo and monitor the incidence of tumours and the evolution of the ensuing epidemiological scenario, and 2) to list the individuals that could have been exposed to DU for different reasons and enrol them in a long-term programme of medical surveillance. A decision was also made to quantify levels of U and other potentially toxic elements - as well as to measure the isotopic ratio 235U/238U for the assessment of DU - in biological samples of soldiers deployed in war theatres where presumably DU weapons were used, together with tentative indexes of contact with possible genotoxic factors. In this paper a general description is given of the activities carried out by the Italian National Institute of Health (ISS, in the Italian acronym) in compliance with both the recommendations of the Committee of Enquiry and the decision to quantify potential exposures. (author)

  6. Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer. A single institutional experience

    International Nuclear Information System (INIS)

    The purpose of this study was to evaluate the treatment outcomes of stereotactic body radiotherapy (SBRT) for Stage I small-cell lung cancer (SCLC). From April 2003 to September 2009, a total of eight patients with Stage I SCLC were treated with SBRT in our institution. In all patients, the lung tumors were proven as SCLC pathologically. The patients' ages were 58-84 years (median: 74). The T-stage of the primary tumor was T1a in two, T1b in two and T2a in four patients. Six of the patients were inoperable because of poor cardiac and/or pulmonary function, and two patients refused surgery. SBRT was given using 7-8 non-coplanar beams with 48 Gy in four fractions. Six of the eight patients received 3-4 cycles of chemotherapy using carboplatin (CBDCA) + etoposide (VP-16) or cisplatin (CDDP) + irinotecan (CPT-11). The follow-up period for all patients was 6-60 months (median: 32). Six patients were still alive without any recurrence. One patient died from this disease and one died from another disease. The overall and disease-specific survival rate at three years was 72% and 86%, respectively. There were no patients with local progression of the lesion targeted by SBRT. Only one patient had nodal recurrence in the mediastinum at 12 months after treatment. The progression-free survival rate was 71%. No Grade 2 or higher SBRT-related toxicities were observed. SBRT plus chemotherapy could be an alternative to surgery with chemotherapy for inoperable patients with Stage I small-cell lung cancer. However, further investigation is needed using a large series of patients. (author)

  7. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center

    International Nuclear Information System (INIS)

    Thymic epithelial tumors (TETs), which comprise thymoma and thymic carcinoma, are rare cancers with specific morphological and clinical features. Their clinical characteristics and outcomes have gradually been clarified by assessing large-scale, retrospective data obtained with international cooperation. The study is a retrospective review of 187 Japanese patients with TETs who attended our institution from 1976 to 2012. Relevant clinical features of patients with TETs and their tumors, including histology, staging, treatment strategies, and overall survival, were investigated. Differences in survival were assessed by the Kaplan–Meier method and uni- and multi-variate Cox proportional hazards regression analyses. The 187 patients included 52 patients with stage I, 37 with stage II, 22 with stage III, and 76 with stage IVa/IVb tumors according to the Masaoka–Koga Staging System. As to histological type, five patients had type A, 33 type AB, 19 type B1, 39 type B2, and 15 type B3 thymomas, whereas 68 patients had thymic carcinoma, including 11 with neuroendocrine carcinomas according to the 2004 WHO classification. Either insufficient data were available to classify the tumors of the remaining eight patients or they had rare types. Immunological abnormalities were present in 26 patients, most of whom had thymomas (21.8% of the thymoma group). Most of the patients who presented with symptoms had myasthenia gravis or extensive thymic carcinoma. Secondary cancers were present in 25 patients (13.3%). The overall 5- and 10-year survival rates for thymoma were 85.4 and 71.5%, respectively, and those for thymic carcinoma were 33.8 and 2.3%, respectively. OS differed significantly between stage IVa thymomas and thymic carcinomas. The stage and whether the tumors were thymomas or thymic carcinomas were significant determinants of survival according to multivariate analysis. The efficacy of treatments for thymoma and thymic carcinoma should be investigated separately

  8. 77 FR 9666 - National Institute of Child Health and Human Development; New Proposed Collection; Comment...

    Science.gov (United States)

    2012-02-17

    ... HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development... Institute of Child Health and Human Development (NICHD), the National Institutes of Health (NIH) will... purpose of this section to authorize the National Institute of Child Health and Human Development...

  9. 78 FR 12369 - United States Government Policy for Institutional Oversight of Life Sciences Dual Use Research of...

    Science.gov (United States)

    2013-02-22

    ... registered an Institutional Biosafety Committee (IBC) with the NIH Office of Biotechnology Activities in... IBC to conduct the DURC institutional review process? What are the benefits or limitations of...

  10. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana

    International Nuclear Information System (INIS)

    Prophylactic cranial irradiation (PCI) has been used in patients with small-cell lung cancer (SCLC) to reduce the incidence of brain metastases (BM) and thus increase overall survival. The aim of this retrospective study was to analyze the characteristics of patients with SCLC referred to the Institute of Oncology Ljubljana, their eligibility for PCI, patterns of dissemination, and survival. Medical charts of 357 patients with SCLC, referred to the Institute of Oncology Ljubljana between January 2004 and December 2006, were reviewed to determine characteristics of patients chosen for PCI. The following data were collected: age, gender, performance status (PS), extent of the disease, smoking status, type of primary treatment with outcome, haematological and biochemical parameters, PCI use, and finally brain metastases (BM) status at diagnoses and after treatment. PCI was performed in 24 (6.7%) of all patients. Six (25%) patients developed brain metastases after they were treated with PCI. Brain was the only site of metastases in 4 patients, two progressed to multiple organs. Median overall survival of patients with PCI was 21.9 months, without PCI 12.13 months (p = 0.004). From the collected data there were good prognostic factors: age under 65 years, limited disease (LD), performance status, normal levels of lactate dehydrogenase (LDH) and normal levels of C-reactive protein levels (CRP). Other prognostic factors did not show statistical significant values. Survival of patients with LD, who have had PCI, was significantly better than those who had not. We decided to perform PCI in patients with LD, in those with complete or near complete response, and those with good performance status (≥ 80). We did not use PCI in extended disease (ED). The reason for that shall be addressed in the future. Doses for PCI were not uniform, therefore more standard approach should be considered

  11. The History of Art Therapy at the National Institutes of Health

    Science.gov (United States)

    Robb, Megan

    2012-01-01

    The National Institutes of Health (NIH) Clinical Research Center is a government facility that has a long history of groundbreaking research. Art therapy research began at NIH in 1958 with Hanna Kwiatkowska, whose work contributed to the foundation of art therapy with families, and with Harriet Wadeson, who conducted psychodynamic art therapy…

  12. 76 FR 61722 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

    Science.gov (United States)

    2011-10-05

    ..., DHHS/NIH/NINDS/DER/SRB, 6001 Executive Boulevard, MSC 9529, Neuroscience Center, Room 3208, Bethesda...., Scientific Review Officer, DHHS/NIH/NINDS/DER/SRB, 6001 Executive Boulevard, MSC 9529, Neuroscience Center... Neurosciences, National Institutes of Health, HHS) Dated: September 27, 2011. Jennifer S. Spaeth,...

  13. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer

    International Nuclear Information System (INIS)

    Purpose: Clinical experience of both physicians and institutions has been shown to significantly influence the outcome of patients. We conducted this retrospective cohort study to examine its impact on the outcome of patients undergoing combined chemoradiation therapy for the treatment of locally advanced inoperable non-small-cell lung cancer. Methods and Materials: We compared the clinical data from 239 patients who were enrolled in two consecutive Radiation Therapy Oncology Group (RTOG) trials (RTOG 91-06, RTOG 92-04) according to the number of patients enrolled from each institution in either trial alone or the two trials combined. Results: Overall, patients treated at the institutions that enrolled ≥5 patients survived longer than those treated at the institutions that enrolled <5 patients (median survival 20.5 vs. 13.4 months, p=0.0006) with a more than doubling of the 2- and 3-year survival rates (45% and 31% vs. 20% and 13%, respectively). Multivariate analyses confirmed that the number of patients enrolled from each institution was an important prognostic factor for the entire group (p=0.001) and also for RTOG 91-06 (p=0.05) and RTOG 92-04 (p=0.004) when the data were analyzed separately. Conclusion: Institutional experience has a significant impact on the survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small cell lung cancer

  14. Knowledge and awareness of cervical cancer and its prevention among nursing staff of a tertiary care teaching institute in South India

    Directory of Open Access Journals (Sweden)

    Sneha Badwe Dhodapkar

    2014-08-01

    Full Text Available Background: Cervical cancer is the second leading cause of morbidity and mortality among the females worldwide. India has the highest burden of cervical cancer patients, accounting for approximately one-fifth of the cases in world. Nurses being an important link between the doctors and female patients in OPD or wards, it is imperative that they should be aware of the facts about cervical cancer and especially of screening techniques which can be utilized in low-resource settings. Methods: A cross-sectional interview based study was done among 200 nurses of a tertiary care teaching institute from June 2013 to July 2013, to assess the knowledge and awareness of nursing staff regarding causes of cervical cancer and its prevention and early detection. Results: Among all participated nurses, 85% (n=170 were aware of the term cancer cervix and 45% reported that it is the most frequent gynaecological cancer in India. Only 30.6% reported that it is the leading cause of death among women due to cancer. Young age at first intercourse, multiple sex partners, cigarette smoking, high parity and lower socio-economic status were correctly responded by 13%, 48%, 16%, 9% and 13% of participants respectively, as risk factors for cervical cancer. None of the participants knew about the VIA method of screening for cervical cancer. Among 119 of those participants who knew that cervical cancer can be detected by Pap smear, only 5 (4% had ever undergone Pap smear examination. Conclusions: Nurses identify certain aspects of cervical cancer correctly but their knowledge is not adequate, hence necessary changes should be made in their curriculum. [Int J Reprod Contracept Obstet Gynecol 2014; 3(4.000: 1056-1060

  15. Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium.

    OpenAIRE

    van der Lei, J.; Rudolph, A; Moysich, KB; Behrens, S; Goode, EL.; Bolla, MK; Dennis, J; Dunning, AM; Easton, DF; Wang, Q.; Benitez, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A

    2015-01-01

    Funding for the iCOGS infrastructure came from: the European Community?s Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (NIH, CA128978, CA122443) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112?the GAME-ON initiative), the Department of Defence (W81...

  16. Monitoring of people and workers exposure to the electric, magnetic and electromagnetic fields in an Italian national cancer Institute

    Directory of Open Access Journals (Sweden)

    Palomba Raffaele

    2008-07-01

    Full Text Available Abstract Background The paper reports the electric, magnetic and electromagnetic fields (emf measurements carried out in the Regina Elena National Cancer Institute (NCI. Several devices, used in diagnostics and in medical cures, can represent sources of emf for the workers and for the public subjected to the treatments. The aim is to evaluate their exposition, in order to assess the compliance with the law. Methods The investigations have been carried out in the departments of: intensive care, physiotherapy, MR presstherapy and in the surgical rooms. The measurements have been performed using broad band probes in the frequency ranges 5 Hz÷30 kHz and 100 kHz-3 GHz. Results The variability of the magnetic induction (B(μT levels is between 0,05 μT and 80 μT. The statistical distribution shows that most of the measurements are in the range 0,05 Conclusion The measurement of the emf levels in the NCI is recommended because of the presence of the oncological patients; their long stay near the equipments and their day-long exposure represent additional risk factors for which a prudent avoidance strategy have to de adopted.

  17. Web services-based access to local clinical trial databases: a standards initiative of the Association of American Cancer Institutes.

    Science.gov (United States)

    Stahl, Douglas C; Evans, Richard M; Afrin, Lawrence B; DeTeresa, Richard M; Ko, Dave; Mitchell, Kevin

    2003-01-01

    Electronic discovery of the clinical trials being performed at a specific research center is a challenging task, which presently requires manual review of the center's locally maintained databases or web pages of protocol listings. Near real-time automated discovery of available trials would increase the efficiency and effectiveness of clinical trial searching, and would facilitate the development of new services for information providers and consumers. Automated discovery efforts to date have been hindered by issues such as disparate database schemas, vocabularies, and insufficient standards for easy intersystem exchange of high-level data, but adequate infrastructure now exists that make possible the development of applications for near real-time automated discovery of trials. This paper describes the current state (design and implementation) of the Web Services Specification for Publication and Discovery of Clinical Trials as developed by the Technology Task Force of the Association of American Cancer Institutes. The paper then briefly discusses a prototype web service-based application that implements the specification. Directions for evolution of this specification are also discussed. PMID:14728248

  18. Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan. A multi-institutional survey study of the JROSG

    International Nuclear Information System (INIS)

    In Japan, the use of adjuvant radiotherapy after prostatectomy for prostate cancer has not increased compared with the use of salvage radiotherapy. We retrospectively evaluated the outcome of adjuvant radiotherapy together with prognostic factors of outcome in Japan. Between 2005 and 2007, a total of 87 patients were referred for adjuvant radiotherapy in 23 institutions [median age: 64 years (54–77 years), median initial prostate-specific antigen: 11.0 ng/ml (2.9–284 ng/ml), Gleason score (GS): 6, 7, 8, 9, 10 = 13.8, 35.6, 23.0, 27.6, 0%, respectively]. Rates of positive marginal status, seminal vesicle invasion (SVI) and extra-prostatic extension (EPE) were 74%, 26% and 64%, respectively. Median post-operative PSA nadir: 0.167 ng/ml (0–2.51 ng/ml). Median time from surgery to radiotherapy was 3 months (1–6 months). A total dose of ≥60 Gy and 0.2 (P=0.02), and tended to be more favorable after radiotherapy ≤3 months from surgery than >3 months from surgery (P=0.069). Multivariate analysis identified SVI and post-operative PSA nadir as independent prognostic factors for bRFS (P=0.001 and 0.018, respectively). (author)

  19. ONE STEP NUCLEIC ACID AMPLIFICATION IN BREAST CANCER SENTINEL LYMPH NODE.A SINGLE INSTITUTIONAL EXPERIENCE AND A SHORT REVIEW.

    Directory of Open Access Journals (Sweden)

    Tatiana eBrambilla

    2015-06-01

    Full Text Available Sentinel lymph node (SLN examination is a standard in breast cancer patients, with several methods employed along its 20-years history, the last one represented by OSNA. The latter is a intra-operative molecular assay searching for CK19 mRNA as a surrogate of metastatic cells. Our 3-years experience with OSNA (1122 patients showed results overlapping those recorded in the same Institution with a morphological evaluation (930 patients of SLN. In detail the data of OSNA were almost identical to those observed with standard post-operative procedure in terms of patients with positive SLN (30% and micrometastatic/macrometastatic involvement of SLN (respectively 38-45% and 62-55%. By contrast when OSNA was compared to the standard intra-operatory procedure it was superior in terms of accuracy, prompting the use of this molecular assay as a very valid and reproducible for intra-operative evaluation of SLN.Further possibilities prompting the use of OSNA range from adhesion to quality control programs, saving of medical time, ability to predict, during surgery, additional nodal metatastis and molecular bio-banking.

  20. 75 FR 71134 - National Institutes of Health

    Science.gov (United States)

    2010-11-22

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting..., Cancer Control, National Institutes of Health, HHS) Dated: November 16, 2010. Jennifer S....

  1. Developing Entrepreneurial and Technology Commercialization Policies to Promote Cooperative Ventures Between NIH and Industry

    Science.gov (United States)

    Rossomando, Edward F.

    2001-03-01

    The NIH has had a great influence in guiding the biological research agenda for the last half of the 20th century. This may change if the increases in research funding from the private sector that occurred in the last ten years continue into the 21st century. Ten years ago, industry supplied 55% of the US R&D funds. In 2000, industry support of R&D had increased to 76%, with industry carrying out 70% of the nations applied and 91% of its development research. Given this shift, one of the biggest challenges that NIH may face in coming years is sharing control of America's research agenda with industry. For this to occur policies that encourage cooperative ventures with industry are needed. In a unique experiment, I was invited to the National Institute of Dental and Craniofacial Research (NIDCR), one of the 25 NIH Institutes and Centers, to develop programs and policies that would promote interactions with industry. This talk will introduce the strategy and programs developed to commercialize products and technologies from basic science discoveries and introducing an entrepreneurial atmosphere within the Institute. The results of this experiment will be discussed by comparing differences between discovery-driven and customer-driven innovation. One outcome of this experience is a greater appreciation of the obstacles to introducing disruptive technologies into the market place and of the paradigms that serve as barriers to commercialization. One recommendation is that the NIDCR consider a policy that allows for some participation by industry in setting the research and training agenda of the Institute, and that a mechanism for industry input be introduced into its administrative organization.

  2. Only Half of Rectal Cancer Patients Get Recommended Treatment

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158339.html Only Half of Rectal Cancer Patients Get Recommended Treatment: ... therapy for rectal cancer in the United States, only slightly more than half of patients receive it, ...

  3. Better Lung Cancer Survival? There's an App for That

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_159289.html Better Lung Cancer Survival? There's an App for That Study found ... HealthDay News) -- A new smartphone app may help lung cancer patients live longer and better by monitoring their ...

  4. Many Breast Cancer Patients May Not Need Chemo

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_158365.html Many Breast Cancer Patients May Not Need Chemo: Study Genetic test ... 2016 MONDAY, April 18, 2016 (HealthDay News) -- Many breast cancer patients receive chemotherapy they don't need, according ...

  5. Ovarian Cancer Is More Than One Disease: Report

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_157563.html Ovarian Cancer Is More Than One Disease: Report Better understanding ... 2, 2016 WEDNESDAY, March 2, 2016 (HealthDay News) -- Ovarian cancer isn't a single disease, but rather a ...

  6. Mindfulness Meditation Seems to Soothe Breast Cancer Survivors

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_159172.html Mindfulness Meditation Seems to Soothe Breast Cancer Survivors Six-week ... 2016 THURSDAY, June 2, 2016 (HealthDay News) -- Mindfulness meditation seems to help breast cancer patients better manage ...

  7. What Causes COPD? | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... irritant that causes COPD is cigarette smoke. Pipe, cigar, and other types of tobacco smoke also can ... from your doctor or healthcare provider. The National Cancer Institute has ... does the American Lung Association ( www.lung.org/ ) and the Centers for ...

  8. Online Bioinformatics Tutorials | Office of Cancer Genomics

    Science.gov (United States)

    Bioinformatics is a scientific discipline that applies computer science and information technology to help understand biological processes. The NIH provides a list of free online bioinformatics tutorials, either generated by the NIH Library or other institutes, which includes introductory lectures and "how to" videos on using various tools.

  9. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology

    Directory of Open Access Journals (Sweden)

    Aguinaldo Cesar Nardi

    2012-04-01

    Full Text Available OBJECTIVE: To describe the epidemiological features and patterns of initial care for prostate cancer at public and private institutions in the State of Sao Paulo, Brazil. MATERIALS AND METHODS: A total of 1,082 physicians affiliated to the Sao Paulo Section of the Brazilian Society of Urology were invited to participate in this cross-sectional, web-based survey. Between September 2004 and September 2005, participating urologists entered data on demographic, clinical and pathological characteristics of patients diagnosed with prostate cancer in their practice. Data on patients attended at public institutions were analyzed and compared with those patients attended at private practice. RESULTS: One hundred and ten society members contributed with data from 1915 patients, 1026 (53.6% of whom from public institutions. When compared with patients attended at private institutions, those attended at public institutions were older and more likely to be black, had higher serum prostate specific antigen (PSA levels, had a higher probability of being diagnosed with metastatic disease, but were less likely to undergo prostatectomy (all P < 0.001. In multivariate analysis, age, biopsy Gleason score, and being attended at a public institution were independently associated with metastatic disease upon diagnosis. The significant predictors of nonsurgical treatment were age, black race, and higher serum levels of PSA. CONCLUSIONS: A statewide registry provides valuable information regarding patient demographics, clinical features, and patterns of care. The results of this study suggest that significant disparities exist for patients with prostate cancer attended at different health-care systems. The relative contribution of biological versus socioeconomic features remains uncertain.

  10. Report of National Cancer Institute symposium: comparison of mechanisms of carcinogenesis by radiation and chemical agents. II. Cellular and animal models

    International Nuclear Information System (INIS)

    This segment of the report of the proceedings of the National Cancer Institute symposium is devoted to the presentations about studies with in vitro cell systems, in vitro-in vivo systems, and whole animals including humans. The NCI symposium was designed to cover many aspects of carcinogenesis so that the similarities and differences of the manner in which ionizing radiation and chemical carcinogens initiate cancer and complete its expression could be examined. The hope was that the identification of both the common and the clearly distinct features would help elucidate mechanisms and indicate areas for new research

  11. Engineering behaviour change in an epidemic: the epistemology of NIH-funded HIV prevention science.

    Science.gov (United States)

    Green, Adam; Kolar, Kat

    2015-05-01

    Social scientific and public health literature on National Institutes of Health-funded HIV behavioural prevention science often assumes that this body of work has a strong biomedical epistemological orientation. We explore this assumption by conducting a systematic content analysis of all NIH-funded HIV behavioural prevention grants for men who have sex with men between 1989 and 2012. We find that while intervention research strongly favours a biomedical orientation, research into the antecedents of HIV risk practices favours a sociological, interpretive and structural orientation. Thus, with respect to NIH-funded HIV prevention science, there exists a major disjunct in the guiding epistemological orientations of how scientists understand HIV risk, on the one hand, and how they engineer behaviour change in behavioural interventions, on the other. Building on the extant literature, we suggest that the cause of this disjunct is probably attributable not to an NIH-wide positivist orientation, but to the specific standards of evidence used to adjudicate HIV intervention grant awards, including randomised controlled trials and other quantitative measures of intervention efficacy. PMID:25565009

  12. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection

    Directory of Open Access Journals (Sweden)

    Osterlund P

    2014-07-01

    Full Text Available Pia Osterlund,1,2 Reetta Peltonen,2,3 Tuomo Alanko,1 Petri Bono,1,2 Helena Isoniemi2,3 1Department of Oncology, Helsinki University Central Hospital, Helsinki, 2Institute of Clinical Medicine, University of Helsinki, Helsinki, 3Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland Background: Bevacizumab is active in the treatment of metastatic colorectal cancer (mCRC. However, efficacy of bevacizumab has predominantly been evaluated on selected patients with relatively good performance status and minor comorbidities. We evaluated the efficacy and safety of bevacizumab in unselected patients with mCRC, some of whom underwent liver resection. Material and methods: All patients with inoperable mCRC, fit for combination chemotherapy (n=180, who were initially not resectable, not included into studies and without contraindications to bevacizumab, and initiated on bevacizumab at the Helsinki University Central Hospital between April 2004 and December 2005 were included (n=114. Most (n=70 received 5-fluorouracil/leucovorin/irinotecan plus bevacizumab as first-line therapy. The remainder (n=44 of the patients received bevacizumab in combination with oxaliplatin or irinotecan with or without 5-fluorouracil or capecitabine. Minimum follow-up was 7 years. Treatment response was evaluated every 8–10 weeks according to RECIST criteria. Results: Median age was 59.6 years (range 35–79; male/female ratio was 54%/46%; World Health Organization performance status 0/1/2–3 was 33%/55%/11%, respectively; and the number of metastatic sites, one/two/three or more, was 31%/21%/48%, respectively. Median duration of bevacizumab therapy was 7.8 months (range 0.5–70.5 with pauses. In first-line (n=40, response rate (RR was 62%, progression-free survival (PFS 11.7 months, and overall survival (OS 22.1 months. In second-line (n=43, RR was 44%, PFS 8.7 months, and OS 18.7 months. In later lines (n=31, RR was 14%, PFS 6.7 months, and OS 14

  13. Skin Diseases: NIH Research to Results

    Science.gov (United States)

    ... are focusing on new treatments, including biologic agents, fatty acid supplements, and new forms of phototherapy. Skin cancer —New ways of working with the immune system to fight cancer are being studied. Researchers are ...

  14. National Cancer Institute News

    Science.gov (United States)

    ... and Foundation Medicine, Inc. (FMI), a molecular information company. Newly launched Genomic Data Commons to facilitate data ... of Health FOLLOW US Facebook Twitter Instagram YouTube Google+ LinkedIn GovDelivery RSS CONTACT INFORMATION Contact Us LiveHelp ...

  15. CLINICAL FEATURES AND CLINICAL OUTCOME OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED AT CAIRO NATIONAL CANCER INSTITUTE IN EGYPT

    Directory of Open Access Journals (Sweden)

    Tamer M Fouad

    2011-01-01

    Full Text Available

    The current study reports the clinical features and treatment outcome of 67 patients with acute promyelocytic leukemia (APL presented to National Cancer Institute (NCI-Cairo, in Egypt from January 2007 to January 2011. The median follow-up time was 36 months. All patients were treated with the simultaneous administration of all-trans retinoic acid (ATRA and anthracyclin. The treatment protocol was modified due to resource limitations at the NCI-Cairo by replacing of idarubicin with doxorubicin in most of the cases and the inclusion of cytarbine during the consolidation phase only in pediatric patients. All patients who achieved molecular complete remission (CRm after consolidation received two-year maintenance treatment with low dose chemotherapy composed of 6 mercaptopurine, methotrexate and intermittent ATRA courses. The median age at presentation was 29 years. There was a slight male predominance (53%.  Bleeding was the most common presenting symptom (79%. Most patients had an intermediate risk Sanz score (49% and 34% had a high risk score.  All patients achieved molecular CR at end of consolidation therapy with a median duration of 100 days. The main therapeutic complications during the induction phase were febrile neutropenia (42%, bleeding (18% and differentiation syndrome (11%. Five patients died at diagnosis due to bleeding, three died during induction chemotherapy due to febrile neutropenia (n=2 and bleeding (n=1 and one patient died during consolidation therapy due to febrile neutropenia.  The 3-year OS was 89% and relapse rate was 3%. Adapting standard AIDA treatment protocols to limited resources by reducing dose-intensity during treatment consolidation, using ATRA in the consolidation phase and alternative anthracyclin (doxorubicin may be a valid treatment option in developing countries. In spite of the increased incidence of high and intermediate risk score APL in our sample, we reported an acceptable CR rate

  16. CLINICAL FEATURES AND CLINICAL OUTCOME OF ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS TREATED AT CAIRO NATIONAL CANCER INSTITUTE IN EGYPT

    Directory of Open Access Journals (Sweden)

    Ola Khorshid

    2011-12-01

    Full Text Available The current study reports the clinical features and treatment outcome of 67 patients with acute promyelocytic leukemia (APL presented to National Cancer Institute (NCI-Cairo, in Egypt from January 2007 to January 2011. The median follow-up time was 36 months. All patients were treated with the simultaneous administration of all-trans retinoic acid (ATRA and anthracyclin. The treatment protocol was modified due to resource limitations at the NCI-Cairo by replacing of idarubicin with doxorubicin in most of the cases and the inclusion of cytarbine during the consolidation phase only in pediatric patients. All patients who achieved molecular complete remission (CRm after consolidation received two-year maintenance treatment with low dose chemotherapy composed of 6 mercaptopurine, methotrexate and intermittent ATRA courses. The median age at presentation was 29 years. There was a slight male predominance (53%.  Bleeding was the most common presenting symptom (79%. Most patients had an intermediate risk Sanz score (49% and 34% had a high risk score.  All patients achieved molecular CR at end of consolidation therapy with a median duration of 100 days. The main therapeutic complications during the induction phase were febrile neutropenia (42%, bleeding (18% and differentiation syndrome (11%. Five patients died at diagnosis due to bleeding, three died during induction chemotherapy due to febrile neutropenia (n=2 and bleeding (n=1 and one patient died during consolidation therapy due to febrile neutropenia.  The 3-year OS was 89% and relapse rate was 3%. Adapting standard AIDA treatment protocols to limited resources by reducing dose-intensity during treatment consolidation, using ATRA in the consolidation phase and alternative anthracyclin (doxorubicin may be a valid treatment option in developing countries. In spite of the increased incidence of high and intermediate risk score APL in our sample, we reported an acceptable CR rate, toxicity and OS.

  17. Primary non-Hodgkin's lymphomas of the breast: 23 years of experience at the Colombian national cancer institute

    International Nuclear Information System (INIS)

    Primary non- Hodgkin's lymphomas of the breast (PNHLB) are an infrequent malignancy. In a review of the literature, in which six Latin American journals are included, approximately 450 cases have been reported during the past two decades. in this paper we present the experience of the national cancer institute of Colombia during the last 23 years. Objective: to carry out a retrospective analysis of the characteristics, natural history, prognostic factors, and outcome of patients with PNHLB at the NCI of Colombia. Methods: the medical histories of patients diagnosed with PNHLB between 1980 and 2003 were reviewed; likewise, the clinical characteristics, treatment protocols, and final outcomes were analyzed. Results: 25 patients were identified as PNHLB. The average follow-up was 57 months. The medium age was 58, ranging from 26 to 83. 84% had diffused large cell lymphoma. The Karnofsky index was over 80 in 92% of the patients. 72% received chop chemotherapy. Two patients received a combination without doxorubicin. 68% received combined chemo- and radiation therapy. Two patients refused therapy. Two patients died before receiving any type of treatment. CNS compromise was observed in 20% of patients during the evolution of their disease. The youngest patient, whose case deserves special comment, obtained a second complete remission with simple mastectomy, after having relapsed after conventional chemotherapy, radiotherapy, and autologous bone marrow transplant. No significant prognostic variables were found using the univariate analysis. Conclusions: a high rate of complete remission can be achieved by using combined treatment in patients with PNHLB. The medium overall survival was not reached after 71 months of follow-up. The most frequent relapse site was the CNS

  18. Brachytherapy for T1-T2 floor-of-the-mouth cancers: the Gustave-Roussy Institute experience

    International Nuclear Information System (INIS)

    Purpose: In a retrospective analysis, we evaluated the Gustave-Roussy Institute's experience of locoregional control, survival, and complications of low-dose rate brachytherapy for carcinoma of the floor of the mouth. Methods and Materials: Between 1970 and 1985, 160 patients with previously untreated carcinoma of the floor of the mouth received interstitial brachytherapy as definitive treatment. Of the 160 patients, 79 (49%) had T1 and 81 (51%) had T2 lesions, and 127 (79%) had N0 and 33 (21%) had N1; 84% of tumors arose from the anterior floor of the mouth. Brachytherapy was performed with 192Ir wires, according to the Paris system rules, followed by neck dissection (T2 or N1) or follow-up (T1N0). Results: With a follow-up period of 9-19 years, the observed survival rates were 89% at 2 years and 76% at 5 years, and the local control rates were 93% in T1 and 88% in T2 tumors. A low rate of distant metastases was noticed (5%); 31% of patients developed a second primary cancer. Severe mucosal necrosis was observed in <10% of patients. Any grade of bone necrosis was seen in 18% of cases (only 2.5% had G3 necrosis). This complication occurred more frequently in patients with poor dental status and in those treated without dental protection during implantation (p <0.001). Conclusion: Radical brachytherapy offers excellent local control (89%) and an acceptable rate of complications (<10% severe necrosis) that may be significantly decreased with dental care and the use of protective devices. The high incidence of second malignancies remains a major concern in these patients

  19. Cost and Outcome of Treatment of Adults with Acute Myeloid Leukemia at the National Cancer Institute-Egypt

    International Nuclear Information System (INIS)

    Despite important advances in the therapy of acute myeloid leukemia (AML), the majority of patients die of their disease, unless bone marrow transplantation (BMT) is done. Infection and hemorrhage are still the major causes of mortality in AML patients. Progress in therapy and supportive care has led to gradual improvement in the overall results, but further improvements are still needed. Patients and Methods: The aim of this study is to identify the outcome and costs of adult AML patients treated with conventional chemotherapy (CCT) at the National Cancer Institute (NCI), Cairo University during the time period from April 1999 to January 2002. Clinical, laboratory characteristics were all recorded. Data regarding different types of therapies given for these patients including response, outcome and costs were also collected. Results: The median age of 82 identified AML patients was 34 years. The complete remission (CR) rate after induction with CCT was 52% (42/82 patients) with a median CR duration of 9 months. Twenty-eight percent of patients who achieved CR subsequently relapsed. By January 2003, fifty-eight patients were dead (70.7%). Infections were the major mortality cause, followed by disease progression then bleeding (65%, 28% and 7% respectively). The median treatment cost per patient was 33158 Egyptian Pounds (LE). It was higher for patients who achieved CR compared to those who relapsed and/or died. Drugs contributed by 78 % to the total treatment cost, while hospitalization, investigations and blood-component therapy contributed by 6%, 7% and 8% respectively. Conclusions: Outcome of patients with AML treated at NCI- Cairo University can be enhanced by improvement of supportive therapy; mainly infection control and expanding BMT programs to accommodate all eligible patients

  20. The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Hyo Chun; Kim, Yeon Si; Oh, Se Jin; Lee, Yun Hee; Lee, Dong Soo; Song, Jin Ho; Kang, Jin Hyung; Park, Jae Ki [Seoul St. Mary' s Hospital, The Catholic University of Korea College of Medicine, Seoul (Korea, Republic of)

    2014-09-15

    This study was conducted to observe the outcomes of postoperative radiotherapy (PORT) with or without concurrent chemotherapy in resected non-small cell lung cancer (NSCLC) in single institution. From 2002 to 2013, 78 patients diagnosed with NSCLC after curative resection were treated with radiotherapy alone (RT, n = 48) or concurrent chemoradiation (CCRT, n = 30). The indications of adjuvant radiation therapy were N2 node positive (n = 31), close or involved resection margin (n = 28), or gross residual disease due to incomplete resection (n = 19). The median radiation dose was 57.6 Gy (range, 29.9 to 66 Gy). Median survival time was 33.7 months (range, 4.4 to 140.3 months). The 5-year overall survival (OS) rate was 49.5% (RT 46% vs. CCRT 55.2%; p = 0.731). The 3-year disease-free survival rate was 45.5% (RT 39.4% vs. CCRT 55.3%; p = 0.130). The 3-year local control rate was 68.1% (RT 64.4% vs. CCRT 77.7%; p = 0.165). The 3-year DMFS rate was 56.1% (RT 52.6% vs. CCRT 61.7%; p = 0.314). In multivariate analysis, age > or =66 years and pathologic stage III were significant poor prognostic factors for OS. Treatment failure occurred in 40 patients. Four patients had radiologically confirmed grade 3 radiation pneumonitis. In NSCLC, adjuvant RT or CCRT after curative surgery is a safe and feasible modality of treatment. OS gain was seen in patients less than 66 years. Postoperative CCRT showed a propensity of achieving better local control and improved disease-free survival compared to RT alone according to our data.

  1. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience

    OpenAIRE

    Allal, Abdelkarim Said; Taussky, Daniel; Mach, Nicolas; Becker, Minerva; Bieri, Sabine; Dulguerov, Pavel

    2004-01-01

    Accelerated schedules are effective in overcoming repopulation during radiotherapy (RT) for head-and-neck cancers, but their feasibility is compromised by increased toxicity. The therapeutic ratio may be particularly favorable for 5-week regimens. This study reports the 10-year experience of a single institution in the routine use of concomitant boost RT as standard radical treatment in all but the most favorable stage patients.

  2. Challenges in converting an interviewer-administered food probe database to self-administration in the National Cancer Institute Automated Self-administered 24-Hour Recall (ASA24)

    OpenAIRE

    Zimmerman, Thea Palmer; Hull, Stephen G.; McNutt, Suzanne; Mittl, Beth; Islam, Noemi; Guenther, Patricia M.; Thompson, Frances E; Potischman, Nancy A.; Subar, Amy F.

    2009-01-01

    The National Cancer Institute (NCI) is developing an automated, self-administered 24-hour dietary recall (ASA24) application to collect and code dietary intake data. The goal of the ASA24 development is to create a web-based dietary interview based on the US Department of Agriculture (USDA) Automated Multiple Pass Method (AMPM) instrument currently used in the National Health and Nutrition Examination Survey (NHANES). The ASA24 food list, detail probes, and portion probes were drawn from the ...

  3. Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model

    OpenAIRE

    Meixensberger Jürgen; Gebhardt Rolf; Hengstler Jan; Hermes Matthias; Geiger Kathrin D; Fuchs Beate; Zemitzsch Nadine; Renner Christof; Gaunitz Frank

    2010-01-01

    Abstract Background It was previously demonstrated that the dipeptide carnosine inhibits growth of cultured cells isolated from patients with malignant glioma. In the present work we investigated whether carnosine also affects tumor growth in vivo and may therefore be considered for human cancer therapy. Results A mouse model was used to investigate whether tumor growth in vivo can be inhibited by carnosine. Therefore, NIH3T3 fibroblasts, conditionally expressing the human epidermal growth fa...

  4. T24 HRAS transformed NIH/3T3 mouse cells (GhrasT-NIH/3T3) in serial tumorigenic in vitro/in vivo passages give rise to increasingly aggressive tumorigenic cell lines T1-A and T2-A and metastatic cell lines T3-HA and T4-PA.

    Science.gov (United States)

    Ray, Durwood B; Merrill, Gerald A; Brenner, Frederic J; Lytle, Laurie S; Lam, Tan; McElhinney, Aaron; Anders, Joel; Rock, Tara Tauber; Lyker, Jennifer Kier; Barcus, Scott; Leslie, Kara Hust; Kramer, Jill M; Rubenstein, Eric M; Pryor Schanz, Karen; Parkhurst, Amy J; Peck, Michelle; Good, Kimberly; Granath, Kristi Lemke; Cifra, Nicole; Detweiler, Jessalee Wantz; Stevens, Laura; Albertson, Richard; Deir, Rachael; Stewart, Elisabeth; Wingard, Katherine; Richardson, Micah Rose; Blizard, Sarah B; Gillespie, Lauren E; Kriley, Charles E; Rzewnicki, Daniel I; Jones, David H

    2016-01-01

    Cancer cells often arise progressively from "normal" to "pre-cancer" to "transformed" to "local metastasis" to "metastatic disease" to "aggressive metastatic disease". Recent whole genome sequencing (WGS) and spectral karyotyping (SKY) of cancer cells and tumorigenic models have shown this progression involves three major types of genome rearrangements: ordered small step-wise changes, more dramatic "punctuated evolution" (chromoplexy), and large catastrophic steps (chromothripsis) which all occur in random combinations to generate near infinite numbers of stochastically rearranged metastatic cancer cell genomes. This paper describes a series of mouse cell lines developed sequentially to mimic this type of progression. This starts with the new GhrasT-NIH/Swiss cell line that was produced from the NIH/3T3 cell line that had been transformed by transfection with HRAS oncogene DNA from the T24 human bladder carcinoma. These GhrasT-NIH/Swiss cells were injected s.c. into NIH/Swiss mice to produce primary tumors from which one was used to establish the T1-A cell line. T1-A cells injected i.v. into the tail vein of a NIH/Swiss mouse produced a local metastatic tumor near the base of the tail from which the T2-A cell line was established. T2-A cells injected i.v. into the tail vein of a nude NIH/Swiss mouse produced metastases in the liver and one lung from which the T3-HA (H=hepatic) and T3-PA (P=pulmonary) cell lines were developed, respectively. T3-HA cells injected i.v. into a nude mouse produced a metastasis in the lung from which the T4-PA cell line was established. PCR analysis indicated the human T24 HRAS oncogene was carried along with each in vitro/in vivo transfer step and found in the T2-A and T4-PA cell lines. Light photomicrographs indicate that all transformed cells are morphologically similar. GhrasT-NIH/Swiss cells injected s.c. produced tumors in 4% of NIH/Swiss mice in 6-10 weeks; T1-A cells injected s.c. produced tumors in 100% of NIH/Swiss mice in 7

  5. 78 FR 25460 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-05-01

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA I/START Small Grant Review. Date... Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550,...

  6. 77 FR 47654 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2012-08-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Clinical Trials Research Coordination... of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550,...

  7. 76 FR 31967 - National Institute On Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute On Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA R13 Conference Grant Review. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4226, MSC 9550, 6001 Executive...

  8. 77 FR 75179 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2012-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... of Committee: National Institute on Drug Abuse Special Emphasis Panel; Collaborative Clinical Trials..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  9. 77 FR 54919 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-06

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunities in Medications..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  10. 76 FR 11252 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-01

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Initial Review Group; Training and Career Development... Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,...

  11. 75 FR 14175 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Substance Abuse Treatment Referral..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda,...

  12. 75 FR 63491 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2010-10-15

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA Basic Science Conference Grant (R13..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive, Blvd., Bethesda, MD...

  13. 77 FR 33472 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-06-06

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Training and Career Development... Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC...

  14. 78 FR 33853 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-06-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; PAR 11-109 Grand Opportunity in...@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;...

  15. 78 FR 27410 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-05-10

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; R13 Conference Grant Review. Date: June... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4226, MSC...

  16. 77 FR 58855 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2012-09-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Phased Services Research Studies of Drug... Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001...

  17. 76 FR 3916 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-01-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA B/START R03 Small Grant Review... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4238, MSC 9550, 6001 Executive Blvd.,...

  18. 75 FR 36429 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-06-25

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Medications Development for Substance...@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel,...

  19. 76 FR 35227 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, SecuRX: Preventing Prescription Drug..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, ]...

  20. 78 FR 64960 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-10-30

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; R25 and T32 AIDS Applications. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive...

  1. 76 FR 31968 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Technical Conference Support for DPMCDA... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  2. 76 FR 65517 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2011-10-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, NIDA R13 Conference Grant Review. Date... Affairs, National Institute on Drug Abuse, NIH, 6001 Executive Blvd., Room 4226, MSC 9550, Bethesda,...

  3. 76 FR 31967 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-06-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; N01DA-11-7777: Synthesis and..., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room...

  4. 75 FR 3239 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-01-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Rapid Assessment for Drug Abuse and... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  5. 78 FR 43890 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-07-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Pharmacokinetic Analysis Resource Center..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  6. 77 FR 22579 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel E-Technology Tools for Extending the... Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4229, MSC 9550, Bethesda, MD 20892-9550,...

  7. 78 FR 63994 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-10-25

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Substance Use Disorders and Molecular... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC...

  8. 76 FR 22715 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-04-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Blending Research and Practice... Special Projects Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, NIH,...

  9. 76 FR 35226 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2011-06-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel, 2011 NIDA Avant-Garde Award Program for... Institute on Drug Abuse, NIH, DHHS, Room 4229, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892-9550,...

  10. 75 FR 21006 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-04-22

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; R25 Review (PAR-07-221). Date: April 29... Institute on Drug Abuse, NIH, 6101 Executive Blvd., Rm. 213, MSC 8401, Bethesda, MD 20892,...

  11. 75 FR 9606 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-03

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Web-Enabled Cognitive/Neuropsychological... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  12. 78 FR 63995 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-10-25

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel R13 Conference Grant Review (PA12-212..., Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd.,...

  13. 76 FR 3913 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-01-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... and projects conducted by the National Institute on Drug Abuse, including consideration of personnel... Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD...

  14. 78 FR 27411 - National Institute on Drug Abuse Notice of Closed Meetings

    Science.gov (United States)

    2013-05-10

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meetings... of Committee: National Institute on Drug Abuse Special Emphasis Panel; Medication Ingestion... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  15. 75 FR 42104 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Systems Biology, HIV/AIDS, and Substance..., National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda,...

  16. 77 FR 47654 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-08-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Collaborative Clinical Trials in Drug... Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive...

  17. 77 FR 69640 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-11-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel CEBRA Review. Date: November 29, 2012... Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive Blvd., Bethesda, MD 20892- 9550,...

  18. 77 FR 27075 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-05-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunity in Medications... of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  19. 77 FR 22581 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2012-04-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Multi-site Trials. Date: May 22, 2012... Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4226, MSC 9550,...

  20. 76 FR 65517 - National Institute on Drug Abuse Notice of Closed Meeting

    Science.gov (United States)

    2011-10-21

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meeting... projects conducted by the National Institute on Drug Abuse, including consideration of personnel..., National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21223. Contact...

  1. 75 FR 9420 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-02

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Web-Enabled Cognitive/Neuropsychological... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC 8401, 6101 Executive...

  2. 76 FR 81952 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2011-12-29

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Training and Career Development..., National Institute on Drug Abuse, NIH, DHHS, Room 4245, MSC 9550, 6001 Executive Blvd., Bethesda, MD...

  3. 78 FR 58320 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-23

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel GOMED: Grand Opportunity in Medications... of Extramural Affairs, National Institute on Drug Abuse, NIH, Room 4228, MSC 9550, 6001...

  4. 77 FR 3481 - National Institute on Drug Abuse Notice of Closed Meeting

    Science.gov (United States)

    2012-01-24

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel Recovery Warrior: Behavioral Activation...., Scientific Review Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH,...

  5. 75 FR 42102 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-07-20

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Research Dissemination (1143). Date..., Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,...

  6. 78 FR 56238 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-12

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel Multisite Clinical Trials. Date... Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4234, MSC 9550, 6001 Executive...

  7. 77 FR 27075 - National Institute on Drug Abuse Notice of Closed Meeting

    Science.gov (United States)

    2012-05-08

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Regulatory Affairs Support (8902). Date... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  8. 75 FR 6042 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-02-05

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel, Rapid Assessments Tools of Sexual and... Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 220, MSC...

  9. 78 FR 73866 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2013-12-09

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; NIDA Center for Genetics Studies (7789... Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive...

  10. 75 FR 13136 - National Institute on Drug Abuse; Notice of Closed Meeting

    Science.gov (United States)

    2010-03-18

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting... Committee: National Institute on Drug Abuse Special Emphasis Panel; Loan Repayment. Date: March 22, 2010..., Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH. DHHS,...

  11. 77 FR 75179 - National Institute on Drug Abuse; Notice of Closed Meetings

    Science.gov (United States)

    2012-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings... Committee: National Institute on Drug Abuse Special Emphasis Panel; N43DA13-4417: Video Gaming Targeting..., rogersn2@nida.nih.gov . Name of Committee: National Institute on Drug Abuse Special Emphasis Panel;...

  12. 78 FR 70065 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2013-11-22

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis...@niaid.nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases...

  13. 77 FR 16845 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2012-03-22

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis..., lr228v@nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases...

  14. 78 FR 76847 - National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

    Science.gov (United States)

    2013-12-19

    ... HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases... personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis....nih.gov . Name of Committee: National Institute of Allergy and Infectious Diseases Special...

  15. 78 FR 10621 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2013-02-14

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  16. 76 FR 12744 - National Institute On Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2011-03-08

    ... HUMAN SERVICES National Institutes of Health National Institute On Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  17. 77 FR 59405 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2012-09-27

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other....nih.gov . Name of Committee: National Institute on Deafness and Other Communication Disorders...

  18. 78 FR 56902 - National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings

    Science.gov (United States)

    2013-09-16

    ... HUMAN SERVICES National Institutes of Health National Institute on Deafness and Other Communication... unwarranted invasion of personal privacy. Name of Committee: National Institute on Deafness and Other..., kellya2@nidcd.nih.gov . Name of Committee: National Institute on Deafness and Other...

  19. 75 FR 65642 - National Institute of Mental Health; Notice of Closed Meeting

    Science.gov (United States)

    2010-10-26

    ... of Committee: National Institute of Mental Health Special Emphasis Panel; HIV/AIDS Behavioral..., Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call) Contact Person... Mental Health, NIH, Neuroscience Center, 6001 Executive Boulevard, Room 6132, MSC 9608, Bethesda,...

  20. 76 FR 16432 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2011-03-23

    ... review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001... Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/ NIH/DHHS/Neuroscience... to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences,...

  1. 75 FR 65497 - National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

    Science.gov (United States)

    2010-10-25

    ... of Extramural Research, NINDS/NIH/DHHS, Neuroscience Center, 6001 Executive Blvd., Room 3208, MSC... Research in the Neurosciences, National Institutes of Health, HHS) Dated: October 18, 2010. Jennifer...

  2. Knowledge and attitude towards cervical cancer screening among female students and staff in a tertiary institution in the Niger Delta

    Directory of Open Access Journals (Sweden)

    Owoeye I.O.G

    2013-01-01

    Full Text Available Background: Cervical cancer is a largely preventable disease. In western countries, the incidence of and mortality associated with cervical cancer has reduced substantially following the introduction of effective cervical screening programmes. This is in contrast to what is obtained in Africa including Nigeria where cervical screening is rudimentary or non- existent. Aim: This study seeks to assess the knowledge, level of perception and the attitude of female staff and students of Niger Delta University, Nigeria, towards cervical cancer screening. Methods: A questionnaire was used for data collection. The questions were made to capture the objectives of the study. Results: Most of the respondents 278 (72% were aware of cervical cancer, while only 182 (50.6% were aware of cervical cancer screening. Pap smear was the most popular screening test mentioned by respondents 100 (41.2%, while some respondents (8.5% of staff and 16.3% of students wrongly believed that blood test is used for cervical cancer screening. There is a significant association between awareness and practice of cervical cancer screening amongst staff and students (X2 = 29.4, P=0.00. Conclusion: The study shows that awareness of cervical cancer screening was higher amongst students than staff of Niger Delta University. Uptake was low in both staff and students. There was an association between awareness and practice of cervical cancer screening amongst respondents. Overall, a greater proportion of the staff respondents had little or no knowledge of cervical cancer screening.

  3. Latest Research from NIH's National Institute of Dental and Craniofacial Research | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... engineering, as well as periodontal (gum) disease and tooth decay. NIDCR-supported scientists are designing specialized instruments that ... are focused on comparing DNA from people with tooth decay to those without it to look for genetic ...

  4. Overactive Thyroid Linked to Breast Cancer Risk

    Science.gov (United States)

    ... nih.gov/medlineplus/news/fullstory_157203.html Overactive Thyroid Linked to Breast Cancer Risk But researchers added ... 2016 (HealthDay News) -- Women who have an overactive thyroid gland might be at greater risk for breast ...

  5. Breast Cancer and Estrogen-Alone Update

    Science.gov (United States)

    ... Issues Research News From NIH Breast Cancer and Estrogen-Alone Update Past Issues / Summer 2006 Table of ... version of this page please turn Javascript on. Estrogen-alone hormone therapy does not increase the risk ...

  6. Using Large Institutional or National Databases to Evaluate Prostate Cancer Outcomes and Patterns of Care: Possibilities and Limitations

    OpenAIRE

    Daniel Su; Jang, Thomas L.

    2011-01-01

    Prostate cancer is the most common non–skin-related cancer in men. With advances in technology, the care and treatment for men with this disease continues to become more complex. Large databases offer researchers a unique opportunity to conduct prostate cancer research in various areas, and provide important information that helps patients and providers determine prognosis after treatment. Furthermore, the studies using these databases may provide information on how side effects from various ...

  7. Treatment and prognosis of cervical cancer associated with pregnancy: analysis of 20 cases from a Chinese tumor institution

    OpenAIRE

    Zhang, Xiang; Gao, Yong-liang; Yang, Yue

    2015-01-01

    This study was designed to investigate the therapeutic approaches and prognosis for cervical cancer associated with pregnancy. Clinical information, therapeutic strategies, and follow-up results of 20 patients with cervical cancer associated with pregnancy from Jan. 2000 to June 2009 in the Zhejiang Cancer Hospital were retrospectively analyzed. The International Federation of Gynecology and Obstetrics (FIGO) stages were: in situ (n=1), stage IA1 (n=1), stage IB1 (n=5), stage IB2 (n=1), stage...

  8. ZBIRKA MATEMATIČNIH IGER ZA PREDŠOLSKO OBDOBJE

    OpenAIRE

    Florjančič, Jasmina

    2011-01-01

    POVZETEK Diplomsko delo z naslovom Zbirka matematičnih iger za predšolsko obdobje predstavlja uporabnost in pestrost možnosti izdelave in uporabe matematičnih iger v predšolskem obdobju. Namen in cilj diplomskega dela je bil predstaviti in opisati čimveč različnih oblik matematičnih iger, ki jih lahko uporabimo pri delu in dejavnostih s predšolskimi otroki. Prav tako pa tudi preučiti v kolikšni meri in na kakšen način lahko igre, kot matematično vsebino, uporabljamo in vpletamo v druga vs...

  9. Feature: Controlling Seasonal Allergies | NIH Medlineplus the Magazine

    Science.gov (United States)

    ... this page please turn Javascript on. Feature: Seasonal Allergies Controlling Seasonal Allergies Past Issues / Spring 2012 Table of Contents In ... to allergens, helping to prevent allergic reactions. Seasonal Allergy Research at NIH Allergen and T-Cell Reagent ...

  10. The Zika Virus | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... please turn JavaScript on. Feature: Infectious Diseases The Zika Virus Past Issues / Spring 2016 Table of Contents ... Photo Courtesy of NIH "You could have a Zika virus vaccine in large-scale clinical trials in ...

  11. What is COPD? | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... please turn JavaScript on. Feature: The Challenge of COPD What is COPD? Past Issues / Fall 2014 Table of Contents COPD ... a walk, even washing and dressing. What Is COPD? Watch an animation at: www.nhlbi.nih.gov/ ...

  12. Diabetes Complications | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Feature: Diabetes Complications Tailoring Diabetes Treatment to the Patient Past Issues / Fall 2012 ... been reported for the treatment of type 2 diabetes. How was the NIH involved? These are guidelines ...

  13. Feature: Post Traumatic Stres Disorder PTSD: NIH Research to Results

    Science.gov (United States)

    ... Navigation Bar Home Current Issue Past Issues Feature PTSD NIH Research to Results Past Issues / Winter 2009 ... be a key to a better understanding of PTSD and early identification of those at risk. Early ...

  14. The Zika Virus | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... Photo Courtesy of NIH "You could have a Zika virus vaccine in large-scale clinical trials in 2017, which ... combat it. It is possible that an investigational Zika vaccine will be ready to enter early-stage human ...

  15. Precision Medicine In Action | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... page please turn JavaScript on. Feature: NIH Precision Medicine Initiative Precision Medicine In Action Past Issues / Fall 2015 Table of ... Dishman "I am totally motivated to support precision medicine because I am one of the early prototype ...

  16. The UC Davis/NIH NeuroMab Facility

    Data.gov (United States)

    Federal Laboratory Consortium — The mission of the UC Davis/NIH NeuroMab facility is to generate and distribute high quality, validated mouse monoclonal antibodies against molecular targets found...

  17. GRADNJA DOMENSKO SPECIFIČNIH JEZIKOV V PROGRAMSKEM JEZIKU SCALA

    OpenAIRE

    Kokol, Primož

    2012-01-01

    Scala je razmeroma nov, splošno namenski, statično tipiziran programski jezik, ki združuje principe objektnega in funkcijskega programiranja. Predvsem principi funkcijskega programiranja namigujejo na to, da bi omenjen jezik lahko predstavljal dobro alternativo za implementacijo domensko specifičnih jezikov. V sklopu diplomskega dela smo preučili ustreznost omenjenega programskega jezika za implementacijo domensko specifičnih programskih jezikov na primeru jezika FDL (ang. Feature Description...

  18. Long-Term Survival and Local Relapse Following Surgery Without Radiotherapy for Locally Advanced Upper Rectal Cancer: An International Multi-Institutional Study.

    Science.gov (United States)

    Park, Jun Seok; Sakai, Yoshiharu; Simon, Ng Siu Man; Law, Wai Lun; Kim, Hyeong Rok; Oh, Jae Hwan; Shan, Hester Cheung Yui; Kwak, Sang Gyu; Choi, Gyu-Seog

    2016-05-01

    Controversy remains regarding whether preoperative chemoradiation protocol should be applied uniformly to all rectal cancer patients regardless of tumor height. This pooled analysis was designed to evaluate whether preoperative chemoradiation can be safely omitted in higher rectal cancer.An international consortium of 7 institutions was established. A review of the database that was collected from January 2004 to May 2008 identified a series of 2102 patients with stage II/III rectal or sigmoid cancer (control arm) without concurrent chemoradiation. Data regarding patient demographics, recurrence pattern, and oncological outcomes were analyzed. The primary end point was the 5-year local recurrence rate.The local relapse rate of the sigmoid colon cancer (SC) and upper rectal cancer (UR) cohorts was significantly lower than that of the mid/low rectal cancer group (M-LR), with 5-year estimates of 2.5% for the SC group, 3.5% for the UR group, and 11.1% for the M-LR group, respectively. A multivariate analysis showed that tumor depth, nodal metastasis, venous invasion, and lower tumor level were strongly associated with local recurrence. The cumulative incidence rate of local failure was 90.6%, 92.5%, and 94.4% for tumors located within 5, 7, and 9 cm from the anal verge, respectively.Routine use of preoperative chemoradiation for stage II/III rectal tumors located more than 8 to 9 cm above the anal verge would be excessive. The integration of a more individualized approach focused on systemic control is warranted to improve survival in patients with upper rectal cancer. PMID:27258487

  19. Nove konstrukcije velikih montažnih lučnih mostova

    OpenAIRE

    Čandrlić, Vinko; Mrakovčić, Silvija; Skazlić, Marijan

    2003-01-01

    Opisani su konstrukcijski i tehnološki aspekti gradnje velikih lučnih mostova s montažnim odsječcima primjenom betona od reaktivnog praha. Odsječci se izrađuju betoniranjem sukladnih sljubnica, spajaju epoksidnim smolama i potom prednapinju vanjskim čeličnim šipkama samo na dijelu spojnica. Lukovi se izvode zrakastim ovješenjem konzola preko petnih stupova, a grede obostranim potiskivanjem bez klasičnog kljuna s istodobnim postavljanjem stupova s grede i reguliranjem visine nivelete.

  20. PRESOJANJE BONITETE PODJETJA Z UPORABO FINANČNIH IN NEFINANČNIH KAZALNIKOV

    OpenAIRE

    Platovšek, Boštjan

    2010-01-01

    Poznavanje poslovnega partnerja in njegove bonitete je eden ključnih načinov za zmanjševanje informacijske asimetrije ter tveganj, ki izvirajo iz nje. Preverjanje bonitete podjetja postaja poslovna praksa, ki se je izkazala za zelo učinkovito doma in v svetu. Prav tako pomeni mnogo lažji in predvsem hitrejši način dostopa do kakovostnih informacij, ki jih za učinkovito presojo potrebujemo o določenem poslovnem subjektu. S tem zmanjšujemo nepotrebno izgubo časa, energije, volje, interesa za fi...

  1. Robert Clarke Named as the National Cancer Institute - Sigma Xi Distinguished Lecturer for 2012-2013 — Site

    Science.gov (United States)

    Dr. Clarke is an expert on the effects of hormones and growth factors on breast cancer. He and his laboratory are actively pursuing the cellular and molecular mechanisms responsible for the emergence of resistance in breast cancer cells to endocrine and cytotoxic therapies.

  2. Mobile Technology and Health Care, From NIH Director Dr. Francis S. Collins | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... of this page please turn Javascript on. Mobile Technology and Health Care, From NIH Director Dr. Francis S. ... Where are the largest investments in the new technologies? The largest are in mobile phone and "tele- ...

  3. The Promise and Payoff of Rare Diseases Research, From NIH Director Dr. Francis S. Collins | NIH MedlinePlus the ...

    Science.gov (United States)

    ... turn Javascript on. The Promise and Payoff of Rare Diseases Research, From NIH Director Dr. Francis S. Collins ... of rare diseases. Why should we focus on rare diseases when they affect so few people? If ...

  4. The NIH Extracellular RNA Communication Consortium

    Directory of Open Access Journals (Sweden)

    Alexandra M. Ainsztein

    2015-08-01

    Full Text Available The Extracellular RNA (exRNA Communication Consortium, funded as an initiative of the NIH Common Fund, represents a consortium of investigators assembled to address the critical issues in the exRNA research arena. The overarching goal is to generate a multi-component community resource for sharing fundamental scientific discoveries, protocols, and innovative tools and technologies. The key initiatives include (a generating a reference catalogue of exRNAs present in body fluids of normal healthy individuals that would facilitate disease diagnosis and therapies, (b defining the fundamental principles of exRNA biogenesis, distribution, uptake, and function, as well as development of molecular tools, technologies, and imaging modalities to enable these studies, (c identifying exRNA biomarkers of disease, (d demonstrating clinical utility of exRNAs as therapeutic agents and developing scalable technologies required for these studies, and (e developing a community resource, the exRNA Atlas, to provide the scientific community access to exRNA data, standardized exRNA protocols, and other useful tools and technologies generated by funded investigators.

  5. Current aspects of radiation-induced cancer risk assessment

    International Nuclear Information System (INIS)

    The agenda of the closed meeting of the commission shows the following main topics: 1) Recent dosimetry /Ro 87/ and new data on cancer mortality in the Atomic Bomb survivors of Hiroshima and Nagasaki as a function of age at the time of exposure /Pr 87; Si 87; IC 87.1/. 2) Models and assumptions given in the epidemiological tables of the U.S. National Institute of Health (NIH) /NIH 85/ for assessment of probability of cancer induction due to exposure to ionizing radiation (probability of causation), and possibilities of interpreting these data so as to match them with conditions in the F.R.G. 3) Results of epidemiological studies with occupationally exposed persons working in nuclear installations or medical establishments, and with population groups living in the environs of nuclear installations. 4) Recent knowledge about radon-induced lung cancer, and recommendations of and measures taken by other countries for reducing radon concentrations in buildings. The summarizing appraisals and recommendations agreed upon by the SSK members upon discussion of the items are given in this publication. (orig./MG) With 31 figs., 41 tabs

  6. Evaluation and the NIH clinical and translational science awards: a "top ten" list.

    Science.gov (United States)

    Pincus, Harold Alan; Abedin, Zainab; Blank, Arthur E; Mazmanian, Paul E

    2013-12-01

    Since 2006, a total of 61 Clinical and Translational Science Institutes (CTSAs) have been funded by the National Institutes of Health (NIH), with the aim of reducing translation time from a bench discovery to when it impacts patients. This special issue of Evaluation & the Health Professions focuses on evaluation within and across the large, complex system of the CTSA Program of NIH. Through insights gained by reading the articles in this special edition and the experience of the authors, a "top ten" list of lessons learned and insights gained is presented. The list outlines issues that face those who evaluate the influence of the CTSA Program, as they work to anticipate what will be needed for continuing success. Themes include (1) considering the needs of stakeholders, (2) the perspective of the evaluators, (3) the importance of service improvement, (4) the importance of teams and people, (5) costs and return on investments, (6) methodology considerations to evaluate the CTSA enterprise, (7) innovation in evaluation, (8) defining the transformation of research, (9) evaluating the long-term impact of the CTSAs on public health, and (10) contributing to science policy formulation and implementation. The establishment of the CTSA Program, with its mandated evaluation component, has not only influenced the infrastructure and nature of translational research but will continue to impact policy and management in science. PMID:24214661

  7. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series

    Directory of Open Access Journals (Sweden)

    Zachary B. Koloff

    2015-01-01

    Conclusion: Our results emphasize the importance of TP5 and suggest that criteria for tertiary pattern reporting in prostate cancer should be standardized. Further studies are needed to evaluate the role of tertiary patterns in prognostic models.

  8. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... for biomarkers on tiny, fluid-filled sacs called exosomes. Exosomes are released by cells and circulate in blood. ... Nature on July 9, 2015. The scientists compared exosomes from a human cancer cell line and several ...

  9. Thyroid Cancer Cases in U.S. Level Off, Perhaps Reflecting Diagnostic Changes

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158319.html Thyroid Cancer Cases in U.S. Level Off, Perhaps Reflecting ... 2016 THURSDAY, April 14, 2016 (HealthDay News) -- Fewer thyroid cancers are diagnosed in the United States now ...

  10. Male Childhood Cancer Survivors Less Likely to Have Kids, Study Finds

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_157447.html Male Childhood Cancer Survivors Less Likely to Have Kids, ... in Norway found. The findings "are important for male cancer survivors, seeing as we can identify groups ...

  11. Breast Cancer Meds Won't Raise Chances of Heart Attack, Stroke, Study Suggests

    Science.gov (United States)

    ... nlm.nih.gov/medlineplus/news/fullstory_158441.html Breast Cancer Meds Won't Raise Chances of Heart Attack, ... the risk of heart attacks and strokes among breast cancer survivors, a new study suggests. However, the researchers ...

  12. Multi-institutional phase II trial of intermediate risk prostate cancer treated with combination of external beam radiotherapy and high dose rate iridium brachytherapy

    International Nuclear Information System (INIS)

    A total of 84 intermediate risk prostate cancer (T2b or T2c, or 10< prostate specific antigen (PSA) ≤20 ng/ml, or Gleason score =7) patients were enrolled from five institutions. External beam radiotherapy were 3 Gy x 13 fraction =39 Gy and high dose rate iridium brachytherapy were 9 Gy x 2=18 Gy in one or two days. Primary endpoint of this study is the incidence of grade 3 late toxicity (NCI-CTC Ver.3) and secondary endpoint are acute toxicity and PSA relapse free rate. No grade 3 toxicity was observed and only one patient among 84 patients is noted PSA failure. Combined treatment of external beam radiotherapy and high dose rate iridium brachytherapy against intermediate risk of prostate cancer is safe and effective treatment. (author)

  13. Intraoperative radiation therapy delivered prior to lumpectomy for early-stage breast cancer: a single institution study

    OpenAIRE

    Yu, Wei; Lin, Zhi; Ju, Zhong-Jian; Li, Xi-Ru; ZHANG, YAN-JUN; Kong, Qing-Long; Gong, Han-Shun; Wang, Jian-Dong; Ma, Lin

    2015-01-01

    Objective: To evaluate the safety, cosmesis, and clinical outcome of intraoperative electron radiation therapy (IOERT) delivered prior to lumpectomy for early-stage breast cancer. Methods: From December 2008 to March 2012, 75 breast cancer patients (ages 34-66 years) were treated with IOERT during breast conservative surgery. IOERT was delivered using a mobile linear accelerator. Suitable energy and applicator size were chosen to ensure coverage of the tumor with anterior and posterior margin...

  14. Preoperative Nomograms for Predicting Extracapsular Extension in Korean Men with Localized Prostate Cancer: A Multi-institutional Clinicopathologic Study

    OpenAIRE

    Chung, Jae Seung; Choi, Han Yong; Song, Hae-Ryoung; Byun, Seok-Soo; Seo, Seong Il; Song, Cheryn; Cho, Jin Seon; Lee, Sang Eun; Ahn, Hanjong; Lee, Eun Sik; Kim, Won-Jae; Chung, Moon Kee; Jung, Tae Young; Yu, Ho Song; Choi, Young Deuk

    2010-01-01

    We developed a nomogram to predict the probability of extracapsular extension (ECE) in localized prostate cancer and to determine when the neurovascular bundle (NVB) may be spared. Total 1,471 Korean men who underwent radical prostatectomy for prostate cancer between 1995 and 2008 were included. We drew nonrandom samples of 1,031 for nomogram development, leaving 440 samples for nomogram validation. With multivariate logistic regression analyses, we made a nomogram to predicts the ECE probabi...

  15. Two-fraction high-dose-rate brachytherapy within a single day combined with external beam radiotherapy for prostate cancer: single institution experience and outcomes

    OpenAIRE

    Liu, Junyang; Kaidu, Motoki; Sasamoto, Ryuta; Ayukawa, Fumio; Yamana, Nobuko; Sato, Hiraku; Tanaka, Kensuke; Kawaguchi, Gen; Ohta, Atsushi; Maruyama, Katsuya; Abe, Eisuke; Kasahara, Takashi; Nishiyama, Tsutomu; Tomita, Yoshihiko; Aoyama, Hidefumi

    2016-01-01

    We investigated the outcomes of treatment for patients with localized prostate cancer (PCa) treated with 3D conformal radiation therapy (3D-CRT) followed by two-fraction high-dose-rate brachytherapy within a single day (2-fr.-HDR-BT/day) at a single institution. A total of 156 consecutive Asian males (median age, 67 years) were enrolled. To compare our findings with those of other studies, we analyzed our results using the D'Amico classification, assigning the patients to low- ( n =5; 3.2%), ...

  16. Cancer of Unknown Primary Site:A Review of 28 Cases and the Efficacy of Cisplatin/Docetaxel Therapy at a Single Institute in Japan

    OpenAIRE

    Nishimori, Hisakazu; TAKAHASHI, SHUNJI; Kiura, Katsuyuki; Ennishi, Daisuke; Kobayashi, Takayuki; Sano,Koji; SHINOZAKI, EIJI; Yokoyama, Masahiro; Mishima, Yuko; Terui, Yasuhito; Chin,Keisho; Mizunuma, Nobuyuki; Ito, Yoshinori; Nishimura, Seiichiro; Takeuchi, Kengo

    2010-01-01

    We evaluated the efficacy and toxicity of cisplatin/docetaxel (CDDP/TXT) chemotherapy and identified prognostic factors in Japanese patients with cancer of unknown primary site (CUP). Twenty-eight consecutive patients seen at a single institute were reviewed retrospectively. Sixteen patients were treated with TXT 80mg/m2, followed by CDDP 75mg/m2. The overall response rate to CDDP/TXT treatment was 62.5%, with a median survival time (MST) of 22.7 months. Common adverse reactions were myelosup...

  17. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multi-institutional validation of a post-operative nomogram

    OpenAIRE

    Yates, D R; Hupertan, V.; Colin, P.; Ouzzane, A; Descazeaud, A; Long, J. A.; Pignot, G; Crouzet, S; Rozet, F; Neuzillet, Y; Soulie, M.; Bodin, T; Valeri, A.; Cussenot, O; Rouprêt, M

    2012-01-01

    Background: Owing to the scarcity of upper urinary tract urothelial carcinoma (UUT-UC) it is often necessary for investigators to pool data. A patient-specific survival nomogram based on such data is needed to predict cancer-specific survival (CSS) post nephroureterectomy (NU). Herein, we propose and validate a nomogram to predict CSS post NU. Patients and methods: Twenty-one French institutions contributed data on 1120 patients treated with NU for UUT-UC. A total of 667 had full data for nom...

  18. Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study

    International Nuclear Information System (INIS)

    Compared to static beam Intensity-Modulated Radiation Therapy (IMRT), the main advantage of Volumetric Modulated Arc Therapy (VMAT) is a shortened delivery time, which leads to improved patient comfort and possibly smaller intra-fraction movements. This study aims at a treatment planner-independent comparison of radiotherapy treatment planning of IMRT and VMAT for head-and-neck cancer performed by several institutes and based on the same CT- and contouring data. Five institutes generated IMRT and VMAT plans for five oropharyngeal cancer patients using either Pinnacle3 or Oncentra Masterplan to be delivered on Elekta linear accelerators. Comparison of VMAT and IMRT plans within the same patient and institute showed significantly better sparing for almost all OARs with VMAT. The average mean dose to the parotid glands and oral cavity was reduced from 27.2 Gy and 39.4 Gy for IMRT to 25.0 Gy and 36.7 Gy for VMAT, respectively. The dose conformity at 95% of the prescribed dose for PTVboost and PTVtotal was 1.45 and 1.62 for IMRT and 1.37 and 1.50 for VMAT, respectively. The average effective delivery time was reduced from 13:15 min for IMRT to 5:54 min for VMAT. Independently of institution-specific optimization strategies, the quality of the VMAT plans including double arcs was superior to step-and-shoot IMRT plans including 5–9 beam ports, while the effective treatment delivery time was shortened by ~50% with VMAT

  19. Student Interns Tour Two NIH Facilities | Poster

    Science.gov (United States)

    Thirty-five Werner H. Kirsten student interns toured the National Library of Medicine and the National Institutes of Health Clinical Center in Bethesda in August to learn about the services and opportunities available.

  20. Healthlines | NIH MedlinePlus the Magazine

    Science.gov (United States)

    ... without help—is important for an older person's independence and health. Researchers studied people in their 70s ... Institute on Aging was the primary sponsor. NIA Director Richard J. Hodes, M.D., calls the findings ...